Nephrology / Dialysis Transplantation

Nephrology /DialysisTransplantationOfficial Publication of the European Dialysis and Transplant Association - European Renal Association

Volume 4 Number 1 1989

Original ArticlesAutoantibodies to Glomerular Antigens inPatients with Wegener's GranulomatosisFrances Abbott. Sally Jones, C: M. Lockwood andA. J. Rees

Circadian Rhythm of Proteinuria:Consequences of the Use of Urinary Protein:Creatinine RatiosM. G. Koopman, R. T. Krediet, G. C. M. Koomen,J. Strackee and L Arisz 9

Effect of Fibronectin on C3b and FcReceptor-mediated Phagocytosis byPeripheral Blood Monocytes in UraemicPatientsG. Pertosa, G. Mastrolitti, P. J. Spath, A. R. Fracasso,C. Mannoand F. P. Schena 15

Erythrocyte Sodium and Sodium Flux inRelation to Hypertension in Chronic RenalFailureT. H. Thomas, H. Mansy and R. Wilkinson

Indomethacin Increases Renal LithiumReabsorption in ManA. J. Rabelink, H. A. Koomans, W. H. Boer,E. J. Dorhout Mees and H. J. M. van Rijn

Adequacy of Haemodiaf iltrationM. Surian, F. Malberti, B. Corradi, G. Orlandini,E. Varini, G. Colussi and L. Minetti

Pre-postdilution HaemofiltrationS. David, D.Tagliavini and V. Cambi

Death from Dialysis TerminationD.J.Hirsch

21

27

32

37

41

Parathyroid Sonography in SecondaryHyperparathyroidism: Correlation withClinical FindingsH.Tomi6 Brzac, D. Pavlovid, M. HalbauerandJ. Pasini 45

Can Low-dosage Aluminium HydroxideControl the Plasma Phosphate without BoneToxicity?D. A. S. Jenkins, D. Gouldesbrough, G. D. Smith,J. F. Cowieand R. J. Winney 51

Percutaneous Transluminal Angioplasty ofFailing Arteriovenous Dialysis FistulaeE. Cada, F. Karnel, G. Mayer, F. Langle.H.Schurawitzkiand H.Graf 57

Urokinase: A Treatment for RelapsingPeritonitis due to Coagulase-negativeStaphylococciS. J. Pickering, S. J. Fleming, J. A. Bowley,P. Sissons, B. A. Oppenheim, J. Burnie, A. J. Ralstonand P. Ackrill 62

Contrasting Effects of Acute AngiotensinConverting Enzyme Inhibitors and CalciumAntagonists in Transplant Renal ArteryStenosisG. Mourad, J. Ribstein, A. Argiles, A. Mimran andC. Mion

Pharmacokinetics of Cyclosporin in ManFollowing a Single Oral Dose: Relationship toBody Fat ContentM. R. Waters, Janet D. M. Albano, V. L Sharmanand G. Venkat Raman

Letters

Announcements

66

71

75

78

Incorporating Proceedings of the European Dialysis and Transplant Association - European Renal Association

fi) Springer International

Dow

nloaded from https://academ

ic.oup.com/ndt/issue/4/1 by guest on 06 July 2022

Which wasthe first

companycommitted

onlyto dialysis?

CLUE:Today, more than 75.000 patients all over the world depend on its products.

Dow



NephrologyDialysisTransplantationVOLUME 4:1989

Official Publication of theEuropean Dialysis and TransplantAssociation—European RenalAssociation

Incorporating Proceedings of theEuropean Dialysis and TransplantAssociation—European RenalAssociation

Editor-in-Chief:

Editors:

Advisory Editors:

Alex M. DavisonLeeds. UK

. H. BryngerGoteborg. Sweden

V. CambiParma. Italy

J. S. CameronLondon, UK

J. P. GriinfeldParis. France

J. F. BachParis. Fiance

R. S. BarsoumCairo. Egypt

J. Bergstrom. Stockholm, Sweden

J. BotellaMadrid. Spain

J. D. BriggsGlasgow, UK

M. BroyerParis, France

A. Dal CantonCatanzaro. Italy

G. D'AmicoMilano. Italy

R. A. DonckerwolckeUtrecht. The Netherlands

J. F. DonohoeDublin, Ireland

T. DriiekeParis. France

P. DruetParis. France

J. EgidoMadrid, Spain

H. EliahouTel Heshomer. Israel

D. FalkenhagenRostock. GDR

M. GoldmanBruxelles, Belgium

L. HernandoMadrid. Spain

K. HierholzerBerlin, FRG

H. KlinkmannRostock. GDR

R.GregerFrankfurt. FRG

P. HayryHelsinki, Finland

P. J. HoedemaekerLeiden. The Netherlands

C. JacobsParis. France

R.A. P. KoeneNijmegen, The Netherlands

F. KokotKatowice. Poland

N. H. LameireGent, Belgium

R. MaiorcaBrescia.Italy

N.P. MallickManchester. UK

June MasonBasel, Switzerland

J.Ph. MeryParis. France

C. MionMontpellier. France

K. OlgaardCopenhagen. Denmark

G.OpelzHeidelberg. FRG

A. PasternackTampere, Finland

R. PichlmayrHannover. FRG

H. KreisParis. France

E. RitzHeidelberg, FRG

C. Van YperseleBruxelles. Belgium

M. PolenakoyicSkopje, Yugoslavia

C. PonticelliMilano, Italy

A. T. RafterySheffield. UK

G. RemuzziBergamo. Italy

L. RevertBarcelona, Spain

G. F. RizzoniPadova. Italy

G. SieberthAachen. FRG

I. TarabaBudapest. Hungary

G.ThielBasel, Switzerland

D. W.ThoenesMainz, FRG

D.ThomsonEdinburgh. UK

A. ValekPraha, Czechoslovakia

L. A. Van EsLeiden. The Netherlands

A. J. WingLondon. UK

P. ZucchelliBologna. Italy

Springer International

Dow



Author Index to Volume 4

Aartsen E (abst) 751,754Abbott F, Jones S, Lockwood C M, Rees A J:

Autoantibodies to Glomerular Antigens in Patientswith Wegener's Granulomatosis 1

Abboud H (abst) 426Abdel Ghafler H (abst) 595Abdelhamid S: See Rockel A et al.Abendroth K: See Stein Get al.Aber G M: See Bennett-Jones D N et al.Abouna G M (abst) 589,591,592,594,597,599Abourachid H (abst) 432Abramowicz D (abst) 497,517Ackrill P: See Pickering S J et al.Adachi T (abst) 489Adafer E (abst) 510AduD(abst) 313,314AduD (letter) 758Adu D: See Beaman M et al.Adu D: See Crowson M C et al.Afrasiabi M (abst) 476Agishi T (abst) 485Aguado S, Fdez B de Quiros J, Marin R, Gago E, Gomez E,

Fdez-Vega F, Alvarez Grande J: Acute MercuryVapour Intoxication: Report of Six Cases 133

Aguilo J: See Morales-Barria J et al.Ahipasoglu Y (abst) 590Ahmad T, Coulthard M G, Eastham E J: Reversible Renal

Failure due to the Use of Captopril in a Renal AllograftRecipient Treated with Cyclosporin 311

Ahmed J (abst) 835AimoG(abst) 441Airaghi C (abst) 417Airaghi C: See Colussi G et al.Ait-Slimane A (abst) 499AjzenH(abst) 461,487Akiba T (abst) 467,475Akira Yoshida, Hiroaki Aoki, Seinosuke Nakagawa,

Mitsuo Ogura, Kiyoshi Ozawa, Takao Shoji, TakuoSasaoka: Granulocyte Elastase and a,-ProteaseInhibitor in Dialysis Patients With or Without CarpalTunnel Syndrome S3:134

Akisawa T (abst) 494Akiyama T (abst) 467Akizawa T, Koshikawa S, Nakazawa R, Yoshida T,

Kaneko M, Nitadori Y: Elimination of B,-Microglobulin by a New Polyacrylonitrile MembraneDialyser: Mechanism and Physiokinetics 356

Al-Asfari R (abst) 593Al-Haj K (abst) 597Alaupovic P (abst) 448Albano J D M: See Waters M R et al.

Albers C (abst) 458Albertazzi A (abst) 448AlbrechtKH(abst) 502,521Alegre M (abst) 517Alessio B: See Roccatello D et al.Alessio M: See Roccatello D et al.AlexandreGPJ(abst) 506Alexopoulos A (abst) 594Alexopoulos E, Seron D, Hartley R B, Nolasco F,

Cameron J S: The Role of Interstitial Infiltrates in IgANephropathy: A Study with Monoclonal Antibodies. . 187

Alfani D (abst) 518Alfieri R (abst) 455Algra P R (abst) 751Ali Asghari M (abst) 591,595Alinovi R: See Buzio C et al.Alivanis P (abst) 482,514Aljama P (abst) 451,452,480,489,491Allende M T (abst) 468Alliapoulos J C: See Leichter H E et al.Almirall J: See Campistol J M et al.Alsabadani B (abst) 473Alsina J (letter) 675, 839Altmann P (abst) 518Altmann P (letter) 759Altmann P: See Cunningham J et al.Altmann P: See Sawyer N et al.Altomonte M: See Sabbatini M et al.Altunkans (abst) 518,590,591,593,594, 595,597,598,600,601Alvarez de Buergo M: See Praga M et al.Alvaro F (abst) 500Amin N S: See Sweny P, et al.Amir-Ansari B (abst) 595, 599Amiransari B (abst) 588Amore A (abst) 423,424,430,440,470,490Amore A: See Coppo R et al.Amore A: See Roccatello D et al.Amorim M P S (abst) 461Amoroso A (abst) 440,441,442Amoroso A: See Coppo R et al.Amprimo A (abst) 440Amprimo M C: See Roccatello D et al.Amraoui Z (abst) 497,517Amrein C (abst) 459Anastasio P (abst) 416,455Andersen C B (abst) 502,670Andersen H K (abst) 672Anderson J V (abst) 420Ando R (abst) 467Andre M (abst) 488Andres A: See Praga M et al.

Dow




Andreu J (abst) 492,502,517Andreucci V E (abst) 450,516

See Fuiano G, et al.Andreucci V E: See Sabbatini M et al.Andrew S M: See Hamdy N A T et al.Andrulli S: See Buzio C et al.Antonaci S abst) 430Antonov S (letter) 75,602Antonsen S (abst) 671,673AntonucciF(abst) 485Aparicio M (abst) 513Apostoli P (abst) 486Apperl A (abst) 488, 508Araj G (abst) 594, 597Aranda P (abst) 435Arap S (abst) 504, 507Arfeen S (abst) 470,495,833Argiles A (abst) 492Argiles A: See Mourad G et al.Aris L: See Morales-Barria J et al.AriszL(abst) .' . 420,450,498,501,752,754,755Arisz L: See Koopman M G et al.Arndt R (abst) 520Aroldi A (abst) 508,514Arrobas M (abst) 496Arslan G (abst) 593, 597Asghar S S (abst) 450Asskari A (abst) 599Ataman R (letter) 760Atkin S L, Tomson C R V, Venning M C: Life-threatening

Captopril-induced Hyperkalacmia in a Patient onContinuous Ambulatory Peritoneal Dialysis 1084

Atkins R C (abst) 492Attman P-0 (abst) 448AuerJ(abst) 833Aurell M (abst) 447Aurisch R (abst) 487Ausserwinkler M (abst) 145, 149Averbukh Z: See Modai D et al.AwadJ(abst) 428AyedK(abst) 593AyedM(abst) 599Azoulay E (abst) 494Bach J F (abst) 514Bach PH (abst) 448Bachetoni A (abst) 518,520Bahari C (abst) 439Bahner U (abst) 463Baker F (abst) 515,835Baker F: See Jenkins D et al.Baker K: See Bennett-Jones D N et al.Baker L R I: See Edmunds M E, et al.Baker L R I (abst) 495, 833Bakkaloglu M (abst) 594Bakkeren A J M (abst) 754BakrA(abst) 595Balcke P (abst)

147,148,150,151,153,154,456,478,483,488,508,511,518,596

Balcke P: See Biesenbach G et al.Baldet P: See Canaud B et al.Balkanci F (abst) 594BallaA(abst) 482Ballardie F W (abst) 831Ballarin J A (abst) 438,439Ballesta A M (abst) 449

iii

Balletta M: See Fuiano G et al.Balzar E (abst) 145,446Bambauer R (abst) 446BanfiG(abst) 508Bangsgaard Pedersen F (abst) 671Bangsgaard Pedersen F (letter) 676Barany P (abst) .471,478Barbiano di Belgiojoso G (abst) 426Barcelo P (abst) 438,439Bariety J (abst) 472Barnaba A (abst) 485Barnas U (abst) 473Barnes A D: See Crowson M C et al.Barocci S (abst) 517Baronti A: See Grazi G et al.Barradas M A: See Sweny P et al.Barrientos A (abst) 506Barrientos A (letter) 840Barrio V (abst) 451,480,489,491Barros E J G (abst) 448Barsoum R (abst) 600Bartolomeo F (abst) 439Basile C (abst) 470Basolo B (abst) 430,512Bassett A (abst) 458Bassett A H (abst) 316BassiS(abst) 497Bastin G: See Cappello M et al.Bataille P (abst) 432Bateman J M: See Harrison N A et al.Bateson K (abst) 832BatgeB(abst) 520Baudin G: See Floege J et al.Baumann G (abst) 501Baumelou A (abst) 464Baumgartl P (abst) 154Baur X: See Rockel A et al.Baurmeister U, Vienken J, Daum V: High-flux Dialysis

Membranes: Endotoxin Transfer by Backfiltration canbe a Problem S3:89

Bausewein K (abst) 464Baysal C (abst) 590Baz M (abst) 452BeamanM(abst) 313,314Beaman M, Michael J, MacLennan I C M, Adu D:

T-Cell-Independent and T-Cell-DependentAntibody Responses in Patients with Chronic RenalFailure 216

Beardsworth S F, Vernon V, Harrison D, Fructosamines inUraemia and Renal Replacement Therapy 748

Beastall G (abst) 318Beaufils M (abst) 419Becquemont L (abst) 443Bedair A (abst) 600Bedani P L (abst) 513Beelen R H J (abst) 755Belbrik S: See Moriniere Ph et al.Belechri A M (abst) 469Belghiti J (abst) 438Bellas C (abst) 423,428Bellini L (abst) 455Bellizzi V (abst) 450Bello I: See Praga M et al.Belpaire F (abst) 754Beltrame G (abst) 486Ben Abdallah T (abst) 593, 599

Dow



Ben Ayed H (abst) 593Ben Ayed H A (abst) 599Ben Ayed H E (abst) 599Ben-ArieJ(abst) 458,463Benarbia S (abst) 591Benazzi E (abst) 417Benazzi E: See Colussi G et al.Bender-SabelkampfH(abst) 145Bendjelloul A (abst) 499Bennett S E: See Jenkins D et al.Bennett-Jones D N, Aber G M, Baker K: Successful

Pregnancy in a Patient Treated with ContinuousAmbulatory Peritoneal Dialysis 583

Benoit G (abst) 510Benoliel D: See Lock P M et al.Benton M: See Smith W G J et al.Benzakour M: See Vincent D et al.Beraud J J: See Canaud B et al.Berg U (abst) 432Bergbreiter R: See Mann J F E et al.Berger F: See Gamier J L et al.Bergerone S (abst) 465Bergmann M (abst) 473Bergot C (abst) 432Bergstrom J (abst) 471,478Bergstrom J: See Lindholm B et al.Bergstrom R: See Hanas E et al.Berisa F: See Crowson M C et al.Berland Y (abst) 452Berlin Y (abst) 464Berloco P (abst) 518Bernheim J (abst) 417Bernheim J (abst) 421,439,453,457Bernieh B (abst) 492Bernstein K (abst) 462Berquier F (abst) 485Bertani T (abst) 426Berthet P (abst) 454Berthoux F: See Guerin C et al.Bertoli S (abst) 426Bessalem S (abst) 591Bessho M (abst) 475Better O S (abst) 458,463Betuel H: See Gamier J L et al.Bewick M (abst) 319,838Bewick M: See Henning P H et al.Bianchi A M (abst) 424Bianchi A M: See Grazi G et al.Bianco O (abst) 437Biesenbach G (abst) 145, 148,511Biesenbach G, Zazgornik J, Kaiser W, Stoger H, Derfler K,

Balcke P, Hauser Ch: Cyclosporin Requirement DuringPregnancy in Renal Transplant Recipients 667

Bijman J T (abst) 445Bilgin N (abst) 518,590,591,593,598,600,601Bilo H J G (abst) 459,511Binda P (abst) 440,442BindiP(abst) 499Binswanger U (abst) 509Bird A G (abst) 832Birtwistle R J (abst) 314Bittar A E, Ratcliffe P J, Richardson A J, Brown R C,

Woodhead J S, Morris P J: Hyperparathyroidism,Hypertension and Loop Diuretic Medication in RenalTransplant Recipients 740

Bittner K (abst) 509


Blaehr H (abst) 670Blanc N: See Gamier J L et al.Blohme I (abst) 510Bloom S R (abst) 463Blum W (abst) 451Blumenstein M, Ziegler-Heitbrock H W L, Schiller B,

Schmidt B, Ward R A, Gurland H J: Activation ofMononuclear Cells by Aqueous Extracts from Hollow-fibre Haemodialysers 569

Blumenstein M: See Bosch Th et al.Bobrie G (abst) 438

See Pochet J-M et alBobrie G: See Kleinknecht D et al.Bochenek A (abst) 505Bock A: See Raine A E G et al.Boelaert J (abst) 480,754Boelaert J R (letter) 676Boelaert J R, De Smedt R A, De Baere Y A, Godard C A,

Matthys E G, Schurgers M L, Daneels R F, Gordts B Z,Van Landuyt H W: The Influence of CalciumMupirocin Nasal Ointment on the Incidence of S.Aureus 278

Boer P, Koomans H A, Boer W H, Dorhout Mees E J:Urinary Angiotensin Excretion During SodiumRestriction and Diuretics 713

Boer W H: See Boer P et al.Boer W H: See Rabelink A J et al.Boero R(abst) 512Boeschoten E W (abst) 498,501,752,755Bogaert A M (abst) 483,484Bogaert M (abst) 754Boggio-Bertinet D (letter) 238Bogicevic M (abst) 444Bogin E: See Modai D et al.Bohdanecka M (abst) 457Bohler J (abst) 416,454Bohler J, Hauenstein K-H, Hasler K, Schollmeyer P: Renal

Vein Thrombosis in a Dehydrated Patient on an OralContraceptive Agent 993

Bohler J: See Keller E et al.Bohman S-0 (abst) 447BoimMA(abst) 448,454,516Boitard C (abst) 514Boletis J: See Hamdy N A T et al.Bolli P: See Raine A E G et al.Bommer G (abst) 471BommerJ(abst) 471,489Bommer W (abst) ' 453Bone J M (abst) 444,445Bone JM (letter) 917Bone J M: See Williams P S and Bone J MBonello F (abst) 486Boner G: See Cohen S L et al.Bonomelli D (abst) 440Bonzel K E (abst) 495Boogaerts M A (abst) 479Borelli I (abst) 440,441Borgialli R: See Roccatello D et al.Borris L C (abst) 673Bos HJ (abst) 755Bosch Dr (letter) 839Bosch FH (letter) 239Bosch R J (abst) 503Bosch Th, Blumenstein M, Gurland H J:

Biocompatibility—Review and Ex VivoEvaluation S3:41

Dow




Bosman F T:See Knols G et al.Botey A.See Campistol J M et al.Boucher A (abst) 510Boudaillez B (abst) 432,467Boudailliez B: See Moriniere Ph et al.Bouillon R (abst) 432BoultbeeJE(abst) 447,508Boulton-Jones J M (abst) 831Boulton-Jones J M: See Sutcliffe N P et al.Bourdon R (abst) 470Bowley J A: See Pickering S J et al.Brabant E G (abst) 478Brady A J B and Wing A J: Hyperpigmentation due to

Cyclosporin Therapy 309Brandi L (abst) 480, 672Brando B (abst) 481Branger B (abst) 473Branger B: See Floege J et al.Braquet P: See Mampaso F M et al.Braquet P (abst) 448,516BraunW(abst) '. 495Breborowicz A (abst) 498Breddin K (abst) 473Bregman R (abst) 454,487,516Breitenfellner P (abst) 144,153,154Brenchley P E: See Short C D et al.Brenchley P E C (abst) 831Brewer Y (abst) 319,838Brezis M (abst) 417Bricio T (abst) 423,428Bricio T: See Mampaso F M et al.Bridges J M (abst) 420, 476Bridges J M: See Brown J H et al.Briggs J D (abst) 318Bright C: See Coles G A et al.Brindley F (abst) 512Brocklebank J T: See Heney D et al.BrockmollerJ(abst) 477Bronswijk H v (abst) 752Brooke 1 P: See Dische F E et al.Broomhead V (abst) 832Brown A L (abst) 495,833Brown C B: See Hamdy N A T et al.Brown C B: See Smith W G J et al.Brown E A (abst) 318,495Brown E A: See Sethi D et al.Brown J H, Lappin T R J, Elder G E, Taylor T N, Bridges

J M, McGeown M G: The Initiation of ErythropoiesisFollowing Renal Transplantation 1076

Brown R C: See Bittar A E et al.Browne D (abst) 317Browne O: See O'Meara Y et al.Brownjohn A M: See Young G A et al.Broyer M: See Brunner F P et al.; Ehrich J H H et al.;

Tufveson G et al.Broyet C: See Guerin C et al.BruckS (abst) 151Bruggeman C A (abst) 521Bruijn J A (abst) 423,424,425Brunati C (abst) 472,481Bruneval P (abst) 472Brunkhorst R (abst) 433Brunkhorst U (abst) 433Brunner F P, Fassbinder W, Broyer M, Brynger H,

Dykes S R, Ehrich J H H, Geerlings W, Rizzoni G,Selwood N H, Tufveson G, Wing A J: Combined Report

on Regular Dialysis and Transplantation in Europe,XVIII, 1987 S2:5

Brunner F P: See Ehrich J H H et al.; Raine A E G et al.;Rizzoni G et al.; Tufveson G et al.; Zuber M et al.

Brunori G: See Maiorca R et al.Brynger H (abst) 510,521Brynger H: See Brunner F P et al.; Ehrich J H H et al.;

Rizzoni G et al.; Tufveson G et al.Buchholz B (abst) 521Buczko W (abst) 452Buhler F R: See Raine A E G et al.BullaM(abst) 446BulutO(abst) 518,591,592,594,597,601Bunzendahl H (abst) 511Burden RP (abst) 435Burdiel L G (abst) 451,489Burger E (abst) 440Burnett JCJr (abst) 463Burnie J: See Pickering S J et al.Burton P R: See Jenkins D et al.Burton P R: See Williams B et al.Busch R (abst) 520Busing M (abst) 597Butter K C: See Cunningham J et al.BuzioC(abst) 429Buzio C, Mutti A, Capani F, Andrulli S, Perazzoli F,

Alinovi R, Negro A, Rustichelli R: CircadianRhythm of Proteinuria: Effects of an Evening MeatMeal 266

Bygren P, Cederholm B, Heinegard D, Wieslander J: Non-Goodpasture Anti-GBM Antibodies in Patients withGlomerulonephritis 254

Cabello M (abst) 435Cada E, Karnel F, Mayer G, Langle F, Schurawitzki H,

Graf H: Percutaneous Transluminal Angioplasty ofFailing Arteriovenous Dialysis Fistulae 57

Cada EM (abst) 146, 147Caglar S (abst) 594,601Cahen R, Francois B, Trolliet P, Gilly J, Parchoux B:

Aetiology of Membranous Glomerulonephritis: AProspective Study of 82 Adult Patients 172

Cairns H S (abst) 835Caldara R (abst) 507Calero F (abst) 439Callard P: See Kleinknecht D et al.Callebert J (abst) 480Cambar J (abst) 513Cambi V: See David S et al.Cambridge G (abst) 832Camerini R: See Maiorca R et al.Cameron J S (abst) 426Cameron J S: See Alexopoulos E et al.Cameron J S: See Cheng H-F et al.Camilleri J P (abst) 472Campanini M(abst) 431Campbell E: See O'Meara Y et al.Campbell T (abst) 444Campioli D (letter) 1083Campise M: See Casati S et al.Campistol J M (abst) 492,502,517Campistol J M, Almirall J, Montoliu J, Revert LI:

Electrographic Alterations Induced by HyperkalaemiaSimulating Acute Myocardial Infarction 233

Campistol J M, Galofre J, Botey A, Torras A, Revert LI:Reversible Membranous Nephritis Associated withDiclofenac 393

Dow



Campistol J M: See Lens X M et al.Camussi G (abst) 491Canaud B (abst) 482Canaud B, Beraud J J, Mion C, Baldet P, Mimran A:

Successful Treatment of Legionella-associatedHaemolytic Uraemic Syndrome with Acute RenalFailure and Malignant Hypertension by Prostacyclin(Epoprostenol) 995

Canaud B, Nguyen Q V, Garred L J, Nicholle R, Mion C:Germicidal Effectiveness of Dialox, A New StablePeroxyacetic Acid Solution, in the Re-use of High-FluxDialysers 999

Canavese C (abst) 442,466,467Cancarini G C: See Maiorca R et al.Canepa A (abst) 497Cannata B (abst) 468Cannata J B (abst) 468Cantaluppi A (abst) 475,490,496Cantarovich D (abst) 503Capaldo B (abst) 450Capani F: See Buzio C et al.Capasso G (abst) : 416,455Capdeville P (abst) 445Cappelli P (abst) 448Cappellini M D (abst) 472Cappello M, De Pauw L, Bastin G, Prospert F, Delcour C,

Thaysse C, Dhaene M, Venherweghem J L, Kinnaert P:Central Venous Access for Haemodialysis Using theHickman Catheter 987

Caravaca F (abst) 496Carayon A (abst) 464Carey C (abst) 477Carlisle E (letter) 237Carlsen O (abst) 673Carlsson M (abst) 417Carmody M: See O'Meara Y et al.Carozzi S (abst) 475,490,496,517Carpentier A (abst) 459Carthy J (abst) 452Caruso A (abst) 513Cary N R B: See Sethi D, et al.Casadevall N (abst) 472Casadevall N (letter) 675Casado S (abst) 503Casarosa L (abst) 424Casati S, Campise M, Crepaldi M, Lobo J, Graziani G,

Ponticelli C: Haemodialysis Efficiency After Long-Term Treatment with Recombinant HumanErythropoietin 718

Casciani C U (letter) 76Casciani C U: See Taccone-Gallucci M et al.Cases A (abst) 449Cases A: See Lens X M et al.Cashman S J (abst) 314,315,837Cashman S J: See Dische F E et al.Cashman S J: See Sutcliffe N P et al.Caslake M (abst) 831Cassader M (letter) 238Castelao A M (letter) 675Castellani A (abst) 497Castelnovo C (abst) 496,514Castillo D (abst) 451,452,480,489,491Castillo R (abst) 449Cattell V (abst) 315,836Cattell W R (abst) 420,466,495,836Catto G R D (abst) 838


Caudwell V (abst) 492Cavaillon J-M (abst) 480Cavalli G (abst) 440Cavalli G: See Roccatello D et al.CavigliaMP(abst) 475,496Caviglia P M (abst) 517Ceballos I (abst) 450Cecchin E (abst) .433,489Cederholm B: See Bygren P et al.Cenci A M (letter) .1083Cesana B: See Passerini Patrizia et al.Chan C Y: See Chan M K et al.Chan M K, Chan P C K, Cheng IP K, Chan C Y, Ng W S F:

Pseudomonas Peritonitis in CAPD patients:Characteristics and Outcome of Treatment 814

Chan M K, Chan P C K, Wong K, K, Cheng IK P, Li M K,Chang W K.: Hepatitis B Infection and RenalTransplantation 297

Chan P C K : See Chan M K et al.Chanard J (abst) 438,492Chanard J, Toupance O, Lavaud S, Jaisser F, Gillery P:

Serum p2 Microglobulin and Extracellular FluidVolume During Haemodialysis 549

Chang W K: See Chan M K et al.Channon S M (abst) 454Channon S M: See Tomson C R V et al.Chantler C (abst) 313Chantler C: See Clarke A G B et al.Chantler C: See Henning P H et al.Chapuis-Cellier C: See Gamier J L et al.Charbonnel B (abst) 503Charmes J P: See Vincent D et al.Charpen tier B (abst) 510Chauveau P (abst) 450,480Chen-Gal B (abst) 513Cheng H-F, Nolasco F, Cameron J S, Hildreth G, Neild G,

Hartley B: HLA-DR Display by Renal TubularEpithelium and Phenotype of Infiltrate in InterstitialNephritis 205

Cheng I K P: See Chan M K et al.Cheng I P K: See Chan M K et al.Cheriex EC, Leunissen K M L , Janssen J H A,

Mooy J M V, van Hooff J P: Echography of the InferiorVena Cava is a Simple and Reliable Tool for Estimationof'Dry Weight'in Haemodialysis Patients 563

Cheriex E C: See Leunissen K M L e t al.ChidaY(abst) 467ChleqC(abst) '. 454Christensen L A, Schmidt E B, Mortensen P B, Hojhus J H:

Pneumatosis Intestinalis in a Patient on ChronicHaemodialysis Treatment 745

Chrzanowski W (abst) 451Chugh K. S (letter) 157Chugh K S: See Pereira B J G et al.Chung T G: See Ogawa H et al.Cianciaruso B (abst) 450Ciccarelli M (abst) 468Cierniewski C S (abst) 451CintiP(abst) 518,520Cirami C (abst) 424Cirami C: See Grazi G et al.Cirillo D (abst) 455Ciscato M (abst) 485Citti G: See Taccone-Gallucci M et al.Civati G (abst) 472,481,488Cizman B (abst) 593

Dow




Clark A G B (abst) 313Clark A G B, Oner A, Ward G, Turner C, Rigden SPA,

Haycock G B, Chantler C: Safety and Efficacy ofCalcium Carbonate in Children with Chronic RenalFailure 539

Clark W F (abst) 477Clarke B F (abst) 317,436Coad N A G (abst) 313,433Coakley J (abst) 444Cobo M E: See Mampaso F M et al.Cocchi R (abst) 433Cochlin D L (abst) 319Cohen S L (abst) 317Cohen S L, Boner G, Shmueli D, Yusim A, Rosenfeld J,

Shapira Z: Cyclosporin: Poorly Tolerated in FamilialMediterranean Fever 201

Cohen S L: See Woolf A S et al.Cohen Solal M: See Moriniere Ph et al.Cohen Solal M E (abst) 467Cohn M: See Modai D et al..Colantonio G (abst) 487Coles G A (abst) 318,319,476Coles G A, Meadows J H, Bright C, Tomlinson K: The

Estimation of Dietary Protein Intake in Chronic RenalFailure 877

Coles G A: See Smith W G J et al.Colhoun E N: See Madden B et al.Colizzi M (abst) 430Collart F (abst) 497Collart F E: See Tielemans C L et al.Colussi G (abst) 417Colussi G (letter) 678Colussi G, Rombola G, Surian M, De Ferrari M E, Airaghi

C, Benazzi E, Malberti F, Minetti L: Effects of AcuteAdministration of Acetazolamide and Frusemide onLithium Clearance in Humans 707

Colussi G: See Surian M et al.Comans E F I (abst) 418Comberti E: See Vigano G et al.Comi N: See Fuiano G et al.Cominotto R: See Grazi G et al.Conte G: See Sabbatini M et al.Come JJ (abst) 434Cook D (abst) 470CookHT(abst) 315Cook T (abst) 836Coolen L (abst) 479CoppoB(abst) 424CoppoR(abst) 423,430,440,470,490Coppo R: See Roccatello D et al.Coppo R, Amore A, Roccatello D, Amoroso A, Maffei S,

Quattrocchio G, Molino A, Gianoglio B, Piccoli G:Complement Receptor (CR1) and IgG or IgA onErythrocytes 932

Coppola S (abst) 416,455. Copur M S (abst) 601Corbetta C (abst) 497Cordes M (abst) 436Cordonnier D (abst) 421Cordonnier D (letter) 839Cordy P E (abst) 477Coronel F (letter) 840Corradi B: See Surian M et al.Cortesini R (abst) 518,520Corver W E (abst) 424Coscarella G (abst) 416,455

Cosseddu D (abst) 437CosynsJP(abst) 434,506Cotes P M (abst) 833Couetil J P (abst) 459Coulthard M G: See Ahmad T et al.Coupes B M: See Short C D et al.Courteau M (abst) 429,837Couttenye M (abst) 479Cowan P (abst) 317,436Cowie J F: See Jenkins D A S et al.Craig K(abst) 317Crepaldi M: See Casati S et al.Crevat A (abst) 452Cristinelli L (abst) 441Crowson M C, Berisa F, McGonigle R J S, Adu D,

Michael J, Barnes A D: Selective Conversion fromAzathioprine to Cyclosporin for Steroid-resistantRejection in Renal Transplants: An AlternativeTherapy 129

Cubero J J (abst) 496Cumming A D (abst) 481Cunningham J (abst) 428,477,518Cunningham J (letter) 759Cunningham J: See Edmunds M E et al.Cunningham J: See Sawyer N et al.Cunningham J, Altmann P, Gleed J H, Butter K. C, Marsh

F P, O'Riordan J L H: Effect of Direction and rate ofChange of Calcium on Parathyroid Hormone Secretionin Uraemia 339

Curatola A (abst) 468Curatola G (abst) 492Curtis J R: See Sampson B et al.Cutrupi S (abst) 492Cuzzola F (abst) 463,468Dadah S (abst) 594Daelemans R (abst) 479DagenM(abst) 831DahaMR(abst) 521Dal Canton A (abst) 516Dal Canton A: See Sabbatini M et al.Dall'AglioPP(abst) 429D'Amico G (abst) 431Danby P (abst). . . 834Danby P (letter) 918-19Daneels R (abst) 754Daneels R F (letter) 676Daneels R F: See Boelaert J R et al.Daniel V (abst) 506Daniel WG (abst) 478Darvili A (abst) 831Da Silva J L (abst) 472Daugaard H (abst) 480, 672Daum V: See Baurmeister U et al.Davenport A (abst) 443,503,512Davenport A, Will E J, Davison A M: The Effect of

Lactate-Buffered Solutions on the Acid-Base Status ofPatients with Renal Failure 800

David B(abst) 480David S, Tagliavini D, Cambi V: Pre-postdilution

Haemofiltration 37David-Neto E (abst) 504Davies J A: See Hopper A H et al.Davies M (abst) 419,427Davies M E (abst) 319,476Davies S: See Sampson B et al.Davison A M (abst) 435,443,503,512

Dow



VIII

Davison A M: See Davenport A et al.Davison A M: See Worth D P et al.DawesJ(abst) 481Dawnay A (abst) 420,466,836De Backer W A: See Heyrman R M et al.De Baere Y A: See Boelaert J R et al.De Baz H (abst) 485De Bock V, Verbeelen D, Meas V, Sennesael J:

Pharmacokinetics of Vancomycin in PatientsUndergoing Haemodialysis and Haemofiltration.... 635

De Broe M E (abst) 479De Broe M E: See Heyrman R M et al.De Broe M E: See Van de Vyver F L et al.de Paepe M (abst) 753de Vinuesa S G (abst) 484Decaux G (abst) 421Deelder A (abst) 431De Ferrari M E (abst) 417De Ferrari M E (letter) 678De Ferrari M E: See Colussi G et al.de Fijter C W H (abst) 418,752,755Defregger M (abst) 149, 151,152Degli Esposti E (abst) 433Delcour C: See Cappello M et al.Delgado A (abst) 514Delons S (abst) 480Del Principe D: See Taccone-Gallucci M et al.delRio G (abst) 438Delvallez L (letter) 76Demaine A G (abst) 313De Marchi S (abst) 433,489De Maria G (abst) 486De Meyer M (abst) 434,481De Nicola L (abst) 516De Nicola L: See Sabbatini M et al.de Nicolas R (abst) 427Denis M C (abst) 421Denneberg T (abst) 417,434De Oleo P (abst) 506De Pauw L (abst) 517De Pauw L: See Cappello M et al.DepierreuxM (abst) 517De Plaen J F (abst) 444,493Deppisch R (abst) 489Deray G (abst) 464Derfler K (abst) . . . 150,151,153,154,456,483,488,511,518Derfler K: See Biesenbach G et al.Derveniotis V (abst) 482,514DeSanto N G (abst) 416,455Deschodt G (abst) 473Deschodt G: See Floege J et al.Deschodt-Lanckman M (abst) 517Deschryver F: See Najean Y et al.Desgres J (abst) 500DeSimone G (abst) 455De Smedt R A: See Boelaert J R et al.De Sousa C: See Rogerson M E at al.DeTommaso G (abst) 416Devaux S (abst) 487De Vecchi A (abst) 496, 514DewarJ(abst) 470Dewar J H: See Rodger R S C et al.Dhaene M: See Cappello M et al.D'Haese P C: See Van de Vyver F L et al.Dharmasena A D (abst) 318Dharmasena A D: See Smith W G J et al.


Diaz-Tejeiro R, Diez J, Maduell F, Esparza N, Errasti P,Purroy A: Successful Treatment with Ciprofloxacin ofMultiresistant Salmonella Arthritis in a RenalTransplant Recipient 390

Dibble J B: See Young G A et al.Di Carlo V (abst) 507DienstI E (abst) 148DietlP(abst) 149,152Diez J (abst) 443Diez J: See Diaz-Tejeiro R et al.Diles K (abst) 594, 598Dion R (abst) 481Disch F (abst) 838Dische F E, Brooke IP, Cashman S J, Severn A, Taube D,

Parsons V, Kershaw M, Reed A, Pusey C D: Reactivityof Monoclonal Antibody PI with Glomerular BasementMembrane in Thin-Membrane Nephropathy 611

Dittmer R (abst) 520Dittrich P (abst) 149,151,152,154DocheC(abst) 460Dodds R A (abst) 419Doerge L (abst) 512Dogliani M (abst) 442,466Doherty C C (abst) 438Doherty C C (letter) 237DonkerAJ(abst) 455DonkerAJM(abst) 418,422,457,459,511,752Donohoe J: See O'Meara Y et al.Donohoe M (abst) 435Doorenbos C J (abst) 751Dorhour Mees E J: See Rabelink A J et al.Dorhout Mees E J: See Boer P et al.Dosquet P: See Rondeau E et al.Dossetor J B (abst) 428Doubma S N (abst) 462Douglas J F (abst) 476Doumas M N (abst) 462Drachman R, Isacsohn M, Rudensky B, Dmkker A:

Vaccination against Hepatitis B in Children andAdolescent Patients on Dialysis 372

Draibe S A (abst) 448,454,461,487,516Dratwa M (abst) 497Dratwa M: See Tielemans C L et al.DrechslerU (abst) 455DreschlerWD(abst) 752Dreyfus G (abst) 459Dreyling K W (abst) 418,472Drif M (abst) 499Drinovec J (abst) 593,599DrozD(abst) 510Drueke T (abst) 470Drueke T: See Najean Y et al.DruetP(abst) 427,517Drukker A: See Drachman R et al.Drukker W: The Founding of the EDTA: Facts and

Lessons 401DubbelmanR(abst) 751,754Dubernard J M: See Gamier J L et al.Dubois M (abst) 454Dubost C (abst) 470Dueymes J M (abst) 434Dulawa J (abst) 505Dumann H (abst) 424, 520Duncker W D: See Waldherr R et al.Dupuy C A (abst) 482Duquel(abst) 515

Dow




Dykes S R: See Brunner F P et al.; Ehrich J H H et al.;Rizzoni G et al.; Tufveson G et al.

Eadington D (letter) 77Earle K (abst) 317Eastham E J: See Ahmad T et al.Eckardt K-U: See Kindler J et al.Edefonti A (abst) 497Edmunds M E: See Williams B et al.Edmunds M E, Walls J, Tucker B, Baker L R I, Tomson

C R V, Ward M, Cunningham J, Moore R, WinearlsC G: Seizures in Haemodialysis Patients Treated withRecombinant Human Erythropoietin 1065

Edwards B S (abst) 463Efremidis S C (abst) 463Egfjord M (abst) 673EgidoJ(abst) 423,427,429,512

See Mampaso F M et al.Ehmer B (abst) 474Ehmer B: See Kindler J et al.Ehrich J H H (abst) 425Ehrich J H H, Rizzoni G, Broyer M, Brunner F P,

Brynger H, Dykes S R, Geerlings W, Fassbinder W,Tufveson G, Selwood N H, Wing A J: Combined Reporton Regular Dialysis and Transplantation of Children inEurope, 1987 S2:33

Ehrich J H H: See Brunner F P et al.; Rizzoni G et al.;Tufveson G et al.

Eigler F W (abst) 502, 521Eilles Ch (abst) 464Eisenbach G (abst) 433Eisenbach G M: See Floege J et al.Eiskjaer H (abst) 461,464EklofO(abst) 436Elder G (abst) 419Elder G E: See Brown J H et al.ElEsperN(abst) 418Eliasson K (abst) 462Elli M: See Taccone-Gallucci M et al.Elliott H L (abst) 835El Matri A (abst) 593, 599El Nahas A M (abst) 316,456,458El Nahas A M: Glomerulosclerosis: Insights Into

Pathogenesis and Treatment 843El Nahas A M: See Smith W G J et al.El Ouakdi M (abst) 593El Quakdi M (abst) 599ElsenR(abst) 452Emancipator S N (abst) 426Emanuelsson B-M (abst) 417EmoriT(abst) 467Endler M (abst) 150Enestrom S (abst) 434Engelhardt E (abst) 487Engemann D (abst) 595Englund M (abst) 432

.Era K (abst) 485Erek E (letter) 760Eren Z (abst) 590Erenoglu E (abst) 590Erkan I (abst) 594ErmanA(abst) 513Erne P: See Raine A E G et al.Ernst W (abst) 504Errasti P: See Diaz-Tejeiro R et al.ErtlG(abst) 464Esbrit P: See Manzano F et al.

ix

Escassi A (abst) 480,489Escolar G (abst) 449Esparrago J (abst) 496Esparza N (abst) 443Esparza N: See Diaz-Tejeiro R et al.Esposito A: See Fuiano G et al.Esposito C (abst) 516Esposito C: See Sabbatini M et al.Etienne A (abst) 482Evangelista M (abst) 448Evangelisti R (abst) 513Evans D J (abst) 314,435,832FagelWJ(abst) 751Failla S (abst) 496Fairbanks L D (abst) 835Fairley K E (abst) 831FargeD(abst) 459FarmoA(abst) 487Farradini M (abst) 486FarrellP(abst) 499Fasciolo F (abst) 497Fassbinder W: See Brunner F P et al.; Ehrich J H H et al.;

Noronha I L et al.; Rizzoni G et al.; Tufveson G et al.Fauchald P (abst) 509Faure J L: See Gamier J L et al.Faure M (abst) 421Fauvel J P (abst) 460Faxell(abst) 588FayWP(abst) 477Fazekas F (abst) 474Fazel I (abst) 589Fdez B de Quiros J: See Aguado S et al.Fdezl(abst) 468Fdez JL (abst) 468Fdez-Vega F: See Aguado S et al.Fecht H: See Keller E et al.FeehallyJ(abst) 515,833,834,835FeehallyJ (letter) 918-19Feehally J: See Williams B et al.Feest T G (abst) 435Felix R (abst) 436Feller P (abst) 486Feller P: See Maiorca R et al.Fellstrom B: See Hanas E et al.Ferhaoui S (abst) 591Fernandez C (abst) 438,439Fernandez E (letter) . 8 4 0Fernandez Martin J L (abst) 468Fernandez Mdez M J (abst) 468Fernando O N: See Lui S F et al.Fernando O N: See Sweny P et al.Ferradini M (abst) 487Ferrari G (abst) 507Ferrario F (abst) 425Fervenza F (abst) 472Fianchino O (abst) 442FichC(abst) 434Fiegel P: See Rockel A et al.Fieren M W J A (abst) 751FiersW(abst) 497Fievet P (abst) 418FilellaX(abst) 449Fine R N: See Leichter H E et al.Fiocchi O (abst) 513FiorelliG(abst) 472Fischbach M (abst) 482

Dow



X

Fitting C (abst) 480FjeldborgO(abst) 670Flatmark A (abst) 509FlavierJL(abst) 482Fleming S (abst) 315,835Fleming S, Jones D B, Moore K: B-cell Markers in the

Human Kidney 85Fleming S J: See Pickering S J et al.Fleuren G J (abst) 423,424FloegeJ(abst) 422,425,493Floege J, Granolleras C, Deschodt G, Heck M, Baudin G,

Branger B, Tournier O, Reinhard B, Eisenbach G M,Smeby L C, Koch K M, Shaldon S: High-Flux SyntheticVersus Cellulosic Membranes for P2-MicroglobulinRemoval 653

Floege J. Granolleras C, Shaldon S, Koch K M: Dialysis-related Amyloidosis: Pathogenetic Aspects and OpenQuestions S3:3

Floren T (abst) 469FodaM(abst) 519Foged N (abst) 672Fogh-Andersen N (abst) 504,672Forman E (abst) 472Formica M (abst) 470,490,512Forneris G (abst) 512Forsythe J L R: See Kirby J A et al.Fort J (abst) 493Foulon T (abst) 421Fournier A (abst) 418,432,467Fournier A: See Moriniere Ph et al.Fox J G: See Sutcliffe N P et al.Fracasso A R: See Pertosa G et al.Frampton G (abst) 426Franco A (abst) 486Francois B: See Cahen R et al.Frankenschmidt A (abst) 418Franklin H (abst) 751,754Franks C R (abst) 445Freestone S: See Jeffrey R F et al.Frei D (abst) 509FreiU(abst) 478,511Frenken L A M , Verberckmoes R, Michielsen P, Koene

RAP: Efficacy and Tolerance of Treatment withRecombinant-Human Erythropoietin in Chronic RenalFailure (Pre-Dialysis) Patients 782

Fries D (abst) 510Fritschka E (abst) 477FrohlingPT(abst) 451,453Frutos M A (abst) 435FryczJ(abst) 505Fuiano G (abst) 516Fuiano G, Stanziale P, Balletta M, Sepe V, Marinelli G,

Comi N, Esposito A, Andreucci V E: Effectiveness ofSteroid Therapy in Different Stages of MembranousNephropathy 1022

Fumiaki Marumo, Yusuke Tsukamoto, Shigeru Iwanami:Trace Elements in Chronic Renal Failure Patients. . S3:97

Fumiaki Marumo: See Yusuke Tsukamoto et al.Fumitake Gejyo, Noriyuki Homma, Masaaki Arakawa,

pVMicroglobulin-derived Amyloid and CalciumDeposition in Dialysis Patients S3:11

Funaro A: See Roccatello D et al.Fursch A (abst) 458Fusaroli M (abst) 433Fyhrquist F (abst) 465Gabl F(abst) 153


Gagliardi L (abst) 442Gago E: See Aguado S et al.Gahl G (abst) 436,498Galato R (abst) 488Gale E A M (abst) 420Gallego A (abst) 444Gallice P (abst) 452Galofre J: See Campistol J M et al.Gammelgaard B (abst) 671Gans R O B (abst) : . 459Ganten D (abst) 460,463Garabedian M (abst) 467Garavaglia G (abst) 462Garbis S (abst) 594, 598Garcia M C (abst) 504Garcia M F (abst) 444Garcia R (abst) 832Garcia-Canero R: See Manzano F et al.Garcia-Ocana A: See Manzano F et al.Gardin J P (abst) 510Gamier J L, Berger F, Betuel H, Vuillaume M, Chapuis-

Cellier C, Blanc N, Faure J L, Dubernard J M, Lenoir G,Touraine J L: Epstein-Barr Virus AssociatedLymphoproliferative Diseases (B Cell Lymphoma)After Transplantation 818

Garofalo A R (abst) 430GarredLJ(abst) 482Garred L J: See Canaud B et al.Garrido M (abst) 449Garvie N (abst) 477Gaskin G (abst) 435, 832Gassner H (abst) 154Gaube S (abst) 459Gaucher A (abst) 494Gaudin O: See Guerin C et al.Geerlings W: See Brunner F P et al.; Ehrich J H H et al.;

Rizzoni G et al.; Tufveson G et al.Geiger H (abst) 463,464,472Geisert J (abst) 482Geissler K (abst) 147Genderini A (abst) .426Gesualdo L (abst) 426Ghatei M A (abst) 463Ghio L(abst) 497Ghods A (abst) 588, 589Ghoneim M (abst) 431,519,595Ghoneim M A: See Moustafa F E et al.Ghysen J (abst) 493Giachino G (abst) 470Giangrande A: See Vigano G et al.Giani M (abst) 497Gianoglio B (abst) 423,424,490Gianoglio B: See Coppo R et al.Giardini O (letter) 76Giardini O: SeeTaccone-Gallucci M et al.Gibson J: See Young G A et al.Gibson-Knight C (abst) 448Gielow P (abst) 493Giesel R (abst) 460GiessaufW(abst) 144Gilbertson A A (abst) 445Giles G R (abst) 503Gilgin N (abst) 598Gillery P: See Chanard J et al.Gilli G (abst) 487Gilly J: See Cahen R et al.

Dow




Gil-Vernet S (letter) 675Giordani M: See Taccone-Gallucci M et al.Giordano D R (abst) 416,455Giraudo G (abst) 430Gisinger C (abst) 151,459GiuraC(abst) 487Gladziwa U: See Ittel T H et al.Glaros D (abst) 470Gleed J H: See Cunningham J et al.Glez-Posada J M (abst) 504GloerD(abst) 416GloorF(abst) 145GludT(abst) 465Gobran H (abst) 600Godard C A: See Boelaert J R et al.GodinM(abst) 419Goksoy E (letter) 760Gol Danesh S (abst) 595Goldfarb B (abst) 483Goldfarb B: See Pochet J -M et al.Goldman M (abst) '. 497,517Golzio P G (abst) 465GomezC(abst) 427,512Gomez E: See Aguado S et al.Gomez-Chiarri M (abst) 427,512Gomez-Tejada E (letter) 840Gonzales R (abst) 513Gonzalez E: See Mampaso F M et al.Gonzalez E (abst) 427,512Gonzalez M T (letter) 675Gonzalez-Cabrero J (abst) 429Goodship T H J (abst) 437,495,833Gordts B Z: See Boelaert J R et al.Goren E: See Modai D et al.Gotti E: See Vigano G et al.Gotz R (abst) 455,464Gouldesbrough D: See Jenkins D A S et al.GowerPE(abst) 318,494,495Gower P E: See Sethi D et al.Grabensee B (abst) 500,514Grady D (abst) 495,833Graf H (abst) 146,147,153,155,473Graf H: See Cada E et al.Grafinger P (abst) 145Graning M (abst) 495Granolleras C (abst) 473Granolleras C: See Floege J et al.Grant A (abst) 835Grant A C (abst) 318GraziG(abst) 424Grazi G, Cirami C, Panichi V, Bianchi A M, Parrini M,

Baronti A, Cominotto R, Montagnani E, Palla R: RenalEffects of Enalapril in Hypertensive Patients withGlomerulonephritis 396

Graziani G (abst) 514Graziani G: See Casati S et al.Grcevska L (abst) 461Green A: See O'Meara Y et al.Greger B (abst) 597Gregg N J (abst) 448Gregoire I (abst) 418Gregorini G (abst) 431Grekas D (abst) 482,514Griegat K P (abst) 595Griffiths R D (abst) 444Gronhagen-Riska C (abst) 465

Grosoli M (letter) 1083Gross M (abst) 462Gross-Heitfeld E (abst) 474Grosse-Wilde H (abst) 502,521Grossi G: See Vandelli L et al.Groszmann R J (abst) 458Griinfeld J P (abst) 419,438,506,514Grunfeld J P: See Pochet J-M et al.Griinfeld J P: See van den Heuvel L P W J et al.Grutzmacher P (abst) 473,474Grzeszczak W (abst) 475, 505Grzeszczak W: See Kokot F et al.Gu J-H (abst) 446Gualde N: See Vincent D et al.Guarena C (abst) 470,512Guastoni C (abst) 481,488Guerin C, Pozzetto B, Broyet C, Gaudin D, Berthoux F:

Ganciclovir Therapy of Symptomatic CytomegalovirusInfection 906

Gueris J (abst) 467Guerra M G (abst) 430Guerra M G: See Roccatello D et al.Guerrero R (abst) 480,489Guery J-C (abst) 427Guiguet M (abst) 500Guillemain R (abst) 459Guivarch P H (letter) 839Gulay H (abst)

518,590,591,592,593,594,595,597,598,600,601Gupta A: See Pereira B J G et al.Gurioli L (abst) 442,466Gurland H J: See Blumenstein M et al.; Bosch Th et al.;

Ward R A et al.Gusmano R (abst) 497Gwyther S J (abst) 447Haberal H (abst) 590Haberal M (abst)

518,591,592,593,594,595,597,598,600,601Habscheid W (abst) 464Habul V (abst) 443Hackenthal E: See Mann J F E et al.HadidiyS(abst) 593Hadj-Aissa A (abst) 445, 456,460Haentjens D (abst) 753Hafez H (abst) 600HaidA(abst) 154Haimovitch L (abst) 439Hajek-Rosenmayr A (abst) 589Halbauer M: See Tomic B H et al.Halilbasic A (abst) 443HalllP(abst) 435Hall T L: See Leichter H E et al.HalloranPF(abst) 428Hamaloglu E (abst) 518,591,594,597,598,601Hamari N (abst) 591Hamdy NAT, Andrew S M, Shortland J R, Boletis J,

Raftery A T, Kanis J A, Brown C B: Fatal CardiacZygomycosis in a Renal Transplant Patient Treatedwith Desferrioxamine 911

Hamdy NAT, Brown C B, Kanis J A: IntravenousCalcitriol Lowers Serum Calcium Concentrations inUraemic Patients with Severe Hyperparathyroidismand Hypercalcaemia 545

Hamdy NAT, McCloskey E V, Naylor V A, Brown C B,Kanis J A: Phosphate Binding Efficiency of a PolyuronicAcid in Normal Subjects 829

Dow



XII

Hanas E, Totterman T H, Fellstrom B, Bergstrom R,Tufveson G: Circulating T-Lymphocyte Sub-Subsetsand NK-Like Cells in Renal Transplant Patients:Patterns Associated with Rejection 735

Hancock K (letter) 759HankeP(abst) 504Hannedouche T (abst) 419,514Hansch G M (abst) 431Hansen H H (abst) 461Hansen J M (abst) 504,672Hansen P R (abst) 502,670Hanson M E (abst) 447, 508Harada T (abst) 426Harding M: See Vienken J, Harding MHarfmann P (abst) 520Harris K P G (abst) 834Harris K P G (letter) 679Harrison D (letter) 77Harrison D: See Beardsworth S F et al.Harrison N A, Masterton R G, Bateman J M, Rainford

D J: C-Reactive Protein in Acute Renal Failure 864Hartley B: See Cheng H-F et al.Hartley G H (abst) 437Hartley R B: See Alexopoulos E et al.Hartter E (abst) 148Harumitsu Kumajai: See Kaoru Onoyama et al.HasibederW(abst) 154Haskova V (abst) 596Hasler K: See Bohler J et al.Hass R (abst) 422Hassan A (abst) 600Hasslacher Ch: See Mann J F E et al.HasslacherCh, Ritz E, Wahl P, Michael C: Similar Risks of

Nephropathy in Patients with Type I or Type IIDiabetes Mellitus 859

Hattersley J (abst) 833Hauenstein K-H: See Bohler J et al.Hauser A C (abst). . . . 150,153,154,456,483,488,508,518Hauser C (abst) 150, 151Hauser C: See Biesenbach G et al.Hauser I (abst) 504Havemann K (abst) 509Hawkins P N (abst) 494Haycock G B: See Clarke A G B et al.HeafJG(abst) 671Heck M: See Floege J et al.HedJ(abst) 490Heering P (abst) 514HeeziusHCJM(abst) 752Heidbreder E (abst) 455,464Heidland A (abst) 455,463, 464Heidland A, Schaefer R M, Teschner M, Horl W H:

Proteases in Uraemia S3:127Heimburger D: See Lindholm B et al.Heine R J (abst) 459Heinegard D: See Bygren P et al.Heinrich U (abst) 451HeintzAPM(abst) 751,754Heintz B (abst) 474Helliwell T R (abst) 444Heney D, Brocklebank J T, Wilson N: Continuous

Arteriovenous Haemofiltration in the Newlybornwith Acute Renal Failure and Congenital HeartDisease 870

HeninP(abst) 444Henning K (abst) 145


Henning P H, Bewick M, Reidy J F, Rigden SPA, NeildG H, Chantler C: Increased Incidence of RenalTransplant Arterial Stenosis in Children 575

HenonG(abst) 432Herman A: See Vanholder R et al.Hernandez D (abst) 504Hernando L (abst) 427,429,503,512,515Hernando L: See Mampaso F M et al.Hernando N (abst) 503Hernando P (abst) 427Herrero-Beaumont G (abst) 429Hertel J: See Rockel A et al.Hess Thaysen J (abst) 671Heymanns J (abst) 509Heyrman R M, De Backer W A, Van Waeleghem J P,

De Broe M E: The Effect of Acetate on Ventilation inHaemodialysis Patients 1060

Hidalgo L (abst) 506Hidemune Naito, Tetsuo Miyazaki: Haemodialysis with

Protein Permeable Membranes S3:78Hiesse C (abst) 510Hildreth G: See Cheng H-F et al.Hilgers K F (abst) 460Hill C M (abst) 438Hill CM (letter) . .• 237Hillis A N (abst) 419Hilton PJ (abst) 316,516,838HinterbergerW(abst) 147Hirashima K (abst) 475Hiroaki Aoki: See Akira Yoshida et al.Hiroko Nomiyama: See Kazuo Nomiyama,

•Hiroko NomiyamaHiroshi Fukumura: See Susumu Yoshikawa et al.Hiroyuki Kobayakawa: See Kenji Maeda et al.Hirsch D J: Death from Dialysis Termination 41Hitman G A (abst) 428HobbyP(abst) 429,837Hobson S M: See Young G A et al.Hocine Ch: See Moriniere Ph et al.Hodsman A B (abst) 477Hodson A (abst) 508HoedemaekerPhJ(abst) 423HoefsmitECM(abst) 752HoekDJ(abst) 420HoekFJ(abst) 498,501,755Hoffbrand BI (abst) 317Hoffler D (abst) 520Hofstadter F (abst) 484Hofstadter F: See Ittel T H et al.Hoitsma A J (letter) 239Hoitsma A J: See Wetzels J F M et al.Hojhus J H: See Christensen L A et al.Holden M: See Smith W G J et al.Holland MJ (abst) 314HollombyDJ(abst) 477Holscher M (abst) 590Holzer H (abst) 144,474Homatas J (abst) 594,598Hombrouckx R (abst) 483,484Hopferwieser T (abst) 154Hopper A H, Tindall H, Davies J A: Administration of

Aspirin-Dipyridamole Reduces Proteinuria in DiabeticNephropathy 140

HoptUT(abst) 597Horina J (abst) 144,146,474Horl W H (abst) 472

Dow




Horl W H: See Heidland A et al.; Wanner C et al.Homer M (abst) 456Hortal L (letter) 840Horton J (abst) 419HortonJK(abst) 427Hosokawa S, Yoshida O: Vanadium in Patients

Undergoing Chronic Haemodialysis 282Hourmant M (abst) 503Howard J: See Rogerson M E at al.Howie A J (abst) 314HrubyZ(abst) 428Hughes R T (abst) 833Huissoon A P: See Madden B et al.Hulme B (letter) 759Hultman E (abst) 471Hundeshagen H (abst) 493Huser B: See Zuber M et al.Hutton R D (abst) 319,476Huysmans F Th M: See Wetzels J F M et al.Iacone A (abst) 416IainaA(abst) .' 462lanhez L E (abst) 504, 507Ibels L (abst) 499IlanZ(abst) . 462Ilic S (abst) 444Imamovic G (abst) 443Isacsohn M: See Drachman R et al.Iscovici E (abst) 462Iskander I (abst) 600Ittel T H (abst) 484Ittel T H, Hofstadter F, Gladziwa U, Sieberth H G:

Reduced Deposition of Aluminium in Trabecular Boneof Uraemic Rats Treated with Dihydroxylated VitaminD Metabolites 957

Ivanovich P: See Stein G et al.Ivaskova E (abst) 589JacobsC(abst) 443,454,464Jacobsen B A (abst) 671,673Jacobsen L (abst) 671Jacobson S H (abst) 436,490Jacquillat C (abst) 454Jacquot C (letter) 675Jacquot Ch: See Najean Y et al.Jahn C (abst) 478Jaisser F: See Chanard J et al.James E: See Morales-Barria J et al.Jandeleit K (abst) 474Jandeleit K: See Kindler J et al.Janetschko R (abst) 144,153,154Jans I (abst) 432Janssen J H A: See Cheriex E C et al.Jaudon M C (abst) 454Javnikar A M (abst) 477JayneD(abst) 426Jayne D R W (abst) 314

. Jeffrey R F, MacDonald T M, Freestone S, Lee M R:The Effect of Carbidopa and Lithium on the Systemicand Renal Response to Acute Intravenous SalineLoading in Normal Man 271

Jenkins D (letter) 679Jenkins D, Burton P R, Bennett S E, Baker F, Walls J: The

Metabolic Consequences of the Correction of Acidosisin Uraemia 92

Jenkins D A S (abst) 317,436Jenkins D A S , Gouldesbrough D, Smith G D, Cowie J F,

Winney R J: Can Low-dosage Aluminium Hydroxide

xiii

Control the Plasma Phosphate without Bone Toxicity? 51Jensen B N (abst) 673Jensen FT (abst) 461Jeremy J Y: See Sweny P et al.Jespersen B (abst) 461,464Jeung H M (abst) 501,752,755Jimenez Diaz F (abst) 512Jimenez-Clavero M A: See Manzano F et al.JirkaJ(abst) 589,596JoffeP(abst) 671John P (abst) 591,592Johnson R W G: See Short C D et al.Johnston C F (abst) 420Jolain B (letter) 839Jones D B (abst) 315Jones D B: See Fleming S et al.Jones M C (abst) 838Jones S: See Abbott F et al.Jones S J (abst) 314Jones S L (abst) 419Jonges E (abst) 521Jordan S C (abst) 452Jorres A (abst) 498JothyS(abst) 428Judmaier G (abst) 152Juhasz M (abst) 152JulienJ(abst) 459Junco E (abst) 484,486Junge W: See Neumayer H-H et al.Junger E (abst) 440Jungers P (abst) 450Junor B J R (abst) 318JuulNO(abst) 671Kaeser U: See Sundal E, Kaeser U, Kagedal B (abst). . . . 417Kainberger F (abst) 150Kaiser W (abst) 145,148,511Kaiser W: See Biesenbach G et al.Kalafat H (letter) 760Kalawi M (abst) 597Kalef-Ezra J (abst) 470Kalekou H (abst) 514Kambova L (letter) 602Kamgooyan M (abst) 588Kamgouian M (abst) 595Kamoun P (abst) 450KamperAL(abst) 450,672Kandus A (abst) 593Kaneko M: See Akizawa T et al.Kanfer A: See Nehme D et al.Kanfer A: See Rondeau E et al.Kanis J A: See Hamdy N A T et al.Kaoru Onoyama, Harumitsu Kumajai, Kazuto Takeda,

Kazumasa Shimamatsu, Mastoshi Fujishima: Effects ofHuman Recombinant Erythropoietin on Anaemia,Systemic Haemodynamics and Renal Function inPredialysis Renal Failure Patients 966

Kaplan-Pavlovcic S (abst) 599Kapoulas S (abst) 482Karaaslan Y (abst) 594Karamehic J (abst) 520Karamouzis M (abst) 514Karayiannis A J (abst) 462Karcher D: See Mann J F E et al.Kareche M (abst) 499KarglR(abst) 148Karnel F(abst) 152,153

Dow




Karnel F: See Cada E et al.Kaslik J (abst) 596Kaslikova J (abst) 596Kathrein H (abst) 151,152Kauffmann R H (abst) 753Kaufmann J (abst) 479Kazua Ota: See Mitsuyasu Toyoda et al.Kazuko Hayashi: See Susumu Yoshikawa et al.Kazumasa Shimamatsu: See Kaoru Onoyama et al.Kazuo Nomiyama, Hiroko Nomiyama: Some

Considerations in the Determination of Metalsin Biological Materials S3:114

Kazuo Ota, Uri Kitano, Nobuyuki Miyasaka: Clinical andPathophysiological Aspects of Dialysis-associatedAmyloidosis S3:7

Kazuto Takeda: See Kaoru Onoyama et al.Keavey P M (abst) 437Kechrid C (abst) 593,599Kei Furiya: See Mitsuyasu Toyoda et al.Keller E (abst) 416,454Keller E, Fecht H, Bonier J, Schollmeyer P: Single-Dose

Kinetics of Imipenem/Cilastatin During ContinuousArteriovenous Haemofiltration in Intensive CarePatients 640

Kemmer F (abst) 500Kendall S: See Young G A et al.Kenji Maeda, Takahiro Shinzato, Hiroyuki Kobayakawa:

Effect of Convective Transport on Removal of SmallMolecular Proteins—Application of Push/PullHaemodiafiltration S3:83

Kennedy H (abst) 438Keogh JAB: See Madden B et al.Keown P A (abst) 477Kern P (abst) 452Kerr D N S: EDTA to ERA 411Kerr DNS: See Rodger R S C et al.Kershaw M: See Dische F E et al.Keske U (abst) 436Kessel M (abst) 498Kessler M (abst) 494Kesteloot D (abst) 422Kesteloot D: See Vanholder R et al.Keusch G (abst) 509Khodia Bach M (abst) 591Khoss A E (abst) 145,146Khoury G (abst) 481Kiersztejn M (abst) 466Kincaid-Smith P S (abst) 831KindlerJ(abst) 474,484Kindler J, Eckardt K-U, Ehmer B, Jandeleit K, Kurtz A,

Schreiber A, Scigalla P, Sieberth H-G: Single-dosePharmacokinetics of Recombinant HumanErythropoietin in Patients with Various Degrees ofRenal Failure 345

Kinnaert P (abst) 517Kinnaert P: See Cappello M et al.Kiparski A v (abst) 509Kirby J A, Forsythe J L R, Simm A, Proud G, Taylor

R M R: Renal Allograft Rejection: Protection of RenalTubular Epithelial Cells from Lymphokine ActivatedKiller Cell Mediated Lysis by Pretreatment withCytokines 824

Kirjakov Z (letter) 75,602Kirkwood A (abst) 495, 833Kishimoto T (abst) 489Kitano Y (abst) 485

Kitaoka T (abst) 494KitasG(abst) 313Kiyoshi Ozawa: See Akira Yoshida et al.Kiyotaka Sakai: Technical Determination of Optimal

Dimensions of Hollow Fibre Membranes for ClinicalDialysis S3:73

Kizaki T (abst) 314Kjellstrand C M (abst) 462Klare B (abst) 446Klaus G (abst) .469Klauser R (abst) 459Klehr H U (abst) 462KleinknechtD(abst) 419Kleinknecht D, Bobrie G, Meyer O, Noel L H, Callard P,

Ramdane M: Recurrent Thrombosis and Renal Vascu-lar Disease in Patients With a Lupus Anticoagulant . . 854

Klin M (abst) 466,475Klinke B: See Rockel A et al.Klinkmann H (abst) 452KlinkmannH: Summary of Dialysis Update 1988. . . .S3:151Klinkmann H: The First Twenty-five Years 400Kloss M (abst) 831Kluthe R (abst) 501Knapowski J (abst) 498KnappE(abst) 154Knols G, Leunissen K M L, Spaapen L J M, Bosman F T,

Wiel T W M v d, Kootstra G, van Hooff J P: Recurrenceof Nephrocalcinosis After Renal Transplantation in anAdult Patient with Primary Hyperoxaluria Type I . . . 137

Kobryn A (abst) 589Kocandrle V (abst) 589, 596Koch KM (abst) 425,433,448,478,493Koch K M: See Floege J et al.Koch M (letter) 399Koene R A P (letter) 239Koene RAP: See Frenken L A M et al.Koene RAP: See Wetzels J F M et al.Kohler H (abst) 424, 520Koivula T: See Pietila K et al.KokotF(abst) 466,475,505Kokot F, Grzeszczak W, Wiecek A: Water Immersion

Induced Alterations of Atrial Natriuretic Peptide inPatients with Non-Inflammatory Acute Renal Failure . 691

KonigP(abst) 149, 151, 152Kontessis P S (abst) 419Koomans H A: See Boer P et al.Koomans H A: See Rabelink A J et al.KoomenGCM(abst) 420,450,498,501,755Koomen G C M: See Koopman M G et al.Koopman M G (abst) 420Koopman M G, Krediet R T, Koomen G C M, Strackee J,

Arisz L: Circadian Rhythm of Proteinuria:Consequences of the Use of Urinary Protein:CreatinineRatios 9

Koostra G (abst) 590Kootstra G: See Knols G et al.KootteAMM(abst) 505Kopple J D (abst) 450KopsaH(abst) 153,505,596Korninger Ch (abst) 148Korstanje M J (abst) 511Korzets A (letter) 918-19Korzets Z (abst) 439,453Koselj M (abst) 599Koshikawa S (abst) 494Koshikawa S: See Akizawa T et al.

Dow




Koshino Y (abst) 315,837Kostakis A (abst) 594, 598Koteva A (letter) 75Kottgen E (abst) 498Ko varik J (abst) 149,150, 152,459, 506, 519,520, 588, 589, 596KoxW(abst) 447Kramar R (abst) 144Kramer W (abst) 479Kraus L (abst) 453Krause P H (abst) 510Krediet R J (abst) 755Krediet R T (abst) 420,450,498,501,754,755Krediet R T: See Koopman M G et al.KreisH(abst) 510,519Krivoshiev S (letter) 75,602Krouri A (abst) 499Kuczera M (abst) 460,466Kufner A: See Neumayer H-H et al.Kumar L (letter) 157Kumar M S A (abst) 589,591,592,594,597,599Ki-.ndi M (abst) ' 596Kuntziger H (abst) 482Kurihara S (abst) 475Kuriyama R (abst) 467Kurtz A: See Kindler J et al.KyriakidisST(abst) 594,598Kyrle P A (abst) 148Laaban J P (abst) 443Labeeuw M (abst) 437,456,460,468Lacerda M H: See Ponce P et al.Lacombe C (abst) 472Lacour B (abst) 470,514Ladefoged J (abst) 670Ladefoged S (abst) 502, 670Ladefoged S D (abst) 504,672Laekeman G: See Vanholder R et al.Lahdensua A: See Puolijoki H et al.Laidlaw S: See Leichter H E et al.Laker M F (abst) 454Laker M F: See Tomson C R V et al.Lakhdar B (abst) 513Lamas S (abst) 515Lamb E (abst) 420Lamberights G (abst) 753Lambie A T (abst) 481Lameire N (abst) 422,497,753Lameire N: See Vanholder R et al.Lamm M F (abst) 426Lamperi S (abst) 475,490,496Landais P: See Pochet J -M et al.Landais P (abst) 519Landon J (abst) 466, 836Landriani N (abst) 426Lange H (abst) 509Langer K (abst) 453Langle F: See Cada E et al.Lanigan C: See Rogerson M E at al.LantzO(abst) 510LapinA(abst) 150, 153,505Lappin TTU (abst) 420,476Lappin T R J: See Brown J H et al.Laradi A (abst) 499LarealMC(abst) 437,468Largiader F (abst) 509La Rocca E (abst) 507Launay J-M (abst) 480

XV

Laupacis A (abst) 477Lauritsen H K (abst) 504, 672Lauritzen H K (abst) 502, 670Laval Jeantet A M (abst) 432Lavaud S (abst) 492Lavaud S: See Chanard J et al.Lavelle J M (letter) 679Laville M (abst) 456,460Le Bras J-H (abst) 456Leaker B (abst) 832LeCarpentierJE(abst) 316,456,458Lechner K (abst) 148Lecrique T (abst) 438Lee M R: See Jeffrey R F et al.Legendre Ch (abst) 519Legrand J C (abst) 464Leichter H E, Salusky I B, Lilien T v, Laidlaw S,

Alliapoulos J C, Hall T L, Fine R N: PeritonealClearances with Different Dialysis Regimens inChildren Undergoing Continuous Cycling PeritonealDialysis 893

Leimenstoll G (abst) 595Leitner E (abst) 144, 153, 154LemkeE(abst) 451Lenclud C M: See Tielemans C L et al.Lenoir G: See Gamier J L et al.Lens X M, Montoliu J, Cases A, Campistol J M, Revert L:

Treatment of Hyperkalaemia in Renal Failure:Salbutamol v. Insulin 228

Leo O (abst) 517LercheD(abst) 476Lerma J L (abst) 512Leroux-Robert C: See Vincent D et al.Leroy F (abst) 483,484Lesavre P (abst) 438Leunissen K M L (abst) 515Leunissen K M L: See Cheriex E C et al.Leunissen K M L: See Knots G et al.Leunissen K M L, Menheere P P C A, Cheriex E C, van den

Berg B W, Noordzij T C, van Hooff J P: Plasma Alpha-human Atrial Natriuretic Peptide and Volume Status inChronic Haemodialysis Patients 382

Levy M: See Rondeau E et al.Lewis N P (abst) 319LhottaK(abst) 149,152Li M K: See Chan M K et al.Liano F (abst) 423,428,444Liberatore S (letter) 839Lichodziejewska M (abst) 437Licina A (abst) 599Lienhart C (abst) 144Lilian T v: See Leichter H E et al.Lillevang S T (letter) 676Linari F (abst) 437Lindell A (abst) 434Lindenau K (abst) 451,453Lindgren S (abst) 417Lindholm B (abst) 499Lindholm B, Heimburger O, Waniewski J, Werynski A,

Bergstrom J: Peritoneal Ultrafiltration and FluidReabsorption During Peritoneal Dialysis 805

Lindsay R M (abst) 477Lins L-E (abst) 436,490Lins R L (abst) 479Lison A E (abst) 521Lobo J: See Casati S et al.

Dow



Locatelli F (abst) 457Loch K M: See Floege J et al.Lock P M, Benoliel D, Parsons V: Success of

Communication About Renal TransplantationBetween Patient and Doctor 119

Lockwood C M (abst) 314Lockwood C M: See Abbott F et al.Lockwood C M: See van den Heuvel L P W J et al.Lockwood M (abst) 426Logue F(abst) 318Loibl U (abst) 473,478Lombardi A (abst) 455London G (abst) 483Lopez de Novales E (abst) 435Lopez Gomez J M (abst) 486Lopez O (abst) 438,439Lopez-Novoa J M (abst) 515Lopez-Novoa M (abst) 503Ldpez-Pedret J (abst) 449Lorenzo V (abst) 504Losada M (abst) 504LowryR(abst) 428L-Rivas A (abst) 500Lubrano R (letter) 76Lubrano R: See Taccone-Gallucci M et al.Lubrich-Birkner I (abst) 501Lucas E (abst) 428LugerA(abst) 146Lui S F: See Sweny P et al.Lui S F, Sweny P, Scoble J E, Varghese Z, Moorhead J F,

Fernando O N: Low-dose vs High-dose IntravenousMethylprednisolone Therapy for Acute Renal AllograftRejection in Patients Receiving Cyclosporin Therapy . 387

Lund L (abst) 671Lundahl J (abst) 490Luno J (abst) 484,486Lurdes F M: See Ponce P et al.Lusvarghi E (letter) 1083Lysaght M (abst) 499McCauley J, Sorkin M I: Exacerbation of

Aluminium Encephalopathy After Treatment withDesferrioxamine 110

McClelland P (abst) 444,445McClelland P (letter) 917McCloskey E V: See Hamdy N A T et al.Macdonald N J (abst) 835MacDonald T M: See Jeffrey R F et al.Macdougall IC (abst) 318,319,476Maceira B (abst) 504McGeown M G (abst) 420McGeown M G: See Brown J H et al.McGibben P D (abst) 438McGonigle R J S: See Crowson M C et al.Macia M (abst) 506Mackay I G (abst) 420Mackenzie J C (abst) 420Mackenzie R (abst) 437McLean C (abst) 466, 836MacLennan I C M: See Beaman M et al.McNally P G (abst) 515,835Macurova H (abst) 589McVie J G (abst) 751,754Madden B, Huissoon A P, Colhoun E N, Keogh JAB:

Superior Vena Caval Obstruction: A RareComplication of Quinton Double-lumenHaemodialysis Catheters 586


Madrenas J (abst) 428Madsen B (abst) 461MadsenHT(abst) 673Madsen M (abst) 670, 671Maduell F: See Diaz-Tejeiro R et al.Maeda K: See Niwa T et al.Maekawa M (abst) 489Maffei S (abst) 424Maffei S: See Coppo R et al.Magen H (abst) 453Maggiore Q (abst) 439,492Maggiore Q: See Zoccali C et al.Maher E R (abst) 317Mahiout A (abst) 498Main J (abst) 834Main J (letter) 602MainaA(abst) 442Maini R N (abst) 318,495Maiorca R (abst) 440,441,442,486Maiorca R, Cancarini G C, Camerini C, Brunori G, Manili

L, Movilli E, Feller P, Mombelloni S: Is CAPDCompetitive with Haemodialysis for Long-termTreatment of Uraemic Patients? 244

Mairbaurl H (abst) 154Maistre G (abst) 464Makiko Tsutsui, Masashi Suzuki, Yoshihei Hirasawa:

Renewed Cardiovascular Dynamics Induced byRecombinant Erythropoietin Administration . . . . S3:146

Malacarne F (abst) 513Malara E (abst) 492Malavasi F (abst) 430Malberti F (abst) 485Malberti F (letter) 678,759Malberti F: See Colussi G et al.Malberti F: See Surian M et al.Malisiovas N (abst) 482Mallamaci F (abst) 463,468Mallick M P: See Short C D et al.Malovrh M (abst) 593Malyszko J (abst) 452Mampaso F (abst) 423,428,512Mampaso F M, Egido J, Martinez-Montero J C, Bricio T,

Gonzalez E, Cobo M E, Pirotzky E, Braquet P,Hernando L: Interstitial Mononuclear Cell Infiltratesin Experimental Nephrosis: Effect of PAFAntagonist 1037

Mancini E: See Zucchelli P et al.Manganoni A (abst) 440,441,442Mangiarotti G (abst) 467Manili L: See Maiorca R et al.Manker W (abst) 478Mann J (abst) 460Mann J F E (abst) 460Mann J F E, Murtz H, Sis J, Usadel K H, Hasslacher Ch,

Ritz E: Specific Binding of Angiotensin II and AtrialNatriuretic Factor in Non-nephropathic Type IDiabetes Mellitus 530

Mann J F E, Reisch C, Bergbreiter R, Karcher D,Hackenthal E, Vecsei P, Nussberger J, Ritz E: Effects ofWY47987 (Atrial Natriuretic Factor 102-126) inPatients with Renal Insufficiency 776

Mannhalter Ch (abst) 150Manno C: See Pertosa G et al.MansellMA(abst) 317MansyH(abst) 437Mansy H: See Thomas T H et al.

Dow




Manzano F, Esbrit P, Garcia-Ocana A, Garcia-Canero R,Jimenez-Clavero M A: Partial Purification andCharacterisation of a Renal Growth Factor fromPlasma of Uninephrectomised Rats 334

MaraiP(abst) 457Marangella M (abst) 437Marcelli D (abst) 457Marchini M (abst) 485Marelli A (abst) 487Margreiter R (abst) 145Marie A (abst) 467Marin R: See Aguado S et al.Maninelli G: See Fuiano G et al.Marsh F (abst) 518Marsh F (letter) 759Marsh F P (abst) 428,477Marsh F P: See Cunningham J et al.Marsh F: See Sawyer N et al.Marshall P D (abst) 314Marshall T (abst) 433Martani C (abst) ' 507Martin S: See Short C D et al.Martin X (abst) 437,468Martin-Malo A (abst) 451,452,480,489,491Martin-Reyes G (abst) 435Martina G (abst) 430,512Martinelli D (abst) 487Martinez F (abst) 464Martinez JC (abst) 512Martinez M A: See Praga M et al.Martinez M T (abst) 484Martinez-Montero J C (abst) 429Martinez-Montero J C: See Mampaso F M et al.Martini C (abst) 437Martorano C (abst) 439Martorano C: See Zoccali C et al.Marumo F (abst) 467,475Marx M (abst) 424,520Masaaki Arakawa: See Fumitake Gejyo et al.Masanobu Maekawa: See Taketoshi Kishimoto et al.Masao Shibata: Current Topics in Nutrition for Dialysis

Patients S3:138Masaru Miya: See Susumu Yoshikawa et al.Masashi Suzuki, Sachio Takahashi, Yoshihei Hirasawa:

Therapeutic Approach to Dialysis-relatedOsteoarthropathy S3:32

Masashi Suzuki: See Makiko Tsutui et al.Massara C (abst) 466,486Masterton R G: See Harrison N A et al.Mastoshi Fujishima: See Kaoru Onoyama et al.Mastrolitti G: See Pertosa G et al.Matousovic K (abst) 457Matsuoka M (abst) 485Matsuyama M (abst) 314Matthess A (abst) 458Matthijs E (abst) 754Matthys D (abst) 753Matthys E (abst) 753Matthys E G (letter) 676Matthys E G: See Boelaert J R et al.Maxwell A P (abst) 420,438,476MayerG(abst) 146,147,153,155,473Mayer G: See Cada E et al.Mayeux D (abst) 494Mazengo M (abst) 490Mazzarella V see Taccone-Gallucci M et al.

Mazzola G (abst) 440Mazzucco G (abst) 424,440Meadows J H: See Coles G A et al.Meager A (abst) 837Meas V: See De Bock V et al.Mecca G (abst) 487MeeAD(abst) 508Megumo Hino: See Toshihiko Ono et al.MehlsO(abst) 432,451,469,495Mehmel H C (abst) 453Meier W (abst) 476Meisl F (abst) 473Meissl F (abst) 478Melhado V E R (abst) 454Melin J P (abst) 438Mellert J (abst) 597Meloni C: See Taccone-Gallucci M et al.Memmos D (abst) 469Menault P (abst) 445Mendiluce A (abst) 512Mengus L (abst) 482Menheere PPC A: See Leunissen KMLet al.Menicelli A see Taccone-Gallucci M et al.Menoyo V (abst) 517Mercantini F (abst) 485Mercatello A (abst) 445MerkeJ(abst) 431,469Merkel F (abst) 520MeronG(abst) 519Meschini L: See Taccone-Gallucci M et al.MesicE(abst) 443Messerli F H (abst) 462Messinger D (abst) 474Metsarinne K (abst) 465MeuerS(abst) 520Meuer S C (abst) 424Meuwissen S G M (abst) 422Meyer O: See Kleinknecht D et al.Meyer zum Biischenfelde K H (abst) 424, 520Meyrier A (abst) 443Meyrier A: Treatment of Glomerular Disease with

Cyclosporin A 923Michael C: See Hasslacher Ch et al.Michael J (abst) 313,314Michael J: See Beaman M et al.Michael J: See Crowson M C et al.Michalak E (abst) 451Michel C(abst) 499,500Michielsen P: See Frenken L A M et al.Michihito Okubo: See Yusuke Tsukamoto et al.Mignon F (abst) 499, 500Migone L (abst) 429Miguel M A (abst) 468Mikhailidis D P: See Sweny P et al.MildeP(abst) 469Milford D V (abst) 433Millar N D (abst) 420Millet V G: See Praga M et al.Mimran A: See Canaud B et al.Mimran A: See Mourad G et al.Mineshima M (abst) 485MinettiL(abst) 417,472,481,488Minetti L (letter) 678Minetti L: See Colussi G et al.Minetti L: See Surian M et al.MionC(abst) 482,492

Dow




Mion C: See Canaud B et al.Mion C: See Mourad G et al.Mistry N (abst) 515,835Mitsuma T: See Niwa T et al.Mitsuo Ogura: See Akira Yoshida et al.Mitsuyasu Toyoda, Kei Furiya, Sumie Manno,

Shigeo Kita, Tsutomu Sanaka, Kazua Ota,Yoshiyuki Osamura: Recent Advances in ALAmyloidosis S3:19

Miyagawa T (abst) 467Mocarquer A: See Morales-Barria J et al.Modai D, Averbukh Z, Weissgarten J, Bogin E,

Rosenmann E, Cohn M, Goren E, Shaked U:Uninephrectomy and Repetitive Pregnancies in Mice: ACombined Stimulus for Renal Hypertrophy 701

Molina A (abst) 423Molina R (abst) 449Molino A (abst) 423,430Molino A: See Coppo R et al.Mombelloni S (abst) 486Mombelloni S: See Maiorca R et al.Monnens L A H (abst) 754Montagnani E (abst) 424Montagnani E: See Grazi G et al.Montagnino G (abst) 508Monteagudo J (abst) 449Montessori M L M (abst) 753Monti J P (abst) 452Montoli A (abst) 485Montoli A (letter) 759Montoliu J: See Campistol J M et al.Montoliu J: See Lens X M et al.Moonen M M J (abst) 751Moore K: See Fleming S et al.Moore R (abst) 518Moore R: See Edmunds M E et al.Moore R H (abst) 428,477Moorhead F (abst) 316,317,837Moorhead J F: See Lui S F et al.Moorhead J F: See Sweny P et al.Mooy J M V: See Cheriex E C et at.Morales J Ma: See Praga M et al.Morales-Barria J, Zehnder C, Mocarquer A, James E,

Aris L, Trivino R, Aguilo J: A Prospective One-yearStudy Evaluating the Clinical Outcome of Recipients ofLiving Donor Kidneys Treated with Cyclosporin andAzathioprine 293

Moreau J F: See Nehme D et al.Moriniere Ph (abst) 467Moriniere Ph, Boudailliez B, Hocine Ch, Belbrik S, Renaud

H, Westeel P F, Cohen Solal M, Fournier A: Preventionof Osteitis Fibrosa, Aluminium Bone Disease, and Soft-Tissue Calcification in Dialysis Patients 1045

Morland C M (abst) 314Morosetti M: See Taccone-Gallucci M et al.Morris P J: See Bittar A E et al.Morsky P: See Pietila K et al.Mortensen P B (abst) 673Mortensen P B: See Christensen L A et al.MoserE(abst) 144,153, 154Moskovtchenko J F (abst) 445MossoR(abst) 470Mostafa F (abst) 431Mostafa S M (abst) 445MotzW(abst) 148Mougenot B: See Rondeau E et al.

Moulart J (abst) 497Moulonguet-Doleris L (abst) 517MoultPJA(abst) 317Mourad G (abst) 492Mourad G, Ribstein J, Argiles A, Mimran A, Mion C:

Contrasting Effects of Acute Angiotensin ConvertingEnzyme Inhibitors and Calcium Antagonists inTransplant Renal Artery Stenosis 66

Mousson Ch (abst) 500Moustafa F E, Sobh M A, Ghoneim M A: Peripheral Blood

Morphology: Could it be of Value in Prediction andDiagnosis of Renal Allograft Rejection? 302

Movilli E (abst) 486Movilli E: See Maiorca R et al.Moynot A: See Najean Y et al.Miihlbacher F (abst) 152,508Muirhead N (abst) 477MullerC(abst) 498Muller F B: See Raine A E G et al.Muller-Wiefel D E (abst) 446Mumcuoglu E (abst) 477Munekazu Kyo: See Taketoshi Kishimoto et al.MunlaF(abst) 593MunozJ(abst) 500Muiioz-Gomez J (abst) 492Murat A (abst) 503Murray A (abst) 836Murray A E (abst) 445Murtz H: See Mann J F E et al.Mustonen J: See Pietila K et al.Mustonen J: See Puolijoki H et al.Mutti A: See Buzio C et al.Mysliwiec M (abst) 452NairDR(abst) 837NaishP(abst) 836Najean Y, Moynot A, Deschryver F, Zins B, Naret C,

Jacquot Ch, Drueke T: Kinetics of Erythropoiesis inDialysis Patients Receiving RecombinantErythropoietin Treatment 350

Nakajima M: See Ogawa H et al.Nakashima Y (abst) 494Nakazawa R: See Akizawa T et al.Narang A: See Pereira B J G et al.Naranjo P (abst) 506Naranjo P (letter) 840Naret C (letter) 675Naret C: See Najean Y et al.Nasini M G (abst) ' 475,490,496,517Naylor V A: See Hamdy N A T et a!.Negrier S (abst) 445Negro A: See Buzio C et al.Nehme D, Rondeau E, Paillard F, Moreau J F, Nussaume

O, Kanfer A, Sraer J-D: Aseptic Necrosis of BoneFollowing Renal Transplantation: Relation withHyperparathyroidism 123

Neild G: See Cheng H-F et al.Neild G H (abst) 835Neild G H: See Henning P H et al.Neimoller U M (abst) 596, 597Nejad Ghashti H (abst) 588Nelson S R (abst) 494Nelson WE (abst) 438Nemmar M (abst) 591NeriM(abst) 424Neri T M (abst) 429NetterP(abst) 494

Dow




Neumayer H-H (abst) 477Neumayer H-H, Junge W, Kufner A, Wenning A:

Prevention of Radiocontrast-media-inducedNephrotoxicity by the Calcium Channel BlockerNitrendipine: A Prospective Randomised ClinicalTrial 1028

Newstead C (abst) 518Newstead C G (abst) 477Newstead C G: Jejunal Dialysis in Man Using Mannitol as

thePerfusate 658Newton K E (abst) 503NeyerU(abst) 145, 154Ng W S F: See Chan M K et al.Nguyen Q V: See Canaud B et al.NiagT(abst) 446Nicholle R: See Canaud B et al.NiebelW(abst) 502,521Niederkorn K. (abst) 474Niedermayer W (abst) 595Nielsen F W (abst) 752Nielsen H K (abst) ." 673Nielsen S L (abst) 450,672Nikbin B (abst) 588, 589Nitadori Y: See Akizawa T et al.Niwa M (abst) 489Niwa T, Sobue G, Maeda K, Mitsuma T: Myoinositol

Inhibits Proliferation of Cultured Schwann Cells:Evidence for Neurotoxicity of Myoinositol 662

Nobuyuki Miyasaka: See Kazuo Ota et al.Noel L: See van den Heuvel L P W J et al.Noel L H (abst) 438,506,510,519Noel L H: See Kleinknecht D et al.Nolasco F: See Alexopoulos E et al.Nolasco F: See Cheng H-F et al.Nolph K (abst) 499Nonnast-Daniel B (abst) 478,493Noonan K (letter) 759Noonan K: See Sawyer N et al.Noordzij T C (abst) 515Noordzij T C: See Leunissen K M L et al.Nordlander M (abst) 447Noriyuki Homma: See Fumitake Gejyo et al.Noriyuki Iwamoto: See Toshihiko Ono et al.Noronha I L (abst) 506Noronha I L, Ritz E, Waldherr R, Stein G, Fassbinder W:

Renal Cell Carcinoma in Dialysis Patients withAcquired Renal Cysts 763

North R A (abst) 831Nortier J (abst) 497Novara A (abst) 424Novara R (abst) 430Nowack A (abst) 458Nowotny C (abst) 150Nunez B (abst) 462Nussaume O: See Nehme D et al.

. Nussberger J: See Mann J F E et al.Obregon L (abst) 515Obrezl(abst) 599Oda O: See Ogawa H et al.O'Donoghue D J (abst) 831Oe PL (abst) 418,752,755Offermann G (abst) 510Ogasawara K (abst) 494Ogawa H, Saito A, Ono M, Oda O, Nakajima M,

Chung T G: Novel P2-Microglobulin andits Amyloidogenic Predisposition in Patients on

Haemodialysis S3:14Ohrenberger G (abst) 152Olaizola I (abst) 468Olbert F (abst) 15201dhafer K (abst) 511Olgaard K (abst) 480,672,673Oliver A (abst) 438,439Oliver D O (abst) 472,494,833OlmosA(abst) 493OlsenF(abst) 671Olsen N V (abst) 504,672O'Meara T, Green A, Carmody M, Donohoe J, Campbell

E, Browne O, Walshe J: Recurrent Glomerulonephritisin Renal Transplants: Fourteen Years' Experience . . . 730

Onen K (letter) 760Oner A: See Clarke A G B et al.Ono M: See Ogawa H et al.O'Nunan T: See Williams B et al.Opelz G (abst) 506, 596Oppenheim B A: See Pickering S J et al.Oppenheimer F (abst) 492,502,517Oppermann F (abst) 487O'Riordan J L H: See Cunningham J et al.Orlandini G: See Surian M et al.Orofino L (abst) 444Ortuno J (abst) 428,444OsmanO(abst) 470Ota K (abst) 485Oudshoorn M (abst) 424Ozono Y (abst) 429, 837Pacitti A (abst) 465,467,486,491Packard C (abst) 831Packham D P (abst) 831PacsaA(abst) 589PaezA(abst) 506Pagliarini A (abst) 513Pagniez D C (letter) 76Paillard F: See Nehme D et al.Paineau J (abst) 503Palkovits M (abst) 463PallaR(abst) 424Palla R: See Grazi G et al.Palmer A (abst) 319,838Palmer P (abst) 445Palmieri P F (abst) 448Pals G (abst) 422Panarello G (abst) 485Panichi V (abst) 424Panichi V: See Grazi G et al.Panjwani D (abst) 594, 597Panjwani D D (abst) 599Panzer S (abst) 150Papachristophorou K (abst) 594Papadimitriou M (abst) 469Papadimitrou M G (abst) 462Papaioannou A (abst) 598Papayianni A (abst) 482,514Papiha S (abst) 428Parchoux B: See Cahen R et al.Pardo-Mindan F J (abst) 443Parfrey N A (abst) 428Parkin A (abst) 512Parlongo S (abst) 468Parravicini C (abst) 426Parrini M (abst) 424Parrini M: See Grazi G et al.

Dow



XX

Parson V: See Rogerson M E et al.Parsons V (abst) 838Parsons V: See Dische F E et al.Parsons V: See Lock P M et al.ParvyP(abst) 450Parzer S (abst) 150Pascual J (abst) 423,428,444Pasini J: See Tomic B H et al.Pasquali S: See Passerini P et al.Passerini P, Pasquali S, Cesana B, Zucchelli P, Ponticelli C:

Long-term Outcome of Patients with MembranousNephropathy After Complete Remission of

Proteinuria 525Passlick-Deetjen J (abst) 500Pasternack A: See Pietila K et al.Pasternack A: See Puolijoki H et al.PasykS(abst) 505Patek E (abst) 508Patte R(abst) 482Paul L S (abst) 505Paulitschke M (abst) 476Pavlovic D: See Tomic B H et al.Pawlowska Z (abst) 451Pecchio A (abst) 465Pecherstorfer M (abst) 149Pedersen E B (abst) 461,464,465PenkoffH(abst) 144Pepys M B (abst) 494Perazzoli F: See Buzio C et al.PereP(abst) 494Perego A (abst) 481,488Pereira B J G(letter) 157Pereira B J G, Narang A, Pereira S, Gupta A, Sakhuja V,

Chugh K S: Acute Renal Failure in Infants in theTropics 535

Pereira S: See Pereira B J G et al.Perez G R (abst) 486Perez R (abst) 484Perfumo F (abst) 497Perkin G D (abst) 318,495Perrino M L (abst) 472,481,488Persuad J W (abst) 837Pertosa G, Mastrolitti G, Spath P J, Fracasso A R, Manno

C, Schena F P: Effect of Fibronectin on C3b and FcReceptor-mediated Phagocytosis by Peripheral BloodMonocytes in Uraemic Patients 15

PetenE(abst) 506Peterlongo F (letter) 675Petit J (abst) 432Petrarulo M (abst) 437Petropoulou E (abst) 469Pettersson E (abst) 478Pettersson E: See Puolijoki H et al.Philip T (abst) 445Philips E M (abst) 592Phillips E M (abst) 599Phillips M E (abst) 447, 508Picard F (letter) 675Picca M (abst) 497Piccoli G (abst) 423,424,430,440,470,490,512Piccoli G: See Coppo R et al.Piccoli G: See Roccatello D et al.Piccoli G B (abst) 486Pichlmayr R (abst) 511Pickering S J, Fleming S J, Bowley J A, Sissons P,

Oppenheim B A, Burnie J, Ralston A J, Ackrill P:


Urokinase: A Treatment for Relapsing Peritonitis due toCoagulase-negative Staphylococci 62

PieraL(abst) 493Piers-BechtTP(abst) 455Pietila K, Mustonen J, Morsky P, Seppala E, Pasternack A,

Koivula T: Effect of One Haemodialysis Treatment onthe Plasma Concentrations of Intact ParathyroidHormone and Ionised Calcium . 116

Pietraszek M (abst) 452Pikielny S (abst) . . 453Pinto G: See Ponce P et al.Pinto J R (abst) 419Pinzani M (abst) 426Pippard M J (abst) 833Pirotzky E (abst) 448,516Pirotzky E: See Mampaso F M et al.Pirson V (abst) 481,506,507Pisani G (abst) 520Pizarro J L (abst) 496Plaza J J (abst) 503Plum J (abst) 500Pochet J M (abst) 507Pochet J-M, Bobrie G, Landais P, Goldfarb B,

Grunfeld J P: Renal Prognosis in Alport's and Relatedsyndromes: Influence of the Mode of Inheritance. . . .1016

Padenphant J (abst) 671Podjarny E (abst) 417,421,457Pogglitsch H (abst) 144,474PohankaE(abst) 149,519,588,589Poignet J-L (abst) 480Polenakovic M (abst) 461Poli L (abst) 520Polio J (abst) 458Pollock C (abst) 499Polloni R (abst) 470Pomer S (abst) 506Pomerantz A (abst) 453Pomeranz A (abst) 439,457Pomeranz M (abst) 439Ponce P, Ramos A, Lurdes Ferreira M, Pinto G, Lacerda

M H: Renal Involvement in Leprosy 81Ponticelli C (abst) 496,508,514Ponticelli C (letter) 839Ponticelli C: See Casati S et al.Ponticelli C: See Passerini P et al.PorcuMC 442,466Poston L (abst) 516,838Postorino M (abst) .' 439,463,492Postorino M: See Zoccali C et al.Potaux L (abst) 513PouxC(abst) 482Povlsen J V (abst) 671Power D A (abst) 838PozetN(abst) 437,445,456,460,468Pozza G (abst) 507Pozzetto B: See Guerin C et al.PozziC(abst) 431Pracht G (abst) 474Praga M, Martinez M A, Andres A, Alvarez de Buergo M,

Bello I, Millet V G, Morales J Ma: Acute Renal Failureand Tubular Dysfunction Associated with MinimalChange Nephrotic Syndrome 914

Prager R (abst) 459Prat V (abst) 457PratiE(abst) 440,441,442PrehnJ(abst) 452

Dow




Pretagostini R (abst) 518Price R G: See van den Heuvel L P W J et al.Proesmans W (abst) 479Pronai W (abst) 152Propper D J (abst) 838Prospert F (abst) 421Prospert F: See Cappello M et al.Proud G: See Kirby J A et al.Prowant B (abst) 499Pugh C W (abst) 494Puolijoki H, Mustonen J, Pettersson E, Pasternack A,

Lahdensuo A: Proteinuria and Haematuria areFrequently Present in Patients with Lung C a n c e r . . . . 947

Purkiss J (abst) 836Purroy A: See Diaz-Tejeiro R et al.Pusey C D (abst) 314,435,832Pusey C D: See Dische F E et al.Pyrpasopoulos M (abst) 482,514QuaiaP(abst) 485Quarello F (abst) 470,486,512Quarenghi M (abst) . . . . . ' 487QuattrocchioG(abst). . . . . . . 423,424,430,440,470,490Quattrocchio G: See Coppo R et al.Quattrocchio G: See Roccatello D et al.Querfeld U (abst) 452Quesada J (abst) 452Quesada J M (abst) 451Quinn A (abst) 832Quiros J (abst) 429Rabelink A J, Koomans H A, Boer W H, Dorhout Mees

E J, van Rijn H J M: Indomethacin Increases RenalLithium Reabsorption in Man 27

Radice A (abst) 431Radkowski M (abst) 498Raftery A T: See Hamdy N A T et al.RagniR(abst) 437,486Rahbar K (abst) 589Raine AEG, Bock A, Muller F B, Erne P, Bolli P, Brunner

F, Buhler F R: Comparative Effects of Haemodialysisand Haemofiltration on Plasma Atrial NatriureticPeptide 222

Rainford D J: See Harrison N A et al.Rainfray M (abst) 443Ralston A J: See Pickering S J et al.Rambausek M (abst) 429,440,506Rambausek M: See Waldherr R et al.Ramdane M: See Kleinknecht D et al.Ramos A: See Ponce P et al.Ramos B (abst) 435Ramos O (abst) 461Ramos O L (abst) 487RamsyR(abst) 431RankeM(abst) 451RappU(abst) 425Rasmussen A (abst) 670,671

. Rasmussen N (abst) 431Rasoul-Rockenschaub S (abst) 596Ratcliffe P J: See Bittar A E et al.Rathaus M (abst) 417,421,457Rauer S (letter) 677Rauterberg E (abst) 440Rauterberg E W (abst) 469,489Ravelli M (abst) 486Ravina M (abst) 504RedonP(abst) 513Reed A: See Dische F E et al.

XXI

ReesAJ(abst) 315,435,832,837Rees A J: See Abbott et al.Regele H (abst) 153Regis G (abst) ' 491Reidy J F: See Henning P H et al.Reijden H J vd (abst) 752Reinhard B: See Floege J et al.Reisch C: See Mann J F E et al.Religa Z (abst) 505Remuzzi G: See Vigano G et al.Renaud H: See Moriniere Ph et al.Rengel M A (abst) 484Renna Molajoni E (abst) 518,520Repp H (abst) 511ReschK(abst) 422,425Reuben A (abst) 458Revert L (abst) 449Revert L: See Campistol J M et al.Revert L: See Lens X M et al.Revillard J P (abst) 492Reynolds J (abst) 314Ribeiro D S (abst) 507Ribstein J: See Mourad G et al.Ricart M J (abst) 492,502,517Richards N (abst) 428Richards N T (abst) 316,516,838Richardson A J: See Bittar A E et al.Richter D (abst) 498Riegel W: See Wanner C et al.Rifle G (abst) 500Rigaud M: See Vincent D et al.Rigden SPA: See Clarke A G B et al.Rigden SPA: See Henning P H et al.RitzE(abst) 429,431,440,453,458,460,469,471,489Ritz E (letter) 399Ritz E: See Hasslacher Ch et al.Ritz E: See Mann J F E et al.Ritz E: See Noronha I L et al.Ritz E: See Waldherr R et al.Ritz R: See Zuber M et al.Rivera M (abst) 444Rizzoni G, Ehrich J H H, Brunner F P, Brynger H,

Dykes S R, Geerlings W, Fassbinder W, Tufveson G,Selwood N H, Wing A J: Combined Report on RegularDialysis and Transplantation of Children in Europe,1988 S4:31

Rizzoni G: See Brunner F P et al.; Ehrich J H H et al.;Tufveson G et al.

Roberts D E (abst) 318Robertson W R (abst) 834Robinson C (abst) 470Robinson K N (abst) 3)7Robinson P J: See Worth D P et al.RobledoC(abst) 443Robles R (abst) 484Roccatello D (abst) 423,424,430,440,470,490Roccatello D: See Coppo R et al.Roccatello D, Coppo R, Piccoli G, Cavalli G, Guerra M G,

Funaro A, Amore A, Roggero S, Borgialli R, AmprimoM C, Scalzo B, Alessio M, Quattrocchio G, Sena L M:Phenotypic and Functional Analysis 618

Rdckel A, Klinke B, Hertel J, Baur X, Thiel Cl,Abdelhamid S, Fiegel P, Walb D: Allergy to DialysisMaterials 646

Rodger R S C (abst) 318,834,835Rodger R S C, Sheldon W L, Watson M J, Dewar J H,

Dow



XXII

Wilkinson R, Ward M K, Kerr DNS: Zinc Deficiencyand Hyperprolactinaemia are not Reversible Causes ofSexual Dysfunction in Uraemia 888

Rodriguez-Puyol D (abst) 515Rodriguez-Puyol M (abst) 515RogersonM E(abst) 835Rogerson M E, Rylance P B, Wilson R, De Sousa C,

Lanigan C, Rose P E, Howard J, Parson V: Carnitineand Weakness in Haemodialysis Patients 366

Roggero S: See Roccatello D et al.RojasR(abst) 491Rolando P (letter) 678RollinoC(abst) 423,430,512Romano G (abst) 516Romao J E (abst) 504, 507Rombola G (abst) 417Rombola G: See Colussi G et al.Rombola R (letter) 678Romero R (letter) 675Rondeau E (letter) 918Rondeau E: See Nehme D et al.Rondeau E, Levy M, Dosquet P, Ruedin P, Mougenot B,

Kanfer A, Sraer J D: Plasma Exchange andImmunosuppression for Rapidly ProgressiveGlomerulonephritis: Prognosis and Complications. . . 196

RoobJ(abst) 144,474Roodhooft A M (abst) 753RoosJC(abst) 418Roots 1 (abst) 477Rose P E: See Rogerson M E et al.Roseler E (abst) 487Rosendahl W (abst) 432Rosenfeld J: See Cohen S L et al.Rosenfeld J B (abst) 513Rosenmann E: See Modai D et al.Rosman J B (abst) 455,457,458Rosseneu M J (abst) 753Rossi R (abst) 487Rossmann P (abst) 457Rousaud F (abst) 439Roza M (abst) 468R-Tarduchy G (abst) 500Rudensky B: See Drachman R et al.Ruder H (abst) 432Rueda P (abst) 500Ruedin P: See Rondeau E et al.Ruffmann K (abst) 453Ruiz C (abst) 519Russell G I (letter) 679Rustichelli R: See Buzio C et al.Ryan J (abst) 837Rylance P B: See Rogerson M E at al.Sabawi N (abst) 599Sabbaga E (abst) 504, 507Sabbatini M (abst) 516Sabbatini M, Esposito C, De Nicola L, Uccello F,

Altomonte M, Conte G, Dal Canton A, Andreucci V E:Reversibility of Acute Cyclosporin Nephrotoxicity byDopamine. Micropuncture Study in the Rat 327

SaccaL(abst) 450Sachio Takahashi: See Masashi Suzuki et al.Saito A: See Ogawa H et al.Sakai K (abst) 494Sakhuja V (letter) 157Sakhuja V: See Pereira B J G et al.SalahH(abst) 591


Saldanha L B (abst) 507Salido E (abst) 504Salit M (abst) 475,490,496Sallusto F (abst) 518Salmon M (abst) 313Salnitro F (abst) 463,468Salnitro F: See Zoccali C et al.Salomone M (abst) 467,486,491Salusky I B: See Leichter H E et al.Samhan M (abst) 591,592,594Sampson B, Curtis J R, Davies S: Survey of Blood Lead and

Plasma Aluminium Concentrations in Patients of aRenal Unit 375

Sanchez-Casada E (abst) 496Sandrini S (abst) 441Santamaria M (abst) 452Santelli G (abst) 510Santiago J (abst) 451Santos D F P (abst) 516Santos O F P (abst) 448Saragananda B: See Vanholder R et al.Saragoca MAS (abst) 487Saraqoca M A S (abst) 461Sariyar M (letter) 760Sato M (abst) 494SatohS(abst) 494Saunders MJ (abst) 319Savage COS: See Sutcliffe N P et al.Savage COS: See van den Heuvel L P W J et al.SaviM(abst) 429Savoldi S (abst) 440,441,442Sawyer N (letter) 759Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham

J: High-dose Calcium Carbonate with StepwiseReduction in Dialysate Calcium Concentration:Effective Phosphate Control and AluminiumAvoidance in Haemodialysis Patients 105

Scaini P (abst) 440,441,442Scalamogna A (abst) 496Scalzo B: See Roccatello D et al.Scaroni P (abst) 486Schaefer K: Uraemic Hyperphosphataemia—What is the

Therapy of choice? 1005Schaefer R M: See Heidland A et al.; Wanner C et al.Schaeffer J (abst) 478Schafer C (abst) 484Scharer K (abst) 432,452,495Schauer A (abst) 451Schedel I (abst) 433Schelotto C (abst) 475,496,517Schena F P (abst) 426,430Schena F P: See Pertosa G et al.Schenkel J (abst) 440ScherberichJE(abst) 458Schernthaner G (abst) 151,459Scheuermann E (abst) 504Schieroni M P (letter) 238Schiffl H (abst) 461Schiller B: See Blumenstein M et al.Schmicker R (abst) 453Schmid M (abst) 458Schmidt B: See Blumenstein M et al.; Ward R A et al.Schmidt EB (abst) 671Schmidt E B: See Christensen L A et al.Schmidt G (abst) 476Schmidt H (abst) 458,487

Dow




Schmidt P (abst) 145, 149Schmieder R (abst) 462Schmitt V (abst) 489Schnack Ch (abst) 151Schneider N (abst) 453Schneider R (abst) 462Schobersberger W (abst) 154Schoeppe W (abst) 458,473,487,504Schollmeyer P (abst) 418,472,501Schollmeyer P (letter) 677Schollmeyer P: See Bohler J et al.Schollmeyer P: See Keller E et al.Schollmeyer PJ (abst) 416,454Schonermark M (abst) 431SchorN(abst) 448,454,516Schor N S (abst) 487Schreiber A: See Kindler J et al.Schroder C H (abst) 754Schulz E (abst) 498Schurawitzki H (abst). 152, 153Schurawitzki H: See Cada E et al.Schurgers J R: See Boelaert J R et al.Schurgers M (abst) 753, 754Schurgers M L (letter) 676Schwab TR (abst) 463Schwaighofer B (abst) 150Schwarz A (abst) 510Schwarz H P (abst) 155Schwarz M (abst) 149Scigalla P (abst) 474,477Scigalla P: See Kindler J et al.Sciuto G (abst) 486Scoble J E (abst) 316,317Scoble J E: See Lui S F et al.Scolari F (abst) 440,441,442SebertJL(abst) 467Secchi A (abst) 507Segal A W (abst) 832Segoloni G (abst) 467,491Segoloni G P (abst) 465,486,512Segoloni G P (letter) 238Seiji Yamagami: See Taketoshi Kishimoto et al.Seinosuke Nakagawa: An Introductory Approach to

Recently Investigated Metabolic and EndocrinologicalProblems in Uraemia S3:123

Seinosuke Nakagawa: See Akira Yoshida et al.SelbB(abst) 487Selgas R (abst) 500Selwood N H: See Brunner F P et al.; Enrich J H H et al.;

Rizzoni G et al.; Tufveson G et al.Sena L M (abst) 424,440Sena L M: See Roccatello D et al.SeniorJCM(abst) 316Sennesael J: See De Bock V et al.SepeV(abst) 516

. Sepe V: See Fuiano G et al.Seppala E: See Pietila K et al.Serdengecti K (letter) 760Serlenga E (abst) 430Seron D: See Alexopoulos E et al.Serrano I (abst) 452Sert $ (abst)

518,590,591,592,593,594,595,597,598,600,601Sertl K (abst) 488, 508Sethi D (abst) 318,494,495Sethi D, Cary N R B, Brown E A, Woodrow D F,

xxiii

Gower P E: Dialysis-Associated Amyloid: Systemic orLocal? 1052

Severn A: See Dische F E et al.Seveso M (abst) 472,488Shaked U: See Modai D et al.Shaldon S (abst) 473,489,493Shaldon S: EDTA and Industry: 25 Years of Symbiotic

Synergism 408Shaldon S: See Floege J et al.Shapira J (abst) 421Shapira Z: See Cohen S L et al.Sharman V L: See Waters M R et al.Shehab A (abst) 595Shehab El-Din A (abst) 519Sheldon W L: See Rodger R S C et al.Shepherd J (abst) 831Shigeo Kita: See Mitsuyasu Toyoda et al.Shigeru Iwanami: See Fumiaki Marumo et al.Shimizu F (abst) 314Shin-ya Inai: See Susumu Yoshikawa et al.Shirota K (abst) 428Shmueli D: See Cohen S L et al.Short C D, Coupes B M, Brenchley P E, Martin S, Williams

S, Johnson R W G, Mallick M P, Williams G:Membranous Nephropathy: Monoclonal IgG andNephrotic-range Proteinuria in a Renal TransplantRecipient 1080

Shortland J R: See Hamdy N A T et al.Shozo Koshikawa: See Tadao Akizawa and Shozo

KoshikawaSiamopoulos K (abst) 470Sieberth H G (abst) 474,484Sieberth H G: See Ittel T H et al.Sieberth H G: See Kindler J et al.Silberbauer K abst) 152Silva C S G (abst) 592Silva F J E: See Van de Vyver F L et al.Silver A (abst) 420Simeoni U (abst) 482Simforoosh N (abst) 591,595,599Simfroosh N (abst) 588Simm A: See Kirby J A et al.Simon P (abst) 442Singh U (letter) 157Singhi P D (letter) 157Sinico R A (abst) 431Sirajeddine K (abst) 421Sis J: See Mann J F E et al.Sisca S (abst) 492Sissons P: See Pickering S J et al.Skogh T (abst) 434Skroder R (abst) 462Slaughter D (abst) 477SlootJAPvd(abst) 751,754Smeby L C: See Floege J et al.Smith G D: See Jenkins D A S et al.Smith J (abst) 315,836Smith W G J, Dharmasena A D, El Nahas A M, Thomas

D M, Coles G A: Short-Term Effect of Captopril onRenal Haemodynamics in Chronic Renal Failure. . . . 696

Smith W G J, Holden M, Benton M, Brown C B:Glycosylated and Carbamylated Haemoglobin inUraemia 96

SmollichBP(abst) 422Smye S W: See Worth D P et al.Snoek F(abst) 752

Dow



XXIV

Snowden S (abst) 838SobhM(abst) 431,519,595Sobh M A: See Moustafa F E et at.Sobue G: See Niwa T et al.Soderstrom T (abst) 510,521Sohtell M (abst) 447Solana R (abst) 452Sold M (abst) 464Sole M (abst) 492Sonnleitner A (abst) 149Sorensen P (abst) 465Serensen S S (abst) 461,465Sorkin M I: See McCauley J and Sorkin M ISotirchos J abst) 598Soubrane C (abst) 454Soulillou J P (abst) 503Soupart A (abst) 421Souvignet C (abst) 421Sozirchos G (abst) 594Spaapen L J M: See Knols G et al.Spagnuolo G (abst) 455Spath P J: See Pertosa G et al.Spechthof E (abst) 512Spencer E (abst) 672Sperschneider H: See Stein G et al.Spielberger M (abst) 151Spindler E (abst) 493Sprenger R (abst) 145,154Squifflet J P (abst) 506Sraer J D: See Nehme D et al.Sraer J D: See Rondeau E et al.Stabellini G (abst) 513Stanek G (abst) 155Stanziale P: See Fuiano G et al.Staudacher C (abst) 507Steadman R (abst) 437Stefanovic V (abst) 444Steffenelli Th (abst) 147Steger G (abst) 153Steger H (abst) 145Stegmeier K (abst) 512Stein G, Sperschneider H, Ivanovich P, Abendroth K:

Dialysis Encephalopathy and Bone Disease Due toAluminium Toxicity S3:100

Stein G: See Noronha I L et al.Steiner G (abst) 520Steinhauer H B (abst) 418,472,501Steininger R (abst) 508Steinmann E: See Zuber M et al.Stelzer N (abst) 151Stenger K O (abst) 520Stephens N (abst) 319Stephenson J R (abst). 495, 833Steropoulos G (abst) 470Sterzel R B (abst) 458Stevens J M (abst) 833Stevens M E (letter) 917Stevens P E (abst) 447, 508Stewart C J (letter) 758Stewart K N (abst) 838Steyrer E (abst) 144Stockenhuber F (abst)

. . 147,148,150,151,153,154,456,478,483,488,508,518Stoger H: See Biesenbach G et al.StoofTJ(abst) 511Storm T (abst) 480,672


Stouthard J M L (abst) 498,754Strackee J: See Koopman M G et al.Strandgaard S (abst) 450, 672Stratta P (abst) 442,466,467Strauch M (abst) 512Strazzullo P (abst) 416Street P R: See Woolf A S et al.Strong C A (abst) 833Struijk D G (abst) 450,498,501,752,755StubyU(abst) .145Stummvoll H K (abst) 144,146,153,154Stumpflein A (abst) 483,488Stumpflen A (abst) 505Stumvoll H K (abst) 147Sturani A (abst) 433Sugimura T (abst) 489Sugiura S (abst) 485Sumie Manno: See Mitsuyasu Toyoda et al.Sundal E, Kaeser U: Correction of Anaemia of Chronic

Renal Failure with Recombinant HumanErythropoietin: Safety and Efficacy of One Year'sTreatment in a European Multicentre Study of 150Haemodialysis-Dependent Patients 979

Sundal E (letter) 675Sunder-PlassmannG(abst). . . . 147,148,150,151,153,154SuriaS(abst) 504Surian M (abst) 485Surian M (letter) 678, 759Surian M: See Colussi G et al.Surian M, Malberti F, Corradi B, Orlandini G,

Varini E, Colussi G, Minetti L: Adequacy ofHaemodiafiltration 32

Susumu Yoshikawa, Kazuko Hayashi, Hiroshi Fukumura,Masaru Miya, Youji Akagaki, Shin-ya Inai:Complement Activation and Thrombogenesis onPolymer Surfaces: Comparative Studies with Ethylene-Vinyl Alcohol Copolymers S3:67

Sutcliffe N P, Cashman S J, Savage COS, Fox J G,Boulton-Jones J M: Variability of the Antigenicity ofthe Glomerular Basement Membrane in Nail-patellaSyndrome 262

Suzuki T (abst) 485Swainson C P (abst) 436Swainson C P, Walker R J: Renal Haemodynamic and

Hormonal Responses to a Mixed High-Protein Meal inNormal Men 683

Swedenborg J (abst) 462SwenyP(abst) .' 316,317Sweny P: See Lui S F et al.Sweny Pheeler D C, Lui S F, Amin N S, Varghese Z,

Fernando O N, Moorehead J F, Barradas M A, JeremyJ Y, Mikhailidis D P: Dietary Fish Oil SupplementsPreserve Renal Function in Renal TransplantRecipients With Chronic Vascular Rejection 1070

Sylven M (abst) 462SyreG(abst) 145Szewczyk Z (abst) 428Szpirt W (abst) 431Tabaqchali S (abst) 495, 833Taccone-Gallucci M (letter) 76Taccone-Gallucci M, Lubrano R, Del Principe D,

Menichelli A, Giordani M, Citti G, Morosetti M,Meloni C, Mazzarella V, Meschini L, Tozzo C, Elli M,Giardini O, Casciani C U: Platelet Lipid Peroxidation inHaemodialysis Patients: Effects of Vitamin ESupplementation 975

Dow




Tadao Akizawa, Shozo Koshikawa: Clinical Effects ofMembrane-induced Complement Activation onHaemodialysis Patients at High Risk S3:5O

Taghavi M (abst) 588, 589Tagliavini D: See David S et al.Takahashi K. (abst) 485Takahiro Shinzato: See Kenji Maeda et al.Takao Shoji: See Akira Yoshida et al.Takehisa Matsuda: Biological Responses at

Non-physiological Interfaces and Molecular Designof Biocompatible Surfaces S3:60

Taketoshi Kishimoto, Munekazu Kyo, Seiji Yamagami,Masanobu Maekawa: Effect of Membrane Area andBlood Flow Rate on Plasma C3a and C5aConcentration During Haemodialysis withRegenerated Cellulosic Membrane Dialysers S3:46

Takuo Sasaoka: See Akira Yoshida et al.Talartschik J (abst) 478Talbot J A (abst) 834Talseth T (abst) 509Tambourin P (abst) 472Tamburro M L (abst) 520Tange R A (abst) 752Tapson J (abst) 508Tapson J S (abst) 437Tarantino A (abst) 508Tasdemir I (abst) 594,601Tattersall J (abst) 836Tattersall J E (abst) 466TaubeD(abst) 319,838Taube D: See Dische F E et al.Tavella M (abst) 448Taylor A E: See Young G A et al.Taylor CM (abst) 433Taylor OM (abst) 313Taylor R M R: See Kirby J A et al.Taylor T N: See Brown J H et al.Teatini U (abst) 481,488Tel N (abst) 590Tempi H (abst) 146ten Bokkel Huinink W W (abst) 751,754ten Kate R W (abst) 422Tentori F (abst) 457Teraoka S (abst) 485TeruelJ L(abst) 444Teschner M: See Heidland A et al.Tesio F (abst) 485,489Tetsuo Miyazaki: See Hidemune Naito, Tetsuo Miyazaki,TettaC(abst) 491Tetta C (letter) 238Thalen P (abst) 447Thaysse C: See Cappello M et al.TheaA(abst) 466Thebaud H E (abst) 442TheilJ(abst) 461Thick M (abst) 319Thiel Cl: See Rockel A et al.Thiel G: See Zuber M et al.Thomas B (letter) 399Thomas D B (abst) 435Thomas D M: See Smith W G J et al.Thomas H: See Van de Vyver F L et al.Thomas T (abst) 834Thomas T (letter) 602Thomas T H, Mansy H, Wilkinson R: Erythrocyte Sodium

and Sodium Flux in Relation to Hypertension in

XXV

Chronic Renal Failure 21Thompson J P: See Williams B et al.Thomsen B (abst) 431Thomson D (abst) 836ThumJ(abst) 146, 147, 155Tidgren B (abst) 462Tielemans C (abst) 488Tielemans C L, Lenclud C M, Wens R, Collart F E, Dratwa

M: Critical Role of Iron Overload in the IncreasedSusceptibility of Haemodialysis Patients to BacterialInfections. Beneficial Effects of Desferrioxamine . . . . 883

Tikkanen I (abst) 465Tincani A (abst) 431Tindall H: See Hopper A H et al.Tjandra Y I (abst) 755Tobies A (abst) 418TodrosT(abst) 442Tognarelli G (abst) 465Tognet E (abst) 445Tomic B H, Pavlovic D, Halbauer M, Pasini J: Parathyroid

Sonography in Secondary Hyperparathyroidism:Correlation with Clinical Findings 45

Tomita K (abst) 467Tomlinson K: See Coles G A et al.Tomosugi N (abst) 315Tompkins L: See Young G A et al.Tomson C R V (abst) 454Tomson C R V: See Atkin S L et al.Tomson C R V: See Edmunds M E et al.Tomson C R V, Channon S M, Ward M K, Laker M F:

Plasma Oxalate Concentration, Oxalate Clearance andCardiac Function in Patients Receiving Haemodialysis. 792

Tonshoff B (abst) 446,451,469Toorn L v d (abst) 459Toothill C (abst) 503TopleyN(abst) 422,425,437Tornero F (abst) 506Torras A: See Campistol J M et al.Torres A (abst) 491,504TorriG(abst) 507Toshihiko Ono, Noriyuki Iwamoto, Megumo Hino:

Clinical and Histological Patterns in Aluminium-relatedBone Disease S3:107

Totterman K.-J (abst) 465Totterman T H: See Hanas E et al.Toupance O (abst) 492Toupance O: See Chanard J et al.Touraine J L: See Gamier J L et al.Tournade H (abst) 427Tournier O: See Floege J et al.Toussaint C (abst) 517Tozzo C: See Taccone-Gallucci M et al.Traindl O (abst) 149,150,506Trautmann M (abst) 418Trevisan R (abst) 419Trevisan R: See Vigano G et al.TrioloG(abst) 465,491Triolo G (letter) 238Trivino R: See Morales-Barria J et al.Trnacevic S (abst) 443Trolliet P: See Cahen R et al.Trovati A (abst) 520Trznadel K (abst) 451Tschope W (letter) 399Tsutomu Sanaka: See Mitsuyasu Toyoda et al.TucciA(abst) 431

Dow



xxvi

Tuncker B: See Edmunds ME et al.Tufveson G, Geelings W, Broyer M, Brunner F P, Brynger

H, Dykes S R, Erich J H H, Fassbinder W, Rizzoni G,Selwood N H, Wing A J: EDTA Registry Centre Survey1986 161

Tufveson G, Geerlings W, Brunner F P, Brynger H,Dykes S R, Enrich J H H, Fassbinder W, Rizzoni G,Selwood N H, Wing A J: Combined Report on RegularDialysis and Transplantation in Europe, XIX, 1988 . . S4:5

Tufveson G: See Brunner F P et al.; Enrich J H H et al.;Hanas E et al.; Rizzoni G et al.

Tuk K. (abst) 752Tulliez M (letter) 675Tulumovic T (abst) 443Turello E (abst) 491Turgan C (abst) 594,601Turner C: See Clarke A G B et al.Turney J H: See Young G A et al.Tvedegaard E (abst) 480,672Uccello F (abst) 516Uccello F: See Sabbatini M et al.Uhlschmid G (abst) 509Ulku U (letter) 760Ullrick W (abst) 596Ulrich W (abst) 153,519UrertaP(abst) 470Urena V (abst) 428Uri Kitano: See Kazuo Ota et al.Urmson J (abst) 428Usadel K H: See Mann J F E et al.Uygur C (abst) 590Vago L(abst) 426Valderrabano F (abst) 484, 486Valente U (abst) 517Valeri R (abst) 507Valetitsch H (abst) 474Van Acker KJ (abst) 753van Bergeijk J D: See Wetzels J F M et al.Van Cutsem J (abst) 480Van Damme-Lombaerts R (abst) 479Vandelli L (letter) 1081Vandenabeele P (abst) 497van den BergB W: See Leunnissen K M L e t al.van den Heuvel L P W J, Savage COS, Wong M, Price R G,

Noel L, Grunfeld J P, Lock wood C M: The GlomerularBasement Membrane Defect in Alport-Type HereditaryNephritis: Absence of Cationic Antigenic

Components 770van der Hem G K (abst) 455van der Hulst R J (abst) 752van der Meer J (abst) 459Van der Merwe W M (abst) 318van der Meulen J (abst) 752, 755van der Veen E A (abst) 459Van Der Vorst P (abst) 517van der Woude F J (abst) 509,521Van de Vyver F L, Visser W J, D'Haese P C, Silva F J E,

Thomas H, De Broe M E: Risk of AluminiumIntoxication in Long-term Acetate Redy Dialysis. . . . 555

Van Dijck M (abst) 479van Dorp W T (abst) 509,521van Elven E H (abst) 424van Es L A (abst) 505,509,521Van Geet C (abst) 479van Gemert G W (abst) 509Vanherweghem J L (abst) 421,497


Vanholder R, Laekeman G, Herman A, Saragananda B,Waterloos M A, Kesteloot D, Lameire N: TheInhibition of Thromboxane Synthesis Has No Influenceon HgClj-Induced Acute Renal Failure in the Rat . . . 625

van HooffJ P (abst) 515van HooffJ P: See Cheriex E C et al.van HooffJ P: See Knols G et al.van HooffJ P: See Leunissen K M L et al.Van Landuyt H W: See Boelaert J R et al.van Rijn H J M: See Rabelink A J et al.Van Saene H K F (abst) 445Van Waeleghem J P: See Heyrman R M et al.van Ypersele de Strihou C (abst) . 434,444,481,493, 506,507Vara F(abst) 500VaretB(abst) 472Varet B (letter) 675Varghese Z (abst) 316,837Varghese Z: See Lui S F et al.Varghese Z: See Sweny P et al.Varini E: See Surian M et al.Vaselov E (letter) 602Vasile G (abst) 485Vassault A (abst) 470VaughanRW(abst) 313Vazelov E (letter). . 75Vecsei P: See Mann J F E et al.Vegeto A (abst) 508Velasco F (abst) 491Venherweghem J L: See Cappello M et al.Veniero P (abst) 516Venkat Raman G: See Waters M R et al.Vennegor M: See Williams B et al.VennekerGT(abst) 450Venning M (abst) 428Venning M C (abst) 832Venning M C: See Atkin S L et al.Verbeelen D (abst) 488Verbeelen D: See De Bock V et al.Verberckmoes R: See Frenken L A M et al.VerbrughHA(abst) 752,755Vercellone A (abst) 442,465,466,467,486,491Vercellone A (letter) 238Vereerstraeten P (abst) 517VerhoefJ(abst) 752Vermylen J (abst) 479Vernier I (abst) 434Vernon V: See Beardsworth S F et al.Verrier Jones K (abst) 419,437Vetter K (abst) 453Viberti G C (abst) 419Vidal M T (abst) 493Vienken J, Harding M: Dialysis Membranes and

P2-Microglobulin: Interactions, Limitations andPerspectives S3:27

Vienken J: See Baurmeister U et al.Vigano G, Gotti E, Comberti E, Giangrande A, Trevisan

R, Remuzzi G: Hyperparathyroidism Does NotInfluence the Abnormal Primary Haemostasis inPatients with Chronic Renal Failure 971

Vijgh W v d (abst) 754Vilardell J (abst) 492,502,517Vilares S (abst) 504Vincent C (abst) 492Vincent D, Charmes J P, Benzakour M, Gualde N, Rigaud

M, Leroux-Robert C: A Simple In Vitro Test toEvaluate Biocompatibility of Dialysis Membranes . . . 306

Dow




Visser W J: See Van de Vyver F L et al.Visset J (abst) 503Vitale C (abst) 437Vlaanderen K (abst) 755Vogeler U (abst) 502,521Vogiatzis K V (abst) 462VogtP(abst) 511von Sperling V (abst) 837Vonesh E (abst) 499Vuillaume M: See Gamier J L et al.VulserC(abst) 459Vyzantiadis A T (abst) 462Wahl P: See Hasslacher Ch et al.Walb D: See Rockel A et al.Waldherr R (abst) 429,440,506Waldherr R: See Noronha I L et al.Waldherr R, Rambausek M, Duncker W D, Ritz E:

Frequency of Mesangial IgA Deposits in a Non-selectedAutopsy Series 943

Walker R G (abst) 426Walker R J: See Swainson C P, Walker R JWalkowiak B (abst) 451Wallner M (abst) 144Walls J (abst) 314,515,833,834,835Walls J (letter) 679,918-19Walls J: See Edmunds M E et al.Walls J: See Jenkins D et al.Walls J: See Williams B et al.Walsley K M: See Woolf A S et al.Walshe J: See O'Meara Y et al.Wandel E (abst) 424Waniewski J: See Lindholm B et al.Wanner C, Riegel W, Schaefer R M, Horl W H: Carnitine

and Carnitine Esters in Acute Renal Failure 951Ward G: See Clarke A G B et al.Ward M (abst) 470, 508Ward M: See Edmunds M E et al.Ward M K (abst) 454,495, 833Ward M K: See Rodger R S C et al.Ward M K: See Tomson C R V et al.Ward R A, Schmidt B, Gurland H J: Biocompatibility of

High-performance Membranes S3:55Ward R A: See Blumenstein M et al.Warwick G (abst) 831Waterloos M A: See Vanholder R et al.Waters M R, Albano J D M, Sharman V L, Venkat Raman

G: Pharmacokinetics of Cyclosporin in Man Followinga Single Oral Dose: Relationship to Body Fat Content. 71

Watschinger B (abst) 146,149,150,151,506Watson M J: See Rodger R S C et al.Watson M L (abst) 317,436Wattenberg M (abst) 477Watzinger U (abst) 473Watzke H (abst) 155Weber M (abst) 424, 520Weemaes C M R (abst) 754WeinreichT(abst) 431,471Weissgarten J: See Modai D et al.Welsh K (abst) 319,838Welsh K I (abst) 313Wenning A: See Neumayer H-H et al.Wens R: See Tielemans C L et al.WenzW(abst) 469Werner E (abst) 469WertheimWJ(abst) 755Werynski A: See Lindholm B et al.

WesteelPF(abst) 418,432,467Westeel P F: See Moriniere Ph et al.Westlie L (abst) 509Westwick J (abst) 835Wetzels J F M, van Bergeijk J D, Hoitsma A J, Huysmans

F Th M, Koene RAP: Triamterene Increases LithiumExcretion in Healthy Subjects: Evidence for LithiumTransport in the Cortical Collecting Tubule 939

Wheeler D C (abst) 837Wheeler D C: See Sweny P et al.White A G (abst) 589, 599Whitworth J (abst) 831Wibom R (abst) 471Wideree T-E (abst) 498Widjaja A (abst) 425Widstam-Attorps U (abst) 432Wiecek A (abst) 466, 475, 505Wiecek A: See Kokot F et al.Wiel T W M v d: See Knob G et al.Wieslander J: See Bygren P et al.Wight J P (abst) 458WijkAv(abst) 751,754Wijnveen A C (abst) 521Wilfling M (abst) 436Wilhelm E (abst) 469Wilkinson R (abst) 437, 508, 834Wilkinson R: See Rodger R S C et al.Wilkinson R: See Thomas T H et al.Wilks M F (abst) 448Will EJ (abst) 443,503,512Will E J: See Davenport A et al.Will EJ: See Worth D Petal.Willems D (abst) 488Williams A J (abst) 314Williams B (abst) 833, 834Williams B, Edmunds M E, Thompson J P, Burton P R,

Feehally J, Walls J: Does Increasing HaemoglobinConcentration and Haematocrit Have a Pressor Effectin Dialysis Patients? 787

Williams B, Vennegoor M, O'Nunan T, Walls J: The Use ofCalcium Carbonate to Treat the Hyperphosphataemiaof Chronic Renal Failure 725

Williams D G (abst) 313,429,837Williams G: See Short C D et al.Williams I (abst) 444Williams J D (abst) 318,319,419,427,437,476Williams P S (abst) 445Williams P S (letter) 917Williams P S, Bone J M: Immunosuppression Can Arrest

Progressive Renal Failure Due to IdiopathicMembranous Glomerulonephritis 181

Williams S: See Short C D et al.Wilson N: See Heney D et al.Wilson R: See Rogerson M E et al.Winberg J (abst) 436Winearls C G (abst) 472,494,833Winearls C G: Erythropoietin 323Winearls C G: See Edmunds M E et al.Wing A J: See Brady A J B, Wing A J; Brunner F P et al.;

Ehrich J. H. H. et al.; Rizzoni G et al.; Tufveson G et al.Wingen A M (abst) 432Winkler H (abst) 146Winkler H M (abst) 144,474Winney R J (letter) 77Winney R J: See Jenkins D A S et al.Wizemann V (abst) 479

Dow



XXV1I1

WoitasRP(abst) 454Wolfram J (abst) 596Woloszczuk W (abst) 148,520Wong C (abst) 477Wong K K: See Chan MKet al.Wong M: See van den Heuvel L P W J et al.Woodhead J S: See Bittar A E et al.Woodrow D F (abst) 508Woodrow D F: See Sethi D et al.Woolf AS(abst) 317Woolf A S: Atrial Natriuretic Peptide, and Renal Disease .1008Woolf A S, Street P R, Walmsley K M, Cohen S L: Portal

Vein Thrombosis in the Nephrotic Syndrome 581Worth D P, Smye S W, Robinson P J, Davison A M,

Will E J: Quantitative Bone Scanning in the Diagnosis ofAluminium Osteomalacia 721

WossE(abst) 145, 154Wramner L (abst) 521Wynckel A (abst) 438WynsW(abst) 481Xatzikonstantinou J (abst) 470Yamagami S (abst) 489Yasavul U (abst) 594, 601Yasuhisa Wakabayashi: See Yusuke Tsukamoto et al.Yoneshima H (abst) 475Yoshida O: See Hosokawa S, Yoshida OYoshida T: See Akizawa T et al.Yoshihei Hirasawa: See Makiko Tsutsui et al.;

Masashi Suzuki et al.Yoshiyama N (abst) 467Yoshiyuki Osamura: See Mitsuyasu Toyoda et al.Youji Akagaki: See Susumu Yoshikawa et al.Young G A, Dibble J B, Hobson S M, Tompkins L, Gibson

J, Turney J H, Brownjohn A M: The Use of an Amino-acid-based CAPD Fluid over 12 weeks 285

Young G A, Dibble J B, Taylor A E, Kendall S, BrownjohnA M: A Longitudinal Study of the Effects of AminoAcid-Based CAPD Fluid on Amino Acid Retention andProtein Losses 900

Yusim A: See Cohen S L et al.Yusuke Tsukamoto, Yasuhisa Wakabayashi, Michihito

Okubo, Fumiaki Marumo: Abnormal Lipid Profiles atVarious Stages of Uraemia S3:142

Yusuke Tsukamoto: See Fumiaki Marumo et al.


ZacheP(abst) 479Zamboulis C X (abst) 462Zanelli P (abst) 429Zazgornik J (abst) 145, 148,511Zazgornik J: See Biesenbach G et al.Zech P (abst) 456,460Zehnder C: See Morales-Barria J et al.ZeierM(abst) 458,471ZemelD(abst) 501,755ZiachehabiF(abst) 144,153,154ZiakE(abst) 144,146,474Zidani R (abst) 591Ziegler-Heitbrock H W L: See Blumenstein M et al.Zimmerman R S (abst) 463ZingraffJ(abst) 470Zins B (letter) 675Zins B: See Najean Y et al.Ziyaie M (abst) 500Zlabinger C J (abst) 588Zlabinger G (abst) 149Zlabinger G J (abst) 506,519,589Zlatarska S (letter) 75,602Zmerli S (abst) 593,599Zoccali C (abst) 439,463,468Zoccali C (letter) 236Zoccali C, Postorino M, Martorano C, Salnitro F,

MaggioreQ: The 'Breakpoint' Test, A New StatisticalMethod for Studying Progression of Chronic RenalFailure 101

Zoellner K. (abst) 476,487Zuber M, Steinmann E, Huser B, Ritz R, Thiel G,

Brunner F: Incidence of Arrhythmias andMyocardial Ischaemia During Haemodialysis andHaemofiltration 632

Zuccala A: See Zucchelli P et al.Zucchelli P: See Passerini P et al.Zucchelli P, Zuccala A, Mancini E: Hypertension in

Primary Glomerulonephritis Without RenalInsufficiency 605

Zukowskas-Szczechowska E (abst) 475

Dow



Subject Index to Volume 4

Ablation Nephropathy, renal transplantation in (abst). . . 457ABO Antibodies, acquired haemolytic anaemia due to

(abst) 671Accessory Cells, in haemodialysis (abst) 490Acetaminophen, photometric determination (abst) . . . . 456Acetate

in haemodialysis 1061in haemodialysis (abst) 481

Acetazolamideeffect on lithium clearance 707effect on lithium clearance (abst) 417

Acid-Base Status, effect of lactate-buffered solutions on . . 800Acidosis

correction in uraemia 92in chronic renal failure (abst) 833

Acinobactor, in CAPD peritonitis (letter) 759Acute Renal Failure

anti-neutrophil cytoplasmic antibodies in (abst) 431APACHE II score (abst) 317atria] natriuretic factor in (abst) 464C-reactive protein (CRP) in 864captoprilin 311carnitinein 951carni tine esters in 951cyclosporin in 311dopamine- and frusemide-resistant (abst) 464erythropoietin (abst) 671felodipine in (abst) 447HgCMnduced 625HgClj-induced (abst) 448hypertension in (abst) 443in infants 535in mercury vapour intoxication 133in nephrotic syndrome 914in newlyborn infants 870in the tropics 535indications for dialysis 537interleukin-2 in (abst) 445

. mean blood pressure (MAP) in 691muscle necrosis in (abst) 444prognosis of (abst) 317renovascular resistance and intrarenal blood flow

(abst) 447sepsis control in (abst) 445thromboxane in 625thyroid hormone profiles in (abst) 444verapamil in (abst) 446

Acute Respiratory Failure, in mercury vapourintoxication 133

Acute Tubular Necrosisin infants 535in the tropics 535

Adaptive Glomerular Hypertrophy 845Adhesion-promoting Glucoprotein

surface expression on granulocytes (abst) 490Adrenal Dysfunction, in renal amyloid (abst) 834Adriamycin

in chronic renal failure (abst) 457innephrosis 1037

Adriamycin (abst) 457AIDS

EDTA Registry Centre Survey 161HIV-related nephropathy in (abst) 434in RRT S2:25

Albuminin insulin-dependent diabetes mellitus (abst) 420in nephrotic syndrome (abst) 466in peritoneal solute transport (abst) 501in pre-eclampsia (abst) 442intraperitoneal human (abst) 755

Albuminuria, circadian rhythm of. 266Aldosterone

in chronic renal failure (abst) 149in uraemia (abst) 673

Allergy, dialysis materials 646Allograft Monitoring, ultrasound (abst) 595Allograft Rejection. See RejectionAI(OH)3

in renal osteodystrophy and soft-tissue calcification. . .1045Alpha-mercaptopropiony lglyci ne

in membranous glomerulonephritis (abst) 434Alport-type Hereditary Nephritis 770Alport-type Nephritis 262Alport's Syndrome 144,611

GBM changes in (abst) 145glomerular basement membrane defect in 770in renal transplantation (abst) 506renal prognosis 1016

Alport's Syndrome (abst) . . 144Aluminium

avoidance in haemodialysis •. . 105determination in biological materials S3:114effect on erythropoiesis and wFe absorption (abst). . . . 468encephalopathy after treatment with desferrioxamine . . 1 1 0encephalopathy exacerbation (letter) 676gastrointestinal absorption in diabetic nephropathy

(letter) 839in bone disease 51,555,957,1045, S3:100,S3:107

Dow



XXX

in CAPD patients (abst) 671in chronic renal failure S3:97in haemodialysis 282in haemodialysis (abst) 488in recombinant human erythropoietin therapy (abst) . . 474in renal transplantation (abst) 503in uraemia (abst) 484in water pollution S3:97intestinal absorption of (abst) 484intoxication risk in long-term acetate Redy dialysis . . . 555mass transfer and plasma kinetics (abst) 467plasma concentrations in CRF 375tissue mobilisation (abst) 470

Aluminium Hydroxideabsorption risk factors (abst) 468in hyperphosphataemia 1005phosphate binders 51plasma phosphate control 51

Aluminium Intoxication S3:97Aluminium Osteomalacia, bone scanning in 721Amino Acids

dialysate containing (abst) 500,501in CAPD 285,900in chronic renal failure (abst) 450in peritoneal dialysis (abst) 495in uraemia (abst) -. 448parenteral nutrition (abst) 673peritoneal dialysate (abst) 833

Aminonucleoside of Puromycin 1037Ampicillin, in salmonella infection 390Amyloid Deposition, pVmicroglobulin-derived S3:11Amyloid Proteins, classification of S3:19Amyloidosis

AA S3:19AL S3:19(3,-microglobulin-related S3:11diagnostic imaging (abst) 494dialysis-associated 1052, S3:83dialysis-related (abst) 493, 494p,-microglobulin in S3:14clinical and pathophysiological aspects S3:7pathogenetic aspects and open questions S3:3haemodialysis-associated (abst) 492in nephrotic syndrome (abst) 438role of AP in S3:20with protein permeable membranes S3:78

Anaemiaacquired haemolytic (abst) 671atrial natriuretic peptide in (abst) 478erythropoietin in (abst) 479in CAPD (abst) 753in chronic renal failure (abst) 597,979in chronic renal failure (abst) 145in dialysis S4:23of end-stage renal disease (abst) 146recombinant human erythropoietin in 966recombinant human erythropoietin

in (abst) 146,147,477,597,979uraemic S3:123see also Erythropoietin

Analgesic Nephropathyafter renal transplantation (abst) 150malignancy in (abst) 150renal insufficiency in (abst) 456

Angiodynography (abst) 150Angiomyolipomas, rupture of (abst) 145


Angiotensingeneration in rat vasculature (abst) 460urinary excretion during sodium restriction

and diuretics 713vascular response (abst) 474

Angiotensin Converting Enzyme (ACE) Inhibitors . . 66,696in chronic renal failure (abst) 444in hypertension 396in insulin-dependent diabetes (abst) 317in renal failure 311

Angiotensin IIplasma concentration of. 532 •specific binding of 530vascular reactivity in pregnancy (abst) 418

Antibody ResponsesT-cell-independent and T-cell-dependent 216

Anti-CD3, Antibodies, nephrotoxicity of (abst) 517Antidiuretic Hormone

syndrome of inappropriate secretion (abst) 421Anti-GBM Antibodies, in glomerulonephritis 254Antiglomerular Basement Membrane Antibodies

in autoimmune glomerulonephritis (abst) 427Anti-HB-C Antibodies, in haemodialysis (abst) 487Antilymphocyte Globulins (ALG)

in EBV lymphoma 818inRRT S2:12,S4:15

Anti-Neutrophil Cytoplasmic Antibodies (ANCA)in vasculitis (abst) 832

Antineutrophil Cytoplasmic Antibodyimmunoperoxydase technique (abst) 438in glomerulonephritis (abst) 438

Anti-Pig Antibodies, identification and removal (abst). . . 319Antiplatelet Agents, oral administration of (abst) 485Anti-Proteases, in haemodialysis (abst) 492Antithymocyte Globulins

in antirejection therapy (abst) 596in release of cytokines (abst) 517inRRT S2:12,S4:15

APACHE II Score, in acute renal failure (abst) 317Apolipoprotein Metabolism, in nephrotic syndrome (abst) 831Apoprotein, in uraemia S3:142Arachidonic Acid Metabolites

biocompatibility with dialysis membranes 306Arginine-glycine-aspartic acid-serine (RGDS) S3:65Arterial Pressure, effect of endothelin (abst) 835Arterial Stenosis, in renal transplant in children 575Arteriovenous Fistulae

diagnosis and therapy (abst) . '. 153duplex sonography of (abst) 152transcatheterembolisationof(abst) 152

Ashing, of biological samples S3M15Aspirin-Dipyridamole, in diabetic nephropathy 140Atenolol, effect on atrial natriuretic factor (abst) 464ATG, in renal transplantation (abst) 506Atherosclerosis, in haemodialysis S3:142ATP, muscle mitochondrial formation (abst) 471Atrial Natriuretic Factor

ANF102-126(WY 47987) 776effect of P-adrenergic receptor blockade (abst) 464in acute renal failure (abst) 464inCHF(abst) 149in chronic renal failure (abst) 317in heart failure (abst) 465plasma concentration of. 532response of renal interstitial pressure to (abst) 463specific binding of 530

Dow




Atrial Natriuretic Peptide 691and renal disease 1008effect on blood pressure and blood volume (abst) . . . . 464immunoradiometric assay (abst) 466, 836in anaemia (abst) 478inCAPD(abst) 500in chronic renal failure 1008in haemodialysis 382in haemodialysis (abst) 500in haemodialysis (letter) 602in haemofiltration (letter) 602in healthy subjects 1008in hypertensive rats (abst) 463in nephrotic syndrome 1010in nephrotic syndrome (abst) 466in polycystic kidney disease (abst) 465in progression of renal disease 1012in recombinant human erythropoietin (abst) 478in uraemia (abst) 464,465in venous renal blood (abst) 466inactivationof(abst) 466plasma concentrations of 222polyclonal antibodies (abst) 466release during nocturnal water immersion (abst) 420

Autoantibodies 1Autoimmune Glomerulonephritis

antiglomerular basement membrane antibodies in (abst) 427Azathioprine

in allograft rejection 387in follow-up cases (abst) 594in heart transplantation (abst) 505in hypertension (abst) 512in idiopathic membranous glomerulonephritis 181in living related donor kidney recipients 293in living related donor kidney transplantation (abst) . . 519in rejection episodes (abst) 152in renal graft recipients returning to haemodialysis (abst) 518in renal transplantation 129in renal transplantation

(abst) 504,508,509,510,514,517,518inRRT S2:12, S2:13,S4:17in salmonella infection 390in Wegener's granulomatosis (abst) 435triple-therapy (abst) 594

Backfiltration, endotoxin transfer by S3:89Balkan Nephropathy, |3,-microglobulin in (abst) 443Balloon-dilatation 57P-adrenergic Blockade, effect on atrial natriuretic factor

(abst) 464B-cell Markers in the Human Kidney 85P:-Microglobulin

amyloidosis imaging (abst) 494collagen beads for removal of (abst) 494dialysis-related amyloid deposits (abst) 493elimination by polyacrylonitrile membrane dialyser . . . 356

. in Balkan nephropathy (abst) 443in dialysis arthropathy (abst) 318in dialysis-associated amyloidosis 1054in dialysis-associated amyloidosis (abst) 494in dialysis-related amyloidosis . . . . S3:3, S3:7, S3:ll, S3:14in haemodialysis 282, 549, S3:43, S3:78in haemodialysis (abst) 490, 492in push/pull haemodiafiltration S3:83influence of membrane characteristics on S3:27mass transfer characteristics of high-performance

modified cellulose membrane S3:55

removal of 653sources of elevated (abst) 589

Beta-blockers, in hypertension (abst) 460Bicarbonate

dialysate modelling (abst) 482Dialysis Buffer S3:43supplementation in uraemia 92

Biocompatibilitybiological responses at non-physiological interfaces

and molecular design of biocompatible surfaces . . S3:60ex-vivo model S3:43in dialysis S3:125in haemodialysis S3:41in haemodialysis (abst) 489in hypoxaemia 489of high-performance membranes S3:55

Biological Specimens, sampling of S3:l 15Blindness, in acute glomerulonephritis (letter) 236Blood, atrial natriuretic peptide estimation (abst) 466Blood Concentration in post-transplant hypertension

(abst) 601Blood Flow Rate, effect on plasma C3a and C5a

concentration S3:46Blood-material Interfaces, thrombus formation S3:60Blood Pressure, in uraemia (abst) 464Blood Transfusion

cyclosporin in pre-transplant (abst) 838donor-specific (abst) 588in renal transplantation (abst) 588inRRT S4:14

Blood Volumecorrelation with VCD and collapse index 563in uraemia (abst) 464

Body Fat Content, effect of cyclosporin 71Body Temperature, in haemodialysis (abst) 483Bone Biopsy, in oxalosis-induced bone disease (abst) . . . 469Bone Density, in calcium stone formers (abst) 432Bone Disease

aluminium in 51,555,957,1045aluminium-induced S3:98, S3:100, S3:107non-aluminic adynamic (abst) 467oxalosis-induced (abst) 469

Bone Marrow Cellscalcium uptake (abst) 475response to erythropoietin (abst) 475

Bone Marrow Fibrosis, in haemodialysis (letter) 674Bone Marrow, immunohistochemical examination . . . S3:23Bone Scanning, in aluminium osteomalacia 721Bopindolol, in renal impairment (abst) 835Bourneville-Pringle disease (abst) 144Breakpoint Test, in chronic renal failure 101Cachetin, production and clearance of (abst) 491Calcitonin-gene-related Peptide, in hypertension (abst) . . 463Calcitriol

in chronic haemodialysis patients (abst) 318in secondary hyperparathyroidism (abst) 318in uraemia (abst) 451,452in uraemia with severe hyperparathyroidism

and hypercalcaemia 545Calcium

absorption in nephrotic syndrome (abst) 469effect on parathyroid hormone secretion in uraemia. . . 339inCAPD(abst) 496in hypertension (abst) 461in renal osteodystrophy and soft-tissue calcification. . .1045in renal transplantation (abst) 514

Dow



XXXII

ionised, effect on haemodialysis 115platelet-free mobilisation (abst) 479uptake by bone marrow target cells (abst) 475

Calcium Antagonistseffect on T-cell proliferation (abst) 520in type II diabetes mellitus (abst) 459

Calcium Carbonatein children 539in children with chronic renal failure 539in haemodialysis 105in haemodialysis (abst) 484in hyperphosphataemia 725,1005

CalciunrCreatinine Ratioin pre-eclampsia (abst) 439in pregnancy (abst) 439

Calcium Deposition, P2-microglobulin-derived S3:11Calcium Intake, in haemodialysis S3:138Calcium Stone Formers

bone density in (abst) 432hypocitraturia in (abst) 437

Cancer. See MalignancyCAPD 41,62

aldosterone concentration (abst) 149aluminium concentration in serum

dialysate, urine and bone (abst) 671amino-acid-based fluid 285, 900amino acid dialysate (abst) 833anaemia in (abst) 753ANF plasma concentration (abst) 149antibody responses 216atrial natriuretic peptide in (abst) 500blood lead and plasma aluminium concentrations. . . . 375captoprilin 1084catheter placement in urinary bladder (abst) 751coagulase-negative staphylococcal peritonitis (abst). . . 495comparison with continuous cyclic peritoneal

dialysis (abst) 752,755comparison with haemodialysis 244cyclic guanosine monophosphate in (abst) 500cytokine release (abst) 496dialysate IgG and peritonitis in (abst) 501,755fluid reabsorption in 805haematocrit in 787haemoglobin in 787hypercholesterolaemia in (abst) 753idiopathic nephrogenic ascites in (letter) 918IgG, deficiency in children (abst) 754in developing countries (abst) 499in pregnancy 583insulin as additive to dialysate (abst) 500interleukin-6 in (abst) 497nephrogenic ascites in (letter) 918nitrogen losses in children (abst) 497ototoxicity monitoring (abst) 752peritoneal fibroblast proliferation (abst) 496peritoneal function in (abst) 495peritoneal IgG in (abst) 496peritoneal lymph flow in (abst) 753peritoneal macrophages in (abst) 496peritoneal solute transport in (abst) 755peritoneal transport kinetics (abst) 498peritoneal ultrafiltration in 805peritonitis (abst) 752, 833peritonitis (letter) 759pseudomonas peritonitis in 814recombinant erythropoietin in (abst) 318


recombinant human erythropoietin in (abst) . . . . 754, 833recombinant human erythropoietin in (letter) 676renal function recovery (abst) 499residual renal function in (abst) 499rickets in infants on (abst) 753sclerosing peritonitis in (abst) 498serum vanadium concentrations S3:98survey in Belgium (abst) •. . 497swan neck catheter in (abst) 154transport of macromolecules from peritoneal cavity

(abst) 498ultrafiltration failure (abst) 751upper gastrointestinal tract pathology in (abst) 496vancomycin in (abst) 751Vitamin E (letter) 75

Captoprileffect on glomerular hyperfiltration (abst) 454effect on thromboxane B, (abst) 421in acute renal failure 311inCAPD 1084in chronic renal failure 696in chronic renal failure (abst) 457in cryoglobulinaemic glomerulonephritis (letter) 839in diabetic nephropathy (abst) 433in hypertension (abst) 461in membranous glomerulonephritis 172in transplant renal artery stenosis 66

Carbamylated Haemoglobin, in uraemia 96Carbidopa, in intravenous saline loading 271Carboplatin, in ovarian cancer (abst) 754Cardiac arrest, in RRT S2:18

kidney donation in (abst) 590Cardiac Arrhythmias

in haemodialysis 632in haemofiltration 632

Cardiac failure, in RRT S2:18Cardiac Function

by echocardiography S3:146in chronic renal failure (abst) 461in haemodialysis 792in uraemia (abst) 465

Cardiac Performanceeffect of erythropoietin (abst) 477in uraemia (abst) 487

Cardiac Zygomycosis, desferrioxamine (DFO) in 911Cardiovascular Accident, in RRT S4:19Cardiovascular Dynamics, effect on recombinant

human erythropoietin S3:146Carpal Tunnel Syndrome

granulocyte elastase-a,-protease inhibitor in S3:134in dialysis S3:134in dialysis-related osteoarthropathy S3:32in haemodialysis S3:14

Carnitinein acute renal failure 951in haemodialysis 366

Carnitine Esters, in acute renal failure 951Carpal Tunnel Syndrome (CTS), inflammation in (abst). . 492Catabolic Patients, creatinine clearance in (abst) 673CCPD, in children 893CCPD (abst) 752, 755CD45 Monoclonal Antibodies (abst) 838Ceftazidime in pseudomonas peritonitis 814Cellular Adhesion, in thrombus formation S3:65Cellulose Acetate Membranes, biocompatibility tests on. . 306Cephradine, in peritonitis (abst) 752

Dow




Cerebral Blood Floweffect of erythropoietin therapy (abst) 474

Cerebrovascular accident, in RRT S2:17Children

regular dialysis and transplantation of. S2:33rehabilitation S2:37, S4:35renal diseases in S4:35RRT in S2:33,S4:31

Chocolate, in transient hyperoxaluria (abst) 154Chronic Ambulatory Peritoneal Dialysis. See CAPDChronic Renal Failure

acidosis in (abst) 833aldosterone in (abst) 149aluminium in S3:97amino acids in (abst) 450anaemia in 979anaemia in (abst) 145,597ANFin(abst) 149and age (abst) 468angiotensin converting enzyme (ACE)

inhibitors in (abst) . . . " 444atrial natriuretic factor in (abst) 317atrial natriuretic peptide in 1009blood lead and plasma aluminium concentrations . . . . 375breakpoint test in 101captopril in 457, 696cardiac function in (abst) 461creatinine in (abst) 450deferoxamine in S3:97dietary protein in 877effects ofANF102-126(WY 47987) 776eicosapentanoic acid in (abst) 454erythrocyte sodium and sodium flux in 2)erythropoietin in (abst) 145factors affecting progression (abst) 457fenoldopam infusion (abst) 418GFRin(abst) 672growth hormone in (abst) 451hereditary renal disorders in (abst) 144human neutrophil elastase (HNE) in (abst) 481hyperparathyroidism in 971hyperparathyroidism in children with 539hyperphosphataemia in 725hypertension in 21hypertension in (abst) 461hyperthyroidism in children with 539in children (abst) 451in Pringle-Bourneville disease (abst) 145insulin resistance in (abst) 450intrahepatic cholestasis in (abst) 590keto acids in (abst) 453lipid abnormality in S3:142lipoprotein in (abst) 448luteinising hormone in (abst) 834nephron adaptation in (abst) 458nifedipine in (abst) 458nitrogen in 877pituitary-adrenal function in (abst) 146platelet storage pool defect in (abst) 148progression of 101prostacyclin (PGI2) in (abst) 148protein-restricted diets in (abst) 457recombinant human erythropoietin in 782recombinant human erythropoietin in (abst) 474renal function in (abst) 672sicca-like syndrome in (abst) 439

xxxiii

T-cell-independent and T-cell-dependent antibodyresponses 216

tertatolol in (abst) 419thromboxane B, in (abst) 148trace elements in S3:97vanadium in S3:97

Cilastatin, in haemofiltration 640Cimino-Brescia Fistula, duplex sonography (abst) 152Ciprofloxacin 390

in CAPD peritonitis (letter) 759Orcadian Rhythm, in glomerulopathies (abst) 420Circadian Rhythm of Proteinuria 9,266cis-Dichlorodiamine Platinum

in glomerular haemodynamic evaluation ( a b s t ) . . . . 448Cisplatin, in ovarian cancer (abst) 754Clindamycin, in peritonitis (abst) 752Clonidine, in restless leg syndrome (abst) 149Coagulase-negative Staphylococci

(abst) 833peritonitis due to 62

Coagulation System, effects of blood-materialinteractions S3:6O

Cocaine, in rha.bdomyolysis (letter) 675Colchicine, in Familial Mediterranean Fever 201Collagen Beads for p2-microglobulin removal ( a b s t ) . . . . 494Colour-coded Doppler Sonography (abst) 150Complement

activation in haemodialysis 646C3 in Mesangial IgA Glomerulonephritis (abst) 440C3d in renal failure (abst) 450

in active in-situ glomerulonephritis (abst) 315terminal complex formation (abst) 489

Complement Activationeffects of blood-material interactions S3:60in haemodialysis S3:41

Complement activation, in thrombogenesis S3:67Complement Activation, membrane-induced S3:50Complement Receptor (CR1)

effect on erythrocytes and in immune complexes 932Concanavallin A (Con A), in kidney graft (abst) 588Congenital Heart Disease, in newlyborn infants 870Continuous Ambulatory Peritoneal Dialysis. See

CAPDContinuous Arteriovenous Haemofiltration (CAVH).

See HaemofiltrationContinuous Cycling Peritoneal Dialysis (CCPD). See

CCPDCoronary Artery Disease, in dialysis patients (abst) . . . . 479Coronary Revascularisation, in haemodialysis (abst) . . . 481Corticosteroids, in RRT S4:17Co-trimoxazole, in salmonella infection 390C-Reactive Protein (CRP), in acute renal failure 864Creatinine

in chronic renal failure (abst) 450reciprocal plasma (abst) 672serial determinations in renal transplantation 1076

Creatinine Clearancein catabolic patients (abst) 673measurement of 266

Cryoglobulinaemiacaptopril in (letter) 839phagocyte cytoskeleton in (abst) 440

Cryoprecipitate, in uraemic thrombopathy (abst) 449Cuprophane Membranes

biocompatibility tests on 306effect on tumour necrosis factor (abst) 490

Dow



Cyclic Guanosine MonophosphateinCAPD(abst) 500in haemodialysis (abst) 500

Cyclophosphamidein idiopathic membranous glomerulonephritis 181in systemic lupus erythematosus (abst) 435in Wegener's granulomatosis (abst) 435

Cyclosporinblood concentration in post-transplant hypertension

(abst) 601chronic nephrotoxicity (abst) 591effect on body fat content 71effect on endothelium-dependent relaxation of human

resistance vessels (abst) 838effect on glomerular dynamics (abst) 516effect on glomeruli and mesangial cells (abst) . . . . 515-16effect on peripheral resistance vessels (abst) 516effect on plasma lipids (letter) 237effect on superficial and juxtamedullary isolated human

glomeruli (abst) 513effect on tubular function (abst) 514effect on vascular endothelium (abst) 316in acute renal failure 311in allograft rejection 387in EBV lymphoma 818in eicosanoid production (abst) 513in Familial Mediterranean Fever 201in glomerulonephritis 923in glomerulonephritis (abst) 425in glycosaminoglycans synthesis of human fibroblasts

(abst) 513in heart transplantation (abst) 459, 505in hyperpigmentation 309in hypertension (abst) 507,512in idiopathic membranous GN (IMGN) 926in IgA nephropathy 926in insulin-dependent diabetics (abst) 514in living related donor kidney transplantation 293in living related donor kidney transplantation (abst) . . 5 1 9in nephrotic syndrome (abst) 432in pre-transplant blood transfusions (abst) 838in pregnancy (abst) 511in pregnancy in renal transplant recipients 667in psoriasis (abst) 511in Raynaud's phenomenon (abst) 512in rejection (abst) 519in renal graft recipients returning to haemodialysis

(abst) 518in renal transplant arterial stenosis 575in renal transplantation 129in renal transplantation (abst)

504, 505, 508, 509, 510, 511, 512, 514, 515, 517, 518, 521inRRT S2:12,S2:13,S2:36,S4:17in systemic lupus erythematosus (SLE) 923in vitro alloreactivity inhibition (abst) 589influence of HLA phenotypes (abst) 589nephrotoxicity (abst) 512,514,515,516,595,835nephrotoxicity reversibility by dopamine 327pharmacokinetics of 71triple-therapy (abst) 594

Cysteinyl Leukotrieneseffect ofsulindac sulphide on synthesis of (abst) 418

Cytokinesin allograft rejection 824in dialysis-associated amyloidosis (abst) 494induction of prostaglandins by (abst) 422


interleukin-1-like (abst) 423release of (abst) 517

Cytomegalovirus Infectionafter renal transplantation (letter) 238detection of cells infected with (abst) 670ganciclovir in 906in MHC Class I expression on endothelial cells

(abst) 521in renal transplantation (abst) 502, 504, 509, 520

Cytoplasmic Antigen, identification of . 3Daltroban

effect on cyclosporin-induced nephrotoxicity (abst) . . . 512Dazoxiben, in acute renal failure 625Death, from dialysis termination 41Deferoxamine

in aluminium-related bone disease S3:98in chronic renal failure S3:97

Defibrotide, in haemodialysis (abst) 487Dehydration, renal vein thrombosis in 992Desferrioxamine

in aluminium encephalopathy 110in aluminium encephalopathy (letter) 676in aluminium-related bone disease S3:107in aluminium osteomalacia 721in aluminium toxicity S3:101in cardiac zygomycosis 911in haemodialysis 883in haemodialysis (abst) ; 486in haemofiltration (abst) 467in mucormycosis (abst) 480in parathyroidectomy (abst) 470

Desmopressin, in uraemia (abst) 452Dextrans, glomerular transport of (abst) 420Diabetes Mellitus

angiotensin-converting enzyme inhibition in (abst) . . . 317cyclosporin in (abst) 514fructosamines in 748glycosylated and carbamylated haemoglobin in 96haemodialysis in (abst) 151hyperglycaemia in (abst) 436hypertension in (abst) 151hypertensive type II (abst) 459in membranous glomerulonephritis 172in renal replacement (letter) 399in renal transplant recipients (abst) 599non-nephropathic Type I 530post-transplant (abst) 509risks of nephropathy in 859type 1 859type I (letter) 399type II 859type II (letter) 399uraemic insulin-dependent (abst) 507vascular disease in (abst) 151

Diabetic Nephropathyaspirin-dipyridamole in 140captopril in (abst) 433glycosylated albumin (abst) 420in insulin-dependent diabetes mellitus (abst) 151secondary hyperparathyroidism in (letter) 839

Dialox, in re-use of high-flux dialysers 999Dialysate

contamination by endotoxins S3:89fluoride contamination in S3:99vanadium contamination in S3:98

Dialysate Calcium, stepwise reduction in 105

Dow




Dialyserscharacterisation and coding S4:21regenerated cellulosic membrane S3:46

Dialysisanaemia in S4:23Pj-microglobulin-derived amyloid and calcium

deposition in S3:11biocompatibility in S3:125carpal-tunnel syndrome in S3:134failing arteriovenous fistulae 57termination by viable patients 41termination of (letter) 602see also Amyloidosis, dialysis-related; Membranes;

Osteoarthropathy, dialysis-relatedDialysis Arthropathy

diagnosis (abst) 494haemodialysis in (abst) 492high-flux haemodialysis (abst) 495treatment of (abst) 318

Dialysis Dementia 110Dialysis Dementia, aluminium-induced S3:97Dialysis Encephalopathy, aluminium-induced S3:100Diastolic Ventricular Performance, in haemodialysis

(abst) 152Diclofenac, in membranous nephritis 393Diet Therapy, in uraemia S3:124Dietary Protein, in chronic renal failure 877Diffusion, hollow fibre membranes S3:73Difluoromethylornithine, in duodenal mucosal atrophy

(abst) 484Digital Subtraction Angiography (DSA) (abst) . . . . 152, 153Diltiazem

effect on thromboxane B, (abst) 421in chronic renal failure (abst) 457

Diphosphoglycerate, in uraemia (abst) 452Diphtheroids, in CAPD peritonitis (letter) 759Dipyridamole, in diabetic nephropathy 140Disequilibrium Syndrome, effect of membrane-induced

complement activation S3:50DNA, immunoglobulin switch region polymorphisms

(abst) 313DNA Synthesis, and renal growth factor 334Donor Nephrectomy, glomerular hyperfiltration after

(abst) 508Dopamine

cyclosporin nephrotoxicity reversibility by 327in renal transplantation (abst) 505in sodium excretion 271

Double-lumen Quinton Catheter 586D-penicillamine, in membranous glomerulonephritis . . . 172Duodenal Mucosal Atrophy, difluoromethylornithine in

(abst) 484Duplex Sonography, of arteriovenous fistulae (abst). . . . 152ECG

hyperkalaemia simulating acute myocardialinfarction 233

in end-stage renal disease (abst) 453Echocardiography, cardiac function by S3:146Echography, inferior vena cava 563EDTA, Registry Centre Survey 161Eicosanoid Production, cyclosporin in (abst) 513Eicosapentanoic Acid, in chronic renal failure (abst). . . . 454Enalapril

in hypertension 396in spontaneously hypertensive rat (abst) 836

Encephalopathy, aluminium (letter) 676

xxxv

Endothelial Cells, effect of cytomegalovirus infection on(abst) 521

Endothelial-Monocyte System (abst) 315Endothelin, effect on arterial pressure, renal blood flow and

GFR(abst) 835Endotoxin, blood concentration in haemodialysis

(abst) 155Endotoxin Antibodies, in haemodialysis (abst) 489Endotoxin Transfer, by backfiltration S3:89Energy Intake, in haemodialysis S3:138Epstein-Barr Virus 818Erythrocyte Sodium 21Erythrocyte Sodium and Sodium Fluxes, in

hypertension 21Erythrocyte Sodium-Potassium Cotransport 24Erythrocytes

and recombinant human erythropoietin (abst 476complement receptor (CR1) and IgG or IgA on 932fragmentation complications (abst) 484glutathione peroxidase in haemodialysis (abst) 479in haematuria (abst) 434in haemodialysis 282

Erythrocytosis, post-transplant (abst) 600Erythron Transferrin Uptake (ETU) 324Erythropoiesis

effect of aluminium (abst) 468in renal transplantation 1076kinetics in haemodialysis 350

Erythropoietic Stimulating Factor (ESF), in renaltransplantation 1076

Erythropoietin 782bone marrow cell response (abst) 475circulating concentrations of 323cloning of gene coding for 323daily self-administered subcutaneous (abst) 473effect on cardiac performance (abst) 477effect on exercise capacity (abst) 477in acute renal failure (abst) 671in anaemia (abst) 479in chronic renal failure (abst) 145in haemodialysis (abst) 471,475,487in renal anaemia (abst) 146in renal cancers associated with polycythaemia (abst). . 472in renal tubular cell production (abst) 420influence on red blood cell glutathione perioxidase andselenium (abst) 479intravenous versus subcutaneous application (abst) . . . 478modulation by monocytes (abst) 472optimal form of (abst) 473serial determinations in renal transplantation 1076synthesis of 323target cells for 324target point for (abst) 147see also Recombinant human Erythropoietin

Escherichia coliin CAPD peritonitis (letter) 759in urinary tract infection (abst) 437in wound infection (abst) 597vertoxin-producing (abst) 314

Ethylene Oxide, allergic reactions 646Exercise Capacity

effect of erythropoietin (abst) 477in haemodialysis (abst) 319

Extracellular Fluid Volume, in haemodialysis 549Extracorporeal Circulation, activation of body defence

mechanisms during S3:60

Dow



Familial Haematuria, diagnosis of (abst) 145Familial IgA Nephropathy, immunological and

immunogenetic studies (abst) 441Familial Mediterranean Fever

colchicinein 201cyclosporin in 201

Familial Primary Glomerulonephritis, genetic mechanismof (abst) 440

Familial Renal Glycosuria, hypoglycaemia in ( a b s t ) . . . . 433Felodipine, in acute renal failure (abst) 447Fenoldopam, effect on natriuresis in chronic renal failure

(abst) 418Fenoprofen, in membranous glomerulonephritis 172Fibrinopeptide, in haemodialysis (abst) . 489Fibronectin

effect on C3b and Fc receptor-mediated phagocytosis. . 15in nephritis (abst) 429

Fine-needle Aspiration Biopsy (FNAB) (abst) 302,595Fish Oil

in psoriasis (abst) 511in renal scarring (abst) 837in renal transplantation 1070

Fistula Blood Flow, in haemodialysis (abst) 319Fluid Reabsorption, in peritoneal dialysis 805Fluoride, contamination in dialysate S3:99Focal Sclerosing Glomerulonephritis

development and evolution of (abst) 457Focal Segmental Glomerulosclerosis, in rats (abst) . . . . 457Follicle-stimulating Hormone

in erythropoietin treatment (abst) 475Formaldehyde, allergic reactions 646Fructosamines

in diabetes mellitus 748in renal transplantation 748in uraemia 748

Frusemideeffect on lithium clearance 707effect on lithium clearance (abst) 417in membranous nephritis 393

Frusemide-sensitive Sodium-Potassium Cotransport . . . 22Gallium, renal scintigraphy 76Ganciclovir, in symptomatic cytomegalovirus infection . . 906Gentamicin, ototoxicity monitoring (abst) 752Glomerular Antigens, autoantibodies to 1Glomerular Basement Membrane (GBM)

anionic site status in rats (abst) 836antigenicity of 262defect in Alport-type hereditary nephritis 770electron microscopy (abst) 145in nail-patella syndrome 262reactivity of monoclonal antibody PI with 611see also Anti-GBM antibodies

Glomerular Cell Culture 1Glomerular Cells, lymphocyte reactivity to (abst) 670Glomerular Cellular Injury and Dysfunction 847Glomerular Disease

and malignancy (abst) 435Schistosoma haematobium in (abst) 431

Glomerular Dynamics, effect of CsA (abst) 516Glomerular Filtration Rate (GFR) 27,66

circadian rhythm 266effect of captopril 696effect of endothelin (abst) 835effect of human recombinant erythropoietin 966effect of lipids (abst) 421effect of nifedipine (abst) 515


effect of nitrendipine 1030in acute renal failure 625in children with chronic renal failure 539in chronic renal failure (abst) 672in renal transplantation (abst) 504in restitution of renal artery blood flow (abst) 462in the elderly (abst) 417measurement of . 141response to mixed protein meal 683

Glomerular Hyperfiltrationafter donor nephrectomy (abst) 508effect of nifedipine and captopril (abst) 454

Glomerular Neutrophil Countseffect of lipopolysaccharide and tumour necrosis factor

(abst) 315Glomerular Transport, of dextrans (abst) 420Glomerulonephritis

active in-situ (abst) 315acute post-streptococcal (abst) 429and cortical blindness (letter) 236antineutrophil cytoplasmic antibodies in (abst) 438autoantibodies in (abst) 314circulating immune complexes in (abst) 153complement depletion in (abst) 315complement receptor (CR1) in 932cryoglobulinaemic (letter) 839cyclosporin in 923cyclosporin in (abst) 425familial occurrence of (abst) 441Goodpasture and non-Goodpasture anti-GBM

antibodies in 254hypertension in 605hypertension in (abst) 461IgA in 932IgGin 932immune-mediated (abst) 423immunosuppression in 196immunosuppression in (letter) 917,918in renal transplantation 730mesangial IgA 943mesangial IgA (abst) 429PGE, in (abst) 836plasma exchange in 196pregnancy in (abst) 831recurrence in transplant recipients 927renal effects of enalapril in hypertensive patients with . . 396strain-dependent experimental autoimmune (abst) . . . 314

Glomerulopathies, circadian rhythm in (abst) 420Glomerulosclerosis

animal model (abst) 837focal segmental (abst) 314hypertension in 846initiation of 843, 846interventions aimed at preventing initiation of 848interventions aimed at preventing progression of . . . . 850pathogenesis and treatment 843progression of 847therapeutic implications 848

Glomerulusdevelopmental biology (abst) 835effect of CsA (abst) 515-16effect of CsA on superficial and juxtamedullary isolated

human (abst) 513Glucocorticoids

effect on erythrocyte sodium transport (abst) 503Glutathione Peroxidase, red blood cell (abst) 479

Dow




Glycocalcin, in haemodialysis (abst) 489Glycosaminoglycan production

effect of cyclosporin (abst) 513Glycosylated Haemoglobin, in uraemia 96Goodpasture and Non-Goodpasture Anti-GBM

antibodies, in glomerulonephritis 254Goodpasture Anti-genetic Determinant 262Goodpasture's Syndrome 1, 611Graft Monitoring, mitogen responsiveness in (abst) . . . . 588Granulocyte Elastase, in uraemia S3:125Granulocyte Elastase-a,-protease Inhibitor, in

carpal-tunnel syndrome S3:134Granulocyte LFA-1, in haemodialysis (abst) 489Granulocyte-specific anti-nuclear antibody (GS-ANA)

(abst) 832Granulocytes, expression of Mac-1 on (abst) 490Grey Turner's Sign, in sclerosing peritonitis (abst) 754Growth Hormone

in chronic renal failure (abst) 451in compensatory renal growth (abst) 456stimulation by amino-acid-containing dialysate (abst). . 500

HaematocritinCAPD 787in haemodialysis 787

Haematuriain lung cancer 947red blood cells in (abst) 434

Haemodianitrationadequacy of 32P2-microglobulin in 653clinical tolerance to 32paired nitration dialysis (abst) 485push/pull S3:83re-use of high-flux dialysers 999

Haemodialysis 15accessory cells in (abst) 490acetate in 1060acetate in (abst) 481allergic reactions 646altitude exposure (abst) 154aluminium avoidance 105aluminium in (abst) 488and renal cell carcinoma 763anti-HB-C-antibodies in (abst) 487anti-proteases in (abst) 492antibody responses 216atherosclerosis in S3M42atrial natriuretic peptide in (abst) 500atrial natriuretic peptide in (letter) 382, 602backfiltration S3:41,S3:89pVmicroglobulin in 549, 653, S3:14, S3:43,S3:78PJ-microglobulin in (abst) 490,492bidirectional roller blood pump (abst) 483biocompatibility in S3:41biocompatibility in (abst) 489biocompatibility in hypoxaemia (abst) 489blood lead and plasma aluminium c o n c e n t r a t i o n s . . . . 375body temperature in (abst) 483calcium carbonate in (abst) 484calcium intake in S3:138cardiac arrhythmias in 632cardiac function in 792carnitinein 366,951carnitine esters in 951central venous access 987communication during 119

xxx vn

comparison with CAPD 244complications related to S3:138coronary revascularisation in (abst) 481cyclic guanosine monophosphate in (abst) 500defibrotide in (abst) 487desferrioxamine in 883desferrioxamine in (abst) 486dialysis-associated amyloid 1054diastolic ventricular performance in (abst) 152"dry weight' estimation 563EDTA Registry Centre Survey 161effect of intravenous calcitriol in 545effect of membrane-induced complement activation . S3:5Oeffect on intracellular cation content and transport (abst) 834effects on plasma atrial natriuretic peptide 222efficiency after treatment with recombinant humanerythropoietin 718endotoxin antibodies in (abst) 489endotoxin concentration (abst) 155energy intake in S3:138erythropoiesis kinetics 350erythropoietin in (abst) 471,475,487exercise performance (abst)'. 154extracellular fluid volume in 549fibrinolytic activity during (abst) . . . 491haematocrit in 787haemoglobin in 787high-flux (abst) 318,484,495high-flux membranes S3:41histamine in (abst) 480HIV infection in (abst) 486hollow-fibre 569human neutrophil elastase (HNE) in (abst) 481hyperoxalaemia in (abst) 454hyperphosphataemia in S3:140in diabetes mellitus (abst) 151in hereditary kidney diseases (abst) 144infection in 883interleukin-1 in S3:42interleukin-2 in (abst) 488iron in 883lipid metabolic abnormalities in S3:139malnutrition in (abst) 485membrane biocompatibility 306metenkephalin retention in (abst) 468mortality in (abst) 486myocardialischaemiain. : 632non-heparin (abst) 485non-steroidal anti-inflammatory drugs (NSAIDs) in(abst) 482non-transferrin-bound iron in (abst) 488nutrition in S3:138oxalate clearance in 792oxalate plasma concentration in 792parathyroid hormone in (abst) 672parathyroid secretion in (abst) 468phosphate control 105picotamidein 1083phosphorus intake in S3:138plasma C3a and C5a concentration in S3:46plasma protein absorption during (abst) 150platelet activating factor (abst) 491platelet lipid peroxidation in 975pneumatosis intestinalis in 745protein intake in S3:138Pseudomonas aeruginosa in (abst) 155

Dow



xxxviii

Quinton double-lumen catheter 586re-use of high-flux dialysers 999re-use of polyacrylonitrile and polysulphone dialysers

(abst) 671recombinant human erythropoietin in 1065recombinant human erythropoietin in (abst) . . . . 319,475Redy dialysis system 555renal function recovery (abst) 499residual renal function in (abst) 499seizures in 1065Staphylococcus aureus infections in 278superior vena caval obstruction 586ten-year follow up (abst) 482terminal complement complex formation by blood-

membrane contact (abst) 489tumour necrosis factor (TNF) in S3:42ultrashort daily auto-dialysis (abst) 483ultrasonic neck examination 45vanadium in 282vancomycin in 635vitamin Din S3:140vitamin D in (abst) 672volume status in 382weakness in 366see also Membranes

Haemofiltrationatrial natriuretic peptide in (letter) 602P2-microglobulin in 653cardiac arrhythmias in 632continuous arteriovenous 640, 870desferrioxamine in (abst) 467effects on plasma atrial natriuretic peptide 222myocardial ischaemia in 632polyacrylonitrile membrane dialyser 356pre-postdilution 37push/pull S3:83urea clearance in 37vancomycin in 635

Haemoglobincarbamylated 96glycosylated 96inCAPD 787in haemodialysis 282,787serial determinations in renal transplantation 1076

Haemoglobin-S Monitoringin renal transplantation (abst) 600

Haemolytic Uraemic Syndromein childhood (abst) 446in infants 535in the tropics 535legionella-associated 995neutrophil count and prognosis in (abst) 433post-enteropathic (abst) 313renal biopsy in (abst) 145types of (abst) 145

Hansen's Disease, renal involvement in 81Hantavirus Nephropathy, in Denmark (abst) 672HBS vaccination, influence of thymopentin (abst) 154Heart failure, atrial naturetic factor in (abst) 465Heart Transplantation

cyclosporin in (abst) 459hypertension in (abst) 459water immersion in (abst) 505

Heart Valve Prostheses, renal siderosis in (abst) 443Henoch Schonlein Nephritis, mesangial cells in (abst) . . . 831Hepatic Adenomectomy (abst) 438


Hepatitis BEDTA Registry Centre Survey 161in membranous glomerulonephritis 172in renal transplant recipients 297in RRT S2:29number of new cases in 1988 S4:27vaccination (abst) 150vaccination in children and adolescents 372

Hepatorenal Failure, prostacyclin in (abst) 443Hereditary Nephritis

Alport-type 770types of (abst) 144without nerve deafness (abst) 145

Hereditary Nephropathy 6115-HETE, biocompatibility with dialysis membranes. . . 30612-HETE, biocompatibility with dialysis membranes . . 30615-HETE, biocompatibility with dialysis membranes . . 306

HgCI2in acute renal failure (abst) 448,625in renal MHC expression (abst) 428

Hickman Catheters for haemodialysis 987Histamine, in haemodialysis (abst) 480Histology, chronic rejection established by (abst) 151HIV Infection

EDTA Registry Centre Survey 161in AIDS nephropathy (abst) 434in haemodialysis (abst) 486in nephrotic syndrome (abst) 433in RRT S2:25, S4:26

HIV Nephropathyabsence of viral antigens in renal tissue in (abst) 426

HLA Class II Antigens 618in nephrotic syndrome (abst) 313

HLA-DR Antigensin allograft rejection 824in renal transplantation (abst) 670renal tubular display 205

HLA Matching, clinical importance of S4:14HTK Solution, renal protection (abst) 590Human Atrial Natriuretic Peptide, measurement of (abst). 148Human Immunodeficiency Virus. See HIVHuman Neutrophil Elastase (HNE)

in chronic renal failure (abst) 481in haemodialysis (abst) 481

Hydralazine, in glomerulosclerosis 848Hydrochlorothiazide, in glomerulosclerosis 848Hypercalcaemia

effect on prostanoid production (abst) 417in children with chronic renal failure 539in renal transplantation (abst) 470in uraemia 545

Hypercalciuria, protein in (abst) 468Hypercholesterolaemia, simvastatin in (abst) 753Hyperfiltration, response to meat meal (abst) 416,455Hyperglycaemia, in diabetes mellitus (abst) 436Hyperinsulinaemia, in pathogenesis of hypertension

(abst) 459Hyperkalaemia

captopril-induced 1084electrocardiographs: manifestations in 233simulating acute myocardial infarction 233treatment in renal failure 228

Hyperoxalaemia, in haemodialysis (abst) 454Hyperoxaluria

influence of chocolate (abst) 154Type I primary 137

Dow




Hyperparathyroidismand renal transplantation 123effect ofl60KDalton globulin (abst) 467end-dialysis values in evaluating suppressibility of. . . . 115in chronic renal failure 971in renal transplantation 740in uraemia 545recombinant human erythropoietin in (abst) 472secondary 45,105secondary (abst) 148,318,672vitamin D in (abst) 469,480

Hyperphosphataemiachoice of therapy 1005in chronic renal failure 725in haemodialysis S3:140

Hyperpigmentation, cyclosporin in 309Hyperplastic Parathyroid Autografts

ultrasonography of (abst) 453Hypertension

atrial natriuretic peptide in (abst) 463azathioprine in (abst) 512calcitonin-gene-related peptide in (abst) 463calcium concentration in (abst) 461captopril in (abst) 461cyclosporin in (abst) 507,512enalapril in 396erythrocyte sodium and sodium fluxes in 21evolution of 530in acute renal failure (abst) 443in chronic renal failure 21in chronic renal failure (abst) 461in combined microalbuminuria and retinopathy (abst) . 151in diabetes mellitus (abst) 151in glomerulonephritis (abst) 461in glomerulosclerosis 846in heart transplantation (abst) 459in primary glomerulonephritis without renal

insufficiency 605in renal transplantation 740in renal transplantation (abst) 507in spontaneously hypertensive rats (abst) 458insulin in (abst) 459microalbuminuria in (abst) 460oxygen-derived free radicals in (abst) 462renal blood flow in (abst) 462renin activity-(PRA)-dependent renovascular (abst). . . 462renovascular (abst) 599sympathetic nervous system in (abst) 462WmTc DTPA clearance (abst) 461thromboxane B2 in (abst) 421

Hypocalcaemic Dialysatein secondary hyperparathyroidism (abst) 318

Hypocitraturiain calcium stone formers (abst) 437of calcium nephrolithiasis (abst) 437

Hypoglycaemia, in familial renal glycosuria (abst) 433Hypophosphataemia, in renal transplantation (abst). . . . 470Hypoxaemia

and pulmonary hypertension (abst) 480haemodialysis-induced (abst) 489

Idiopathic Membranous GN (IMGN), cyclosporin in . . . 926IgA

circulating immune complexes in IgA nephropathy(abst) 423

immune aggregates (abst) 427in chronic renal failure 216

xxxix

mesangial deposits 943nephropathy (abst) 837on erythrocytes and in immune complexes 932

IgA Antibodies, in IgA glomerulonephritis (abst) 426IgA Nephropathy

(abst) 424chemotactic factor (abst) 430cyclosporin in 926DR-associated antigens (abst) 430enzymatic therapy in (abst) 426genetic susceptibility to autoimmunity in (abst) 428IgA in circulating immune complexes in (abst) 429in mice (abst) 424in recurrent glomerulonephritis 730mesangial cells in (abst) 831monoclonal antibodies in 187phagocyte cell function in 618renal function in (abst) 432urinary protein excretion (abst) 432

IgE, allergic reactions 646IgG

and peritonitis (abst) 755and peritonitis in CAPD (abst) 501deficiency in children on CAPD (abst) 754immune aggregates (abst) 427in chronic renal failure 216in renal transplantation 1078incubation with (abst) 424on erythrocytes and in immune complexes 932

IgManti-pig antibodies (abst) 319in chronic renal failure 216

IgM Mesangial Nephropathynosological autonomy of (abst) 442

Imidazole, in acute renal failure . . • 625Imipenem, in haemofiltration 640Immune Complexes, complement receptor (CR1) and IgG

or IgA in 932Immune Glomerular Injury

tumour necrosis factor and protases in (abst) 428Immunoperoxidase, in Wegener's granulomatosis (abst). . 438Immunoradiometric Assay, atrial naturetic peptide

(abst) 466Immunosuppression

EDTA Registry Centre Survey 161in advanced chronic rejection (abst) 151in antibody-mediated rejection (abst) 589in glomerulonephritis 196in glomerulonephritis (letter) 917,918in membranous glomerulonephritis 181in patients with pre-transplant antibodies (abst) 588in renal failure 181in renal graft recipients returning to haemodialysis

(abst) 518regimens used in RRT S2:12,S4:15rejection episodes by recurrent infection under (abst) . . 1 5 2

Immunotactoid Glomeralopathy, clinical study (abst). . . 430Indomethacin

effect on renal lithium reabsorption 27in acute renal failure 625in protein feeding 683

Infectionin haemodialysis 883in renal transplant recipients (abst) 598, 599

Inferior Vena Cava, echography 563Information, renal transplantation 119

Dow



xl

Insulinadditive to dialysate (abst) 500in hyperkalaemia in renal failure 228in hypertension (abst) 459resistance in chronic renal failure (abst) 450secretion in uraemia (abst) 451transperitoneal passage of (abst) 498

Insulin-like Growth Factor I (abst) 316,456Interferon, in renal transplantation (abst) 520Interleukin-1

cytokine production (abst) 423gene expression (abst) 315in dialysis-related osteoarthropathy S3:34in haemodialysis S3:42in haemodialysis (abst) 489in long-term haemodialysis 569

Interleukin-1 peffect on prostanoids (abst) 422in renal transplantation (abst) 520

Interleukin-2in acute renal failure (abst) 445in dialysis-related osteoarthropathy . S3:34in haemodialysis (abst) 488in minimal-change nephropathy (abst) 313in rejection (abst) 508in renal carcinoma (abst) 445in renal transplantation (abst) 506, 520in T-cell proliferation (abst) 424

Interleukin-2 receptor (IL-2R)in minimal-change nephropathy (abst) 313

Interleukin-6 in CAPD (abst) 497Interstitial Cell Infiltrates, in experimental nephrosis. . . .1037Interstitial Nephritis

drug-induced (abst) 428in nephrotic syndrome 393in renal transplantation (abst) 507mechanism for (abst) 427

Interstitial Pressure, atrial naturetic factor response (abst). 463Intrahepatic Cholestasis, in chronic renal failure (abst) . . 590Intraperitoneal Chemotherapy

in ovarian cancer (abst) 754in treatment of cancer (abst) 751

Inulin Diffusion, ECV measurement by 550Iron

effect of aluminium on absorption (abst) 468in haemodialysis 883in mucormycosis (abst) 480mass transfer and plasma kinetics (abst) 467non-transferrin-bound (abst) 488

Isocyanates, allergic reactions 646Isoniazid, accidental poisoning (letter) 156Jejuna! Dialysis, mannitol in 658Jeune Syndrome (abst) 144Keto Acids

in chronic renal failure (abst) 453in uraemia (abst) 448

Kidneyabnormal, in renal transplant (abst) 601long-term functioning cadaver (abst) 591pelvic, for renal transplantation (abst) 591reactivity of monoclonal antibodies with 85small paediatric cadaveric (abst) 592spontaneous rupture of (abst) 145very long cold ischaemia time (abst) 591

Kidney Diseases, hereditary (abst) 144Kidney Donation, in cardiac arrest (abst) 590


Kidney/pancreatic Grafting. See Multiple TransplantsKlinefelter Syndrome with Nephrophthisis (abst) 144Lactate-Buffered Solutions, effect on acid-base status . . . 800Laurence-Moon-Bardet-Biedl Syndrome (LMBB) (abst) . 144Lead

biological monitoring of S3:114effects of leaded petrol on human health S3:114plasma concentrations in CRF . 375

Lecithin-Cholesterol-Acyltransferase (LCAT) DeficiencySyndrome kidney disease in (abst) . 144

Lectins, in IgA nephropathy (abst) 424Legionella Infection, with haemolytic uraemic syndrome . 995Leprosy, renal involvement in 81Leukocyte Aggregation and Activation, in haemodialysis S3:42Leukotrien B4, in peritoneal dialysis (abst) 498Lipid Abnormalities, in uraemia S3:142Lipid Metabolism

abnormalities in haemodialysis S3:139in uraemia S3:123

Lipidseffect of combined diet and physical exercise on 237effect ofCsA therapy (letter) 237effect on GFR (abst) 421effect on renal blood flow (abst) 421peroxidation in haemodialysis 975

Lipopolysaccharide, effect on glomerular neutrophilcounts (abst) 315

Lipoproteinin chronic renal failure (abst) 448in nephrotic syndrome (abst) 831in uraemia S3:142in uraemia (abst) 452

Lithiumin intravenous saline loading 271renal reabsorption 27

Lithium Clearanceeffect of acetazolamide and frusemide 707effect of acetazolamide and frusemide (abst) 417effect of triamterene on 939

Lithium Transport, in cortical collecting tubule 939Loop Diuretic Medication, in renal transplantation . . . . 740LTB4, biocompatibility with dialysis membranes 306Lung Cancer

haematuriain 947proteinuria in 947

Lung, proteases in S3:130Lupus Anticoagulant

recurrent thrombosis in patients with 854renal vascular disease in patients with 854

Lupus Nephritis, genetics of (abst) 424Luteinising Hormone

in chronic renal failure (abst) 834in erythropoietin treatment (abst) 475

Lymphocytesin IgA nephropathy (abst) 430in minimal-change nephropathy (abst) 313reactivity to glomerular and tubular cells (abst) 670

Lymphocytotoxicity, in renal transplantation ( a b s t ) . . . . 588Lymphokine Activated Killer (LAK) Cells 824Lymphoma, B cell 818Magnesium Hydroxide, in hyperphosphataemia 1005Malignancy

adenocarcinomas (abst) 472and glomerular disease (abst) 435B cell lymphoma 818death rates from S2:20

Dow




in analgesic nephropathy after renal transplantation(abst) 150

in nephrotic syndrome (abst) 671in renal transplant recipients (abst) 511,601incidence in 1985/1986 S2:22intraperitoneal chemotherapy in ovarian cancer (abst) . 754intraperitoneal chemotherapy in treatment of cancer

(abst) 751Kaposi sarcoma 601metastatic renal carcinoma (abst) 445renal cancers associated with polycythaemia (abst) . . . 472renal cell carcinoma and haemodialysis 763rhabdomyosarcoma in rats (abst) 454survival rates after diagnosis of S2:23

Malnutrition 15in haemodialysis (abst) 485

Malonyldialdehyde Concentrations, in dialysis-relatedosteoarthropathy S3:35

Malonyldialdehyde (MDA), in haemodialysis 975Mannitol, in jejunal dialysis 658MCA-P1 Monoclonal Antibody 262Mean Blood Pressure (MAP), in acute renal failure . . . . 691Meat Meal, hyperfiltration response (abst). . . . . . . .416,455Medullary Sponge Kidney, clinical studies (abst) 435Membranes

biocompatibility of 306, S3:55effect of granulocyte LFA-1 molecules, plasma

interleukin-l, glycocalcin and fibrinopeptide A(abst) 489

effect of membrane area on plasma C3a and C5aconcentration S3:46

effect on tumour necrosis factor (abst) 493high-flux S3:89high-flux synthetic versus cellulosic 653high-performance modified cellulose S3:55hollow fibre S3:73influence on pVmicroglobulin concentration S3:27protein permeable S3:78

MembranoproliferativeGlomerulonephritisintrarenal microaneurysms in (abst) 425

Membranous Glomerulonephritisaetiology of 172alpha-mercaptopropionylglycine in (abst) 434immunosuppression in 181

Membranous Nephritis, reversible 393Membranous Nephropathy

aetiology of (letter) 757in renal transplantation 1080long-term outcome 525steroids in 1022

Mercaptoacetyltriglycine, imaging study (abst) 436Mercaptopropionylglycine, pharmacokineticsof(abst) . . 417Mercury Vapour Intoxication 133Mesangial Cells

effect of CsA (abst) 515-16• effect of interleukin-1 P and tumour necrosis factor

(abst) 422in Henoch Schonlein nephritis (abst) 831in IgA nephropathy (abst) 831incubated with IgA and IgG immune aggregates (abst) . 427prostanoid generation by growth-arrested (abst) 425vitamin D3 action on (abst) 431

Mesangial IgA Glomerulonephritis 943complement component C3 in (abst) 440

Metals, determination in biological materials S3:114Metastatic Calcification, in rhabdomyolysis (letter) . . . . 675

xli

Metenkephalinplasma (letter) 236retention in haemodialysis (abst) 468

Methylprednisolonein allograft rejection 387in anti-rejection therapy (abst) 590in glomerulonephritis 196in idiopathic membranous glomerulonephritis 181in salmonella infection 390triple-therapy (abst) 594

Mg(OH)2

in renal osteodystrophy and soft-tissue calcification. . .1045MHC Expression, renal class I and II (abst) 428Microalbuminuria

hypertension in (abst) 151in hypertension (abst) 460

Microscopic polyarteritisantibodies to endothelial cells and neutrophil cytoplasm

in (abst) 426Minimal-change Nephropathy, lymphocytes in (abst) . . . 313Mitogen Responsiveness, in graft monitoring (abst) . . . . 588Molecular Proteins, removal rate by push/pull

haemodiafiltration and haemofiltration S3:83Monoclonal Antibodies

allograft pre-treatment (abst) 838CMV(abst) 670Goodpasture anti-genetic determinant study 262in EBV lymphoma 818in IgA Nephropathy 187in renal transplantation (abst) 504,517inRRT S4:15PI 611reactivity on renal endothelium of (abst) 315reactivity with human kidney 85see also under specific monoclonal antibodies

Monocyte Activation, in long-term haemodialysis 569Monokines, generation of 569Mononuclear Cells, activation by aqueous extracts . . . . 569Mortality, in haemodialysis (abst) 486Mucormycosis, roles of desferrioxamine and iron in

(abst) 480Multiple Transplants S4:20, S2:24Mupirocin, effect on Staphylococcus aureus infection . . . 278Muscle Necrosis, in acute renal failure (abst) 444Myocardial Infarction

hyperkalaemia simulating 233inRRT S2:18,S4:20

Myocardial Ischaemiain haemodialysis 632in haemofiltration 632inRRT S2:18,S4:20

Myoinositolin proliferation of Schwann cells 662neurotoxicityof 662

Nail-patella Syndrome, glomerular basement membrane in 262Natriuresis, in intravenous saline loading 271Natural Killer Cells, in uraemia (abst) 452Neck, ultrasonic examination 45Neoplastic Diseases, in renal transplant recipients (abst). . 601Nephrectomy

in mice 701in spontaneously hypertensive rat (abst) 836

NephritisAlport-type 262fibronectin in (abst) 429nephrotoxic PGE in (abst) 836, 837

Dow



xlii

Nephrocalcinosisin renal transplantation 137in-vitro model of (abst) 316

Nephrogenic Ascites, in CAPD (letter) 918Nephron Adaptation, in chronic renal failure (abst) . . . . 458Nephroplathia Epidemica, in Denmark (abst) 672Nephrosis, interstitial mononuclearcell infiltrates in. . . .1037Nephrotic Syndrome

(abst) 432acute renal failure in 914albumin in (abst) 466amyloidosis in (abst) 438apolipoprotein metabolism in (abst) 831atrial natriuretic peptide in 1010atrial natriuretic peptide in (abst) 466calcium absorption in (abst) 469cyclosporin in (abst) '. 432HIV infection in (abst) 433hypercoagulable state of (abst) 438in proteinuria (abst) 455induced by NSAIDs 176long-term outcome 525malignant disease in (abst) 671minimal change 393plasma fibrinolysis in (abst) 439portal vein thrombosis in 581protein diet in (abst) 437steroid-sensitive (abst) 313steroids in 1022tubular dysfunction in 914vitamin D in (abst) 469with or without interstitial nephritis 393

Nephrotoxicitycyclosporin-induced (abst) 512,514,515,516platelet activating factor in (abst). . 512

Newlyborn Infantsacute renal failure in 870congenital heart disease in 870

Nicardipine, in renal impairment (abst) 835Nifedipine

effect on GFR (abst) 515effect on glomerular hyperfiltration (abst) 454in chronic renal failure (abst) 458in cyclosporin nephrotoxicity (abst) 514,515in prevention of cyclosporin nephrotoxicity (abst). . . . 835in transplant renal artery stenosis 66

Nitrendipineeffect on blood pressure (abst) 601in radiocontrast-media-induced nephrotoxicity 1030

Nitrogen, in chronic renal failure 877Non-steroidal Anti-inflammatory Drugs (NSAIDs) . . . . 27

in haemodialysis (abst) 482in membranous nephropathy 393in tubulointerstitial nephritis 205nephrotic syndrome induced by 176

Nutrition, in haemodialysis S3:138Nutritional Assessment

in recombinant human erythropoietin therapy (abst) . . 478Nutritional Assessment (abst) 478Ofloxacin in pseudomonas peritonitis 814OKT3 818

(abst) 149in antirejection therapy (abst) 596, 597in release of cytokines (abst) 517in renal transplantation (abst) 506,517,518,519

Oral Contraceptives, and renal vein thrombosis 992


Orthoclone OKT3. See OKT3Osmotic Disequilibrium Syndrome 549Osteitis Fibrosa, prevention of 1045Osteoarthropathy, dialysis-related S3:32Osteocalcin, in secondary hyperparathyroidism (abst). . . 148Osteomalacia

aluminium intoxication risk 555dialysis-related 51

Osteonecrosis, in renal transplantation 123Ototoxicity, in CAPD (abst) . 752Ouabain-sensitive Sodium Flux 22Ovarian Cancer, intraperitoneal chemotherapy (abst) . . . 754Oxalate

clearance in haemodialysis 792metabolism in relation to urinary stone (book review). . 320plasma concentration in haemodialysis 792

Oxalic Acid, influence of chocolate on urinary excretion(abst) 154

Oxygen Radicals. in hypertension (abst) 462release by mesangial cells (abst) 427

Oxygen Treatment, in pneumatosis intestinalis 745PI, monoclonal antibodies 611Paediatric Registry Data Base S4:31,S2:33PAF Antagonist, in experimental nephrosis 1037Paired Filtration Dialysis, calcium in (abst) 485Pancreas Transplantation, segmental (abst) 503Pancreatic Grafts, in multiple grafting . . . . . . . . . . S2:24Pancreatic Hormones, in erythropoietin therapy (abst) . . 475Pancreaticorenal Transplantation

in uraemic insulin-dependent diabetes mellitus (abst) . . 507Parathyroid Gland, ultrasonography 45Parathyroid Hormone

C-terminal (abst) 467effect of calcium on secretion 339effect of vitamin D (abst) 480effect on haemodialysis 115in chronic renal failure 971in dialysis patients 1045in haemodialysis (abst) 672in recombinant human erythropoietin therapy (abst) . . 474in renal transplantation 740in uraemia 545in use of calcium carbonate and reduced dialysate

calcium concentration (letter) 759Parathyroid Secretion, in haemodialysis (abst) 468Parathyroidectomy

desferrioxamine in (abst) 470effect on plasma alkaline phosphatase activity and tissue

aluminium mobilisation (abst) 470Parenteral Nutrition, amino acids (abst) 673Pepsinogens, tubular reabsorption (abst) 422Peptides, calcitonin-gene-related (abst) 463Percutaneous Transluminal Angioplasty 57

(abst) 153in renovascular hypertension (abst) 599

Pergolide, in sexual dysfunction in uraemia 888Peripheral Blood Monocytes 15Peripineral Blood Morphology, in graft rejection diagnosis 302Peritoneal Dialysate, amino-acid (abst) 495, 833Peritoneal Dialysis

communication during 119continuous ambulatory. See CAPDcontinuous cyclic. See CCPDin infants 535in pregnancy 583

Dow




in the tropics 535leukotrien B4 in (abst) 498nocturnal (abst) 751systemic lupus erythematosus in (abst) 500tumour necrosis factor in (abst) 498

Peritoneal Eosinophilic Reactionafter catheter implantation (abst) 752

Peritoneal Function in CAPD (abst) 495Peritoneal Lymphatic Flow

and pleural effusion (abst) 755inCAPD(abst) 753

Peritoneal Solute Transportalbumin in (abst) 501in CAPD (abst) 755

Peritoneal Ultrafiltration, in peritoneal dialysis 805Peritonitis

and IgG (abst) 755due to coagulase-negative staphylococci 62eosinophilic (abst) 752in CAPD (abst) 752, 833in CAPD (letter) ' 759local defence status in (abst) 755sclerosing (abst) 754Staphylococcus epidermidis in (abst) 752

Peroxyacetic Acid Solution, in re-use of high-flux dialysers 999Phagocyte Cytoskeleton, in cryoglobulinaemia (abst) . . . 440Phagocytic Cells, in IgA nephropathy 618Phagocytosis, C3b and Fc receptor-mediated 15Phosphatase, plasma alkaline (abst) 470Phosphate

cellular sequestration (abst) 482control in haemodialysis 105dialytic removal (abst) 482in haemodialysis 282plasma control 51

Phosphate Bindingaluminium-containing 105aluminium-free 829

Phosphorusin renal transplantation (abst) 470in uraemia (abst) 470

Phosphorus Intake, in haemodialysis S3:138Phthalates, allergic reactions 646Phytohaemagglutinin A (PHA), in kidney graft ( ab s t ) . . . 588Picotamide, in haemodialysis 1083Pituitary-Adrenal Function, in chronic renal failure (abst). 146Plasma C3a and C5a Concentration, in haemodialysis . S3:46Plasma Cell Dyscrasia, diagnosis of 76Plasma Exchange, in glomerulonephritis 196Plasma Proteins

absorption onto dialysis membranes (abst) 150Plasma Renin Activity

in glomerulonephritis 605in intravenous saline loading 271

Plasmapheresis. in acute renal allograft rejection (abst) 590

in antibody-mediated rejection (abst) 589in patients with pre-transplant antibodies (abst) 588in renal transplantation (abst) 518

Plasminogen Activator Inhibitorin nephrotic syndrome (abst) 439

Platelet a-granules, in uraemia (abst) 451Platelet Activating Factor

cyclosporin nephrotoxicity in (abst) 516effect on cis-dichlorodiamine platinum (abst) 448in nephrotoxicity (abst) 512

xliii

production during haemodialysis (abst) 491release by mesangial cells (abst) 427

Platelet Aggregation, in haemodialysis 975Platelet Function

in recombinant human erythropoietin therapy (abst) . . 472Platelet Storage Pool Defect, in chronic renal failure (abst) 148Pleural Effusion, and peritoneal lymphatic flow (abst). . . 755Pneumatosis Intestinalis

in haemodialysis 745oxygen treatment in 745

Polyacrylonitrile, re-use of (abst) 671Polyacrylonitrile Membrane Dialyser 356Polyacrylonitrile Membranes, biocompatibility tests on . . 306Polyarteritis

autoantibodies to myeloperoxidase in microscopic (abst) 431Polycystic Kidney Disease

atrial natriuretic peptide in (abst) 465prognosis of (abst) 442renal reserve capacity in (abst) 458tubular sodium handling in (abst) 465

Polycythaemiapost-renal transplant (abst) 599renal cancers associated with (abst) 472

Polymer Surfacesbiocompatibility S3:60effect of complement activation and thrombogenesis

on S3:67Polymorphonuclear Leucocytes

activation by Tamm-Horsfal! glycoprotein (abst) . . . . 427Polymyxin B, and monokine-inducing activity 569Polysulphone, re-use of (abst) 671Polyunsaturated Fatty Acids, in haemodialysis 975Polyuronic Acid Phosphate Binder 829Portal Hypertension, in rats (abst) 458Portal Vein Thrombosis, in nephrotic syndrome 581Potassium

direct potentiometric analysis (abst) 673in end-stage renal disease (abst) 673

Predialysis Renal Failurehuman recombinant erythropoietin in 966

Prednisolonein follow-up cases (abst) 594in idiopathic membranous glomerulonephritis 181in renal graft recipients returning to haemodialysis

(abst) 518in renal transplantation 129in renal transplantation (abst) 510,517,518in Wegener's granulomatosis (abst) 435

Prednisonein membranous nephritis 393in renal transplantation (abst) 509

Pre-eclampsiaalbumin infusion in (abst) 442calcium: creatinine ratio in (abst) 439diagnosis of (abst) 439proteinuria in (abst) 150vasopressin release in (abst) 442

Pregnancycalciumxreatinine ratio in (abst) 439CAPD in 583cyclosporin in (abst) 511EPH gestosis (abst) 150in glomerulonephritis (abst) 831in mice 701in renal transplantation 667in RRT S4:37,S2:39

Dow



xliv

peritoneal dialysis in 583renal disease in 583vascular reactivity in (abst) 418

Pringle-Bourneville Disease, complications of (abst). . . . 145Probenecid, in tubular urate wasting (letter) 677Progressive Dialysis Encephalopathy, aluminium in . . S3:100Prolactin, in sexual dysfunction in uraemia 888Prostacyclin

endothelium-dependent relaxation mediated by (abst) . 516in chronic renal failure (abst) 148in hepatorenal failure (abst) 443in legionella-associated haemolytic uraemic syndrome . 995

Prostaglandin Ein accelerated nephrotoxic nephritis (abst) 836in glomerulonephritis 605in protein feeding 683

Prostaglandinseffect on indomethacin 27induction by cytokines (abst) 422

Prostanoids, in glomerular haemodynamics (abst) 425Protease Inhibitors

beneficial effects in acutely uraemic rats . S3:131see also Granulocyte Elastase-a,-protease Inhibitor

Proteasesclassification of S3:127in immune glomerular injury (abst) 428in lung S3:13Oin rat extraorbital gland S3:131in uraemia S3:127

Protein, in hypercalciuria (abst) 468Protein C, in recombinant human erythropoietin therapy

(abst) 476Protein:Creatinine Ratio 9Protein Diet, in nephrotic syndrome (abst) 437Protein Ingestion

renal, metabolic and hormonal responses (abst) 419Protein Intake

in chronic renal failure 877in haemodialysis S3:138

Protein Load, renal responses to (abst) 456Protein Loss

inCAPD 900in peritoneal dialysis 896

Protein Mealrenal haemodynamic and hormonal responses 683

Protein-restricted Dietin chronic renal failure (abst) 457in renal function (abst) 455

Protein S, in recombinant human erythropoietin therapy(abst) 476

Proteinase Inhibitors S3:128in uraemia S3:130

Proteinaseseffects of unrestricted release of S3:128in uraemia S3:129mechanisms of release S3:128

Proteins, removal of small molecular S3:83Proteinuria

aspirin-dipyridamole in 140circadian rhythm of 9, 266complete remission of 525effects of evening meat meal 266in EPH gestosis (abst) 150in lung cancer 947in nephrotic syndrome (abst) 455nephrotic-range 1080


Prune-Belly Syndrome, detection of (abst) 144Pseudomonas aeruginosa

in CAPD peritonitis (letter) 759in sclerosing peritonitis (abst) 754

Pseudomonas Peritonitis, in CAPD 814Psoriasis

cyclosporin in (abst) 511fish oil in (abst) . 511

PTFE Fistulae, duplex sonography (abst) 152Pulmonary Hypertension and Hypoxaemia (abst) 480Pyridoxine, in nephrocalcinosis 137Quality Control, in determination of metals in biological

materials S3:116Quinton Double-lumen Catheter 586Radiocontrasl-media-induced Nephrotoxicity

nitrendipine in 1030Radioimmuno Detection, vitamin D (abst) 470Ramipril, in nephrotic syndrome (abst) 455Raynaud's Phenomenon, cyclosporin in (abst) 512RBC mass, determination of (abst) 599Recombinant Human Erythropoietin 324, 325

(abst) 146, 147,478, 754and bone marrow fibrosis (letter) 674and erythropoietic modulation by monocytes (abst). . . 472and red blood cells (abst) 476angiotensin infusion test (abst) 474atrial natriuretic peptide in ( a b s t ) . . . . ' . 478effect on anaemia in dialysis S4:23effect on cardiovascular dynamics S3:146efficacy of (abst) 471hyperparathyroidism in 740hypertension in 740in anaemia (abst) 477, 597, 966,979in CAPD (abst) 833in CAPD (letter) 674in chronic renal failure 782in chronic renal failure (abst) 474in haemodialysis 718, 1065in haemodialysis (abst) 319,475in hyperparathyroidism (abst) 472in predialysis renal failure 966in uraemia 350in uraemia (abst) 479intravenous and intraperitoneal (abst) 318loop diuretic medication in 740parathyroid hormone in 740pharmacokineticsof(abst) . . 477plasmatic coagulation (abst) 473platelet function under (abst) 472role of aluminium and PTH (abst) 474single-dose pharmacokinetics 345subcutaneous versus intravenous administration (abst) . 473thrombocyte function (abst) 473thrombotic complications (abst) 476see also Erythropoietin

Red Blood Cells. See ErythrocytesRedy Dialysis, aluminium intoxication risk 555Reflux Nephropathy, in childhood (abst) 436Rehabilitation

combined report on children S2:37of children S4:35

Rejectionantithymocyte globulin therapy (abst) 596cyclosporin in (abst) 519cytomegalovirus infection in (abst) 520diagnosis by biochemical assay (abst) 595

Dow




diagnosis by peripheral blood morphology 302diagnosis by ultrasound (abst) 508endothelial-monocyte antigen system in (abst) 315fish oil supplement in 1070histologically established (abst) 151in sickle-cell disease (abst) 600interleukin-2 in (abst) 508methylprednisolone therapy for 387NK-like cells in 735OKTj therapy (abst) 596, 597plasmapheresis in (abst) 589, 590recurrent infection in (abst) 152steroid-resistant renal allograft (abst) 597T-lymphocyte sub-subsets in 735tubular epithelial cells in 824

Renal Amyloid, adrenal dysfunction in (abst) 834Renal Artery Stenosis 66

in renal transplantation (abst) 506Renal Blood Flow

autoregulation in ischaemic rat kidney (abst) 422effect of endothelin (abst) 835effect of human recombinant erythropoietin 966effect of lipids (abst) 421GFR after restitution (abst) 462in acute renal failure 625in hypertension (abst) 462response to mixed protein meal 683

Renal Cancers Associated With Polycythaemia (abst). . . 472Renal Cell Carcinoma and Haemodialysis 763Renal Cysts, acquired 763Renal Damage, drug-induced (abst) 456Renal Disease

end-stage 563end-stage (abst) 144,453,473,673in children S4:35in patients accepted for RRT S4:8in pregnancy 583recurrent and de novo (abst) 510

Renal Failureangiotensin-converting enzyme (ACE) inhibitors in . . . 311complement C3d in (abst) 450end-stage (abst) 144,475,593,800hyperkalaemia in 228immunosuppression in 181recombinant human erythropoietin in 345tumour markers in (abst) 449see also Acute Renal Failure: Chronic Renal Failure

Renal Functionduring treatment by angiotensin converting

enzyme inhibitors 66estimation by Tc -DMSA scintigraphy (abst) 673prostanoid-dependent (abst) 417protein-restricted diet in (abst) 455reserve in the elderly (abst) 416

Renal Growth, compensatory (abst) 316,456Renal Growth Factor

and DNA synthesis 334from uninephrectomised rats 334

Renal Haemodynamicseffect of captopril 696in protein feeding 683

Renal Hypertrophy, in mice 701Renal Insufficiency, in analgesic nephropathy ( a b s t ) . . . . 456Renal Osteodystrophy

first indications of 470vitamin Din S3:107

xlv

Renal Plasma Floweffect of captopril 696effect of human recombinant erythropoietin 966

Renal Protection, HTK solution (abst) 590Renal Replacement, diabetes mellitus in (letter) 399Renal Replacement Therapy (RRT)

age distribution and methods of treatment S2:7AIDS in S2:25ALGin S2:12, S4:15annual death rates due to cardiovascular causes and

malignant disease S2:16ATGin S2:12,S4:15azathioprine in S2:12, S2:13,S4:17blood transfusions in S4:14cardiac arrest in S2:18cardiac failure in S2:18cardiovascular accident in S4:19cerebrovascular accident in S2:17corticosteroids in S4:17cyclosporin in S2:12,S2:13,S2:36,S4:17death rates after S4:18demography in Europe (1987) . ' . . . . • S2:5demography in Europe (1988) . S4:5hepatitis Bin S2:29HIV infection in S2:25, S4:26in pregnancy S4:37, S2:39monoclonal antibodies in S4:15myocardial infarction in S2:18, S4:20myocardial ischaemia in S2:18, S4:20of children S2:33,S4:31quadruple therapy S2:13survival after grafting S2:14survival rates for 1982 to 1987 S4:28transplant co-ordination S4:20transplant policies S2:9, S4:10triple-drug therapy S2:12, S2.14, S4.17waiting list for cadaveric transplantation S4:13see also Multiple Transplants

Renal Responses to Protein Load (abst) 456Renal Retransplantations, graft survival (abst) 670Renal Scarring, fish oil in (abst) 837Renal Siderosis, in heart valve prostheses (abst) 443Renal Transplantation

abnormal kidney (abst) 601ABO-incompatible (abst) 593ABO-mismatched (abst) 671allograft pre-treatment (abst) 838Alport's Syndrome in (abst) 506aluminium in (abst) 503analgesic nephropathy after (abst) 150and dialysis arthropathy (abst) 492and hyperparathyroidism 123anti-CD3 antibodies in (abst) 517arterial stenosis incidence in children 575aseptic necrosis of bone following 123ATGin (abst) 506azathioprine in 129azathioprine in (abst). . . . 504,508,509,510,514,517,518blood supply determination (abst) 150blood transfusion in (abst) 588calcium in (abst) 514CD8+ HNK1+lymphocyte subset in (abst) 509chronic graft-versus-host disease (abst) 424circulating T-lymphocyte sub-subsets 735class I and II histocompatibility antigen expression in

(abst) 510

Dow



xlvi

colour flow Doppler sonography (abst) 150communication success 119Concanavallin A in (abst) 588cyclosporin in 129cyclosporin in (abst)

504, 505, 508, 509, 510,511,512, 514, 515, 517, 518, 521cytomegalovirus infection in (abst) . . . . 502, 504, 509, 520cytomegalovirus infection in (letter) 238cytotoxicity of acid eluates recovered from (abst) . . . . 521doctor/patient communication in 119donor quality of life (abst) 509donor-specific presensitisation by flow cytometry (abst). 520dopamine in (abst) 505double-drug therapy (abst) 508effect of combined diet and physical exercise on plasma

lipids (letter) 237erythrocytosis following (abst) 600erythropoiesis in 1076erythropoietic stimulating factor in 1076fish oil in 1070follow-up cases (abst) 593, 594from elderly donors (abst) 594fructosamines in 748GFR in (abst) 504glomerular hyperfiltration after donor nephrectomy

(abst) 508glomerulonephritis in 730hepatitis B infection 297histocompatibility (abst) 589HLA-DR antigens in (abst) 670hypercalcaemia in (abst) 470hyperimmunised recipients (abst) 502hypertension in (abst) 507hypophosphataemia in (abst) 470IgGin 1080immunological impact on primary function (abst). . . . 502immunological risk factors (abst) 596immunomodulators in serum of (abst) 520immunosuppression (abst) 589in ablation nephropathy (abst) 457in children 575in children (abst) 592in end-stage renal failure (abst) 593information 119interleukin-2 in (abst) 506interstitial nephritis in (abst) 507living related donor (abst) 519living unrelated donor (abst) 592lymphocytotoxicity in (abst) 588medical complication in (abst) 599membranous nephropathy in 1080monoclonal antibodies in (abst) 504,517multiple arteries (abst) 600nephrocalcinosis in 137NK-likecells 735OKT3in(abst) 506,517,518,519osteonecrosis in 123pelvic kidney (abst) 591phosphorus in (abst) 470phytohaemagglutin in (abst) 588plasma lipids in letter 237plasmapheresis in (abst) 518prednisolone in 129prednisolone in (abst) 510,517,518prednisone in (abst) 509pregnancy in 667


psychological aspects (abst) 591recurrence of glomerular disease in 927rejection. See Rejectionrenal artery stenosis in (abst) 506renal reserve filtration capacity (abst) 504,672role of non-current cross-match (abst) 502single, small paediatric cadaveric kidneys into

adult recipients (abst) . 592skin lesions and peripheral lymphocyte subsets in (abst). 510social aspects (abst) . 591steroid withdrawal from triple immunosuppression

(abst) 518steroids in (abst) 508,518,521surgical complications (abst) 598,599Syrian patients (abst) 593thrombosis in (letter) 759triple-drug therapy (abst) 508,594tuberculosis in (abst) 594tumour necrosis factor in (abst) 506Tunisian experience (abst) 593,599vascular complications (abst) 599vitamin D in (abst) 470see also Transplantation

Renal Tubular Cells, erythropoietin in (abst) 420Renal Tubular Epithelium, HLA-DR display by 205Renal Vein Thrombosis, in dehydration 992Reserpine, in glomerulosclerosis 848Respiratory Failure, sepsis control in (abst) 445Restless Leg Syndrome, clonidine in (abst) 149Restriction Fragment Length Polymorphism (RFLP)

Analysis (abst) 313Retinol-binding Protein 266Retinopathy, hypertension in (abst) 151Rhabdomyolysis

cocaine in (letter) 675metastatic calcifications in (letter) 675

Rhabdomyosarcomatous Cells, in rats (abst) 454Rickets, in infants on CAPD (abst) 753Rifampicin, accidental poisoning (letter) 156Salbutamol, in hyperkalaemia in renal failure 228Saline Loading, systemic and renal response to 271Salmonella Infection, in renal transplant recipient 390Salmonella Typhimuhum hip joint infection, ciprofloxacin

in 390Salt and Water Homeostasis

in Tamm-Horsfall glycoprotein (abst) 419Sampling, of biological specimens S3:115Sarcoid Nephritis, and renal gallium scintigraphy (letter) . 76Schistosoma Haematobium, in glomerular disease (abst). . 431Schwann Cells, proliferation of 662Scintigraphy, renal gallium (letter) 76Sclerosing Peritonitis

Grey Turner's sign in (abst) 754inCAPD(abst) 498

SDS (Sodium-dodecyl-sulphate) Electrophoresis(abst) 150clinical importance of (abst) 153urinary proteins (abst) 153

Seizures, in haemodialysis 1065Selenium, in haemodialysis (abst) 479Sepsis Control

in acute renal failure (abst) 445in respiratory failure (abst) 445

Septicaemia, epidemiology and prognosis (abst) 597Sexual Dysfunction, in uraemia 888Sicca-like Syndrome, in chronic renal failure (abst) . . . . 439

Dow




Sickle-cell Disease, graft rejection in (abst) 600Silicon, in haemodialysis 282Silymarin, in hepatic dysfunction 297Simvasatin, in hypercholesterolaemia (abst) 753Skeletal Muscle, protease content in uraemia S3:130Skin Graft, donor-specific (abst) 593Sodium

direct potentiometric analysis (abst) 673in end-stage renal disease (abst) 673see also Erythrocyte sodium

Sodium Transport 21in arterial hypertension (abst) 512

Soft-tissue Calcification, in dialysis patients 1045Sorbent Dialysis Syndrome 555Sorbiphos, aluminium-free phosphate binder 829Splanchnic Area

in insulin resistance in chronic renal failure (abst) . . . . 450Staphylococcus aureus

in CAPD peritonitis (letter) 759in haemodialysis 278in wound infection (abst) 597

Siaplniococcus epidermidisin CAPD peritonitis (letter) 759in wound infection (abst) 597peritonitis (abst) 752vancomycin in (abst) 751

Steroidsin membranous nephropathy 1022in nephrotic syndrome 1022in renal transplantation (abst) 508,518,521inRRT S2:12,S2:13

Stone Formers, high-protein intake (abst) 468Stone Recurrence, prevention of (abst) 437Sudden Cardiac Death (letter) 75Sulindac Sulphide

effect on cysteinyl leukotriene synthesis (abst) 418Superior Vena Caval Obstruction 586Superoxide Dismutase, in ostoarthropathy S3:35Surgical Complications, in renal transplantation (abst) 598,599Swan neck catheter in CAPD (abst) 154Sympathetic Nervous System, in hypertension (abst) . . . 462Syphilis, in membranous glomerulonephritis 172Systemic Lupus Erythematosus (SLE)

cyclophosphamide in (abst) 435cyclosporin in 923in membranous glomerulonephritis 172in peritoneal dialysis (abst) 500

Systolic Blood Pressure, in haemodialysis 282Tamm-Horsfall Glycoprotein

(abst) 427salt and water homeostasis in (abst) 419

T-cell Function, in minimal-change nephropathy (abst) . . 313T-cell-independent and T-cell-dependent antibody

responses 216T-cell Proliferation

effects of calcium antagonists (abst) 520interIeukin-2-dependent (abst) 424

T-cell Receptor, in nephrotic syndrome (abst) 313WmTc DIPA Clearance (abst) 461T c DMSA renal scintigraphy (abst) 673Tertatolol

effect on atrial natriuretic factor (abst) 464in chronic renal failure (abst) 419

Tetanus Toxoid, in chronic renal failure 216Thin-membrane Nephropathy 611Thrombogenesis, complement activation in S3:67

xlvii

Thrombogenicity, ex-vivo study S3:43Thrombosis

in renal transplantation (letter) 759recurrence in patients with lupus anticoagulant 854

Thromboxaneeffect of captopril and diltiazem (abst) 421in acute renal failure 625in chronic renal failure (abst) 148in cyclosporin nephrotoxicity (abst) 516in hypertension (abst) 421picotamide inhibition of 1083

Thrombus Formation, at blood-material interfaces. . . S3:60Thymopentin, influence on HBS vaccination effect

in haemodialysis (abst) 154Thyroid Hormone, profiles in acute renal failure (abst) . . 444Thyroiditis, in membranous glomerulonephritis 172Total Lymphoid Irradiation, as pretransplant ( a b s t ) . . . . 518Trace Elements, in chronic renal failure S3:97Transplantation

EDTA Registry Centre Survey 161effect of immunosuppressives (abst) 588effect of plasmapheresis (abst) 588renal artery stenosis 66see also Renal transplantation

Triamterene, effect on lithium excretion 939Tuberculosis, in renal transplantation (abst) 594Tubular Cells, lymphocyte reactivity to (abst) 670Tubular Dysfunction, in nephrotic syndrome 914Tubular Function

during hyperfiltration response to meat meal (abst) . . . 416effect of cyclosporin on (abst) 514in medullary sponge kidney (abst) 435

Tubular Necrosis, prognosis in (abst) 444Tubular Urate Wasting, probenecid in (letter) 677Tubulointerstitial Nephritis, NSAID-induced 205Tumour Markers, in renal failure (abst) 449Tumour Necrosis Factor

(abst) 315effect of cuprophane (abst) 490effect of membrane characteristics (abst) 493effect on prostanoids (abst) 422in immune glomerular injury (abst) 428in nephrotoxic nephritis (abst) 837in peritoneal dialysis (abst) 498in renal transplantation (abst) 506production and clearance of (abst) 491

Two-dimensional Electrophoresis (2-DE) S3:14Ultrafiltration, failure in CAPD (abst) 751Ultrasonography

ofhyperplastic parathyroid autografts (abst) 453parathyroid gland 45

Ultrasoundallograft monitoring (abst) 595rejection diagnosis (abst) 508urinary tract obstruction (letter) 678

Uraemia 15aldosterone in (abst) 673aluminium in (abst) 484amino acids in (abst) 448apoproteinin S3:142arterial natriuretic peptide in (abst) 464,465autonomic neuropathy (letter) 75calcitriol in (abst) 451,452carcinogenesis in 765cardiac performance in (abst) 487comparison of haemodialysis with CAPD 244

Dow



xlviii

correction of acidosis in 92desmopressin in (abst) 452diet therapy in S3.1242,3-diphosphogJycerate in (abst) 452endocrinological problems in S3:123fructosamines in 748granulocyte elastase in S3:125in children with chronic renal failure 539insulin secretion in (abst) 451keto acids in (abst) 448lipid abnormalities in S3:142lipid metabolism in S3:123lipoprotein in ; . . . . S3:142lipoprotein in (abst) 452metabolic problems in S3:123natural killer cells in (abst) 452parathyroid hormone secretion 339phosphorus in (abst) 470platelet a-granules in (abst) 451proteases in S3:127proteases in rat extraorbital gland in S3:131proteinase inhibitors in S3:130proteinases in S3:129"recombinant human erythropoietin in 350recombinant human erythropoietin in (abst) . . . . 147,479restless leg syndrome (abst) 149sexual dysfunction in 888sudden cardiac death (letter) 75vitamin D in (abst) 451,470with and without hypertension 21with severe hyperparathyroidism and hypercalcaemia. . 545

Uraemic Cardiomyopathy (abst) 152Uraemic Hyperphosphataemia, choice of therapy 1005Uraemic Thrombopathy

cryoprecipitate in (abst) 449DDAVP in (abst) 449

Urate Renal Handling (letter) 677Urbasone, in rejection episodes (abst) 152Urea, kinetic modelling (abst) 482Urea Clearance

calculation of 39in haemofiltration 37

Urinary Proteins, SDS electrophoresis (abst) 153Urinary Tract, Escherichia coli infection (abst) 437Urinary Tract Obstruction

plain abdominal X-ray in (letter) 678Urine Sediment Cytology, diagnostic value of (abst). . . . 596Urokinase

in relapsing peritonitis due to coagulase-negativestaphylococci 62

Vanadiumin chronic renal failure S3:97in haemodialysis 282

VancomycininCAPD(abst) 751


in haemodialysis 635in haemofiltration 635in Staphylococcus epidermidis infection (abst) 751ototoxicity monitoring (abst) 752

Vascular Diseasein IDDM and NIDDM (abst) 151recurrence in patients with lupus anticoagulant 854

Vascular Endothelium, effect of cyclosporin (abst). . . . . 316Vascular Reactivity, in pregnancy (abst) 418Vasculitis . 1

anti-neutrophil cytoplasmic antibodies in (abst) 832Vasodilator/ Prostanoids, relaxation mediated by (abst) . 838Vasopressin

in uraemic thrombopathy (abst) 449release in pre-eclampsia (abst) 442

Ventilation, during acetate haemodialysis 1060Verapamil, in acute renal failure (abst) 446Verotoxin-producing E. coli (VTEC) (abst) 314Viscosity Measurement, in haemodialysis (abst) 319Vitamin Bl2, and hollow-fibre membranes S3:73Vitamin D

action on mesangial cells (abst) 431effect on aluminium deposition in bone 957effect on cytokine production (abst) 517effect on vascular reactivity (abst) 460inCAPD(abst) 496in haemodialysis S3:140in haemodialysis (abst) 672in hyperparathyroidism (abst) 469,480in nephrotic syndrome (abst) 469in renal osteodystrophy S3:107in renal osteodystrophy and soft-tissue calcification. . .1045in renal transplantation (abst) 470in uraemia 545in uraemia (abst) 451,470radioimmuno detection (abst) 470

Vitamin Ein CAPD (letter) 75in haemodialysis 975

Water Pollution, aluminium in S3:97Wegener's Antigen 1

identification of 5Wegener's Granulomatosis

antibodies to endothelial cells and neutrophil cytoplasmin (abst) 426

anti-neutrophil cytoplasmic antibodies in (abst) 431autoantibodies to glomerular antigens in 1clinical study (abst) 435immunoperoxidase in (abst) 438long-term follow-up (abst) 832

Wound Infection, in renal transplant recipients (abst) . . . 597X-ray techniques, urinary tract obstruction (letter) 678YTH24.5 Monoclonal Antibodies (abst) 838YTH54.12 Monoclonal Antibodies (abst) 838Zinc, in sexual dysfunction in uraemia 888

Dow



NephrologyDialysisTransplantation



V0LUME4 NUMBER 1 1989Table of Contents

Original ArticlesAutoantibodies to Glomerular Antigens inPatients with Wegener's GranulomatosisFrances Abbott, Sally Jones, C. M. Lockwood andA. J. Rees 1

Circadian Rhythm of Proteinuria:Consequences of the Use of Urinary Protein:Creatinine RatiosM. G. Koopman, R. T. Krediet, G. C. M. Koomen,J. Strackee and L Arisz 9

Effect of Fibronectin on C3b and FcReceptor-mediated Phagocytosis byPeripheral Blood Monocytes in UraemicPatientsG. Pertosa, G. Mastrolitti. P. J! Spath, A. R. Fracasso,C. Mannoand F. P. Schena 15

Erythrocyte Sodium and Sodium Flux inRelation to Hypertension in Chronic RenalFailureT. H. Thomas, H. Mansy and R. Wilkinson 21

Indomethacin Increases Renal LithiumReabsorption in ManA. J. Rabelink, H. A. Koomans, W. H. Boer,E. J. Oorhout Mees and H. J. M. van Rijn 27

Adequacy of HaemodiafiltrationM. Surian, F. Malberti, B. Corradi, G. Orlandini,E. Varini, G. Colussi and L. Minetti 32

Pre-postdilution HaemofiltrationS. David, 0. Tagliavini and V. Cambi 37

Death from Dialysis TerminationD. J. Hirsch 41

Parathyroid Sonography in SecondaryHyperparathyroidism: Correlation withClinical FindingsH.Tomic Brzac, D. Pavlovid, M. HalbauerandJ. Pasini 45

Can Low-dosage Aluminium HydroxideControl the Plasma Phosphate without BoneToxicity?D. A. S. Jenkins, D. Gouldesbrough, G. D. Smith,J. F. Cowie and R. J. Winney 51

Percutaneous Transluminal Angioplasty ofFailing Arteriovenous Dialysis FistulaeE. Cada, F. Karnel, G. Mayer, F. Langle,H. Schurawitzki and H. Graf 57

Urokinase: A Treatment for RelapsingPeritonitis due to Coagulase-negativeStaphylococciS. J. Pickering, S. J. Fleming, J. A. Bowley,P. Sissons, B. A. Oppenheim, J. Burnie, A. J. Ralstonand P. Ackrill 62

Contrasting Effects of Acute AngiotensinConverting Enzyme Inhibitors and CalciumAntagonists in Transplant Renal ArteryStenosisG. Mourad, J. Ribstein, A. Argiles, A. Mimran andC. Mion 66

Pharmacokinetics of Cyclosporin in ManFollowing a Single Oral Dose: Relationship toBody Fat ContentM. R. Waters, Janet D. M. Albano, V. L. Sharmanand G. Venkat Raman 71

Letters

Announcements

75

78

Dow



IMephrologyDialysisTransplantation



V0LUME4 NUMBER2 1989Table of Contents

Original A rticlesRenal Involvement in LeprosyP. Ponce, A. Ramos, M. Lurdes Ferreira, G. Pinto andM. Helena Lacerda 81

B-cell Markers in the Human KidneyS. Fleming, D. B. Jones and K. Moore

The Metabolic Consequences of theCorrection of Acidosis in UraemiaD. Jenkins, P. R. Burton, S. E. Bennett, F. Baker andJ. Walls

Glycosylated and Carbamylated Haemoglobinin UraemiaW. G. J. Smith, M. Holden, M. Benton andC. B. Brown

The 'Breakpoint' Test, A New StatisticalMethod for Studying Progression of ChronicRenal FailureC. Zoccali, M. Postorino, C. Martorano, F. Salnitroand Q. Maggiore

High-dose Calcium Carbonate with StepwiseReduction in Dialysate CalciumConcentration: Effective Phosphate Controland Aluminium Avoidance in HaemodialysisPatientsN. Sawyer, Kate Noonan, P. Altmann, F. Marsh andJ. Cunningham

Exacerbation of Aluminium EncephalopathyAfter Treatment with DesferrioxamineJ. McCauley and M. I. Sorkin

Effect of One Haemodialysis Treatment on thePlasma Concentrations of Intact ParathyroidHormone and Ionised Calcium: Usefulness ofEnd-dialysis Values in Evaluating theSuppressibility of HyperparathyroidismK. Pietila, J. Mustonen, P. Morsky, E. Seppala,A. Pasternack and T. Koivula

85

92

96

101

105

110

Success of Communication About RenalTransplantation Between Patient and DoctorP. M. Lock, D. BenolielandV. Parsons 119

Aseptic Necrosis of Bone Following RenalTransplantation: Relation withHyperparathyroidismDania Nehme, E. Rondeau, Francoise Paillard, J. F.Moreau, O. Nussaume, A. Kanferand J-D. Sraer 123

Selective Conversion from Azathioprine toCyclosporin for Steroid-Resistant Rejectionin Renal Transplants: An Alternative TherapyM. C. Crowson, F. Berisa, R. J. S. McGonigle,D. Adu, J. Michael and A. D. Barnes 129

Case ReportsAcute Mercury Vapour Intoxication: Reportof Six CasesS. Aguado, J. Fdez B. de Quir6s, R. Marin, E. Gago,E. G6mez, F. Fdez-Vega and J. Alvarez Grande 133

Recurrence of Nephrocalcinosis After RenalTransplantation in an Adult Patient withPrimary Hyperoxaluria Type IG. Knols, K. M. L. Leunissen, L. J. M. Spaapen,F. T. Bosman, T. W. M. v.d. Wiel/G. Kootstra andJ. P. vanHooff 137

Brief ReportAdministration of Aspirin-DipyridamoleReduces Proteinuria in Diabetic NephropathyA. H. Hopper, H. Tindall and J. A. Davies 140

Abstracts 1447th Annual Meeting, Austrian Society ofNephrology, 10-11 June 1988

Letters 156

115 Announcements 158

Dow







Registry ReportEDTA Registry Centre Survey. 1986G. Tufveson, W. Geelings, M. Broyer, F. P. Brunner,H. Brynger, S. R. Dykes. J. H. H. Ehrich,W. Fassbinder, G. Rizzoni, N. H. Selwood andA. J. Wing 161

Original ArticlesAetiologyof MembranousGlomerulonephritis:A Prospective Study of 82 Adult PatientsR. Cahen, B. Francois, P. Trolliet, Jacqueline Gillyand Bridgette Parchoux 172

Immunosuppression can Arrest ProgressiveRenal Failure due to Idiopathic MembranousGlomerulonephritisP. S. Williams and J. M. Bone 181

The Role of Interstitial Infiltrates in IgANephropathy: A Study with MonoclonalAntibodiesE. Alexopoulos, D. Seron, R. B. Hartley, F. Nolascoand J. S. Cameron 187

Plasma Exchange and Immunosuppression forRapidly Progressive Glomerulonephritis:Prognosis and ComplicationsE. Rondeau, M. Levy, P. Dosquet. P. Ruedin,B. Mougenot. A. Kanfer and J. D. Sraer 196

Cyclosporin: Poorly Tolerated in FamilialMediterranean FeverS. L. Cohen, G. Boner, D. Shmueli, A. Yusim,J. Rosenfeld and Z. Shapira 201

HLA-DR Display by Renal Tubular Epitheliumand Phenotype of Infiltrate in InterstitialNephritisH.-F. Cheng, F. Nolasco, J. S. Cameron,Gillian Hildreth, G. Neild and B. Hartley 205

T-Cell-lndependent and T-Cell-DependentAntibody Responses in Patients with ChronicRenal FailureM. Beaman, J. Michael, I. C. M. MacLennan andD.Adu 216

Comparative Effects of Haemodialysis andHaemofiltration on Plasma Atrial NatriureticPeptideA. E. G. Raine, A. Bock, F. B. Muller, P. Erne, P. Bolli,F. Brunner and F. R. Buhler 222

Treatment of Hyperkalaemia in Renal Failure:Salbutamol Vs InsulinX. M. Lens, J. Montoliu, A. Cases, J. M. Campistoland L. Revert 228

Case ReportElectrographic Alterations Induced byHyperkalaemia Simulating Acute MyocardialInfarctionJ. M. Campistol, J. Almirall, J. Montoliu andLI. Revert 233

Letters

Announcements

236

240

Dow







Review ArticleIs CAPD Competitive with Haemodialysis forLong-term Treatment of Uraemic Patients?R. Maiorca, G. C. Cancarini, C. Camerini, G. Brunori,L. Manili, E. Movilli, P. Feller and S. Mombelloni 244

Original ArticlesNon-Goodpasture Anti-GBM Antibodies in Patientswith GlomerulonephritisP. Bygren, B. Cederholm, D. Heinegard andJ. Wieslander 2S4

Variability of the Antigenicity of the GlomerularBasement Membrane in Nail-patella SyndromeN. P. Sutcliffe, S. J. Cashman. C. 0. S. Savage,J. G. Fox and J. M. Boulton-Jones

Circadian Rhythm of Proteinuria: Effects of anEvening Meat MealC. Buzio, A. Mutti, F. Capani, S. Andrulli,F. Perazzoli. R. Alinovi, A. Negro and R. Rustichelli

262

266

The Effect of Carbidopa and Lithium on the Systemicand Renal Response to Acute Intravenous SalineLoading in Normal ManR. F. Jeffrey. T. M. MacDonald, S. Freestone andM. R. Lee 271

The Influence of Calcium Mupirocin Nasal Ointmenton the Incidence of Staphylococcus AureusInfections in Haemodialysis PatientsJ. R. Boelaert, Roselyne A. De Smedt. Y. A. De Baere,Claudine A. Godard. E. G. Matthys. M. L. Schurgers.R. F. Daneels. B. Z. Gordts andH.W. Van Landuyt 278

Vanadium in Patients Undergoing ChronicHaemodialysisS. Hosokawa and 0. Yoshida 282

The Use of an Amino-acid-based CAPD Fluid over12 WeeksG. A. Young, J. B. Dibble, S. M. Hobson, L. Tompkins,J. Gibson, J. H. Turney and A. M. Brownjohn 285

A Prospective One-year Study Evaluating theClinical Outcome of Recipients of Living DonorKidneys Treated with Cyclosporin and AzathioprineJ. Morales-Barria, C. Zehnder, A. Mocarquer,E. James, L. Aris, R. Trivino and J. Aguilo 293

Hepatitis B Infection and Renal Transplan-tation: The Absence of Anti-Delta Antibodies andthe Possible Beneficial Effect of Silymarin duringAcute Episodes of Hepatic DysfunctionM. K. Chan, P. C. K. Chan. K. K. Wong, I. K. P. Cheng,M. K. Li and W. K. Chang 297

Peripheral Blood Morphology: Could it be of Valuein Prediction and Diagnosis of Renal AllograftRejection?F. E. Moustafa, M. A. Sobh and M. A. Ghoneim 302

Brief CommunicationA Simple In Vitro Test to Evaluate Biocompatibility ofDialysis MembranesD. Vincent, J. P. Charmes, M. Benzakour, N. Gualde,M. Rigand and C. Leroux-Robert 306

Case ReportsHyperpigmentation Due to Cyclosporin TherapyA. J. B. Brady and A. J. Wing 309

Reversible Renal Failure due to the Use of Captoprilin a Renal Allograft Recipient Treated withCyclosporinT. Ahmad, M. G. Coulthard and E. J. Eastham 311

AbstractsJoint Meeting of the Renal Association and theBritish Association for Paediatric Nephrology—Autumn Meeting, 19 October 1988. Royal College ofPhysicians. London 313

Book Reviews

Announcements

320

321

Dow






VOLUME4 NUMBER5 1989Table of Contents

Review ArticleErythropoietinC. G.Winearls 323

Original A rticlesReversibility of Acute Cyclosporin Nephrotoxicityby Dopamine. Micrqpuncture Study in the RatM. Sabbatini, C. Esposito, L. De Nicola, F. Uccello,M. Altomonte, G. Conte, A. Dal Canton and V. E. Andreucci 327

Partial Purification and Characterisation of a RenalGrowth Factor from Plasma of UninephrectomisedRatsF. Manzano, P. Esbrit, A. Garcia-Ocana, R. Garcla-Caneroand M. A. Jimenez-Clavero 334

Effect of Direction and Rate of Change of Calciumon Parathyroid Hormone Secretion in UraemiaJ. Cunningham. P. Altmann. Janet H. Gleed. K. C. Butter,F. P. Marsh and J. L. H. O'Riordan

Single-dose Pharmacokineticsof RecombinantHuman Erythropoietin in Patients with VariousDegrees of Renal FailureJ. Kindler, K.-U. Eckardt. B. Ehmer, K. Jandeleit, A. Kurtz,A. Schreiber. P. Scigalla and H.-G. Sieberth

Kinetics of Erythropoiesis in Dialysis PatientsReceiving Recombinant Erythropoietin TreatmentY. Najean, A. Moynot, F. Deschryver, B. Zins, C. Naret,Ch. Jacquot and T. Drueke

Elimination of f),-Microglobulin by a NewPolyacrylonitrile Membrane Dialyser: Mechanismand PhysiokineticsT. Akizawa, S. Koshikawa, R. Nakazawa, T. Yoshida.M. Kaneko and Y. Nitadori

Carnitine and Weakness in Haemodialysis PatientsM. E. Rogerson, P. B. Rylance, R. Wilson, C. De Sousa,C. Lanigan, P. E. Rose, J. Howard and V. Parsons

Vaccination Against Hepatitis B in Children andAdolescent Patients on DialysisR. Drachman, M. Isacsohn, B. Rudensky and A. Drukker

Survey of Blood Lead and Plasma AluminiumConcentrations in Patients of a Renal UnitB. Sampson, J. R. Curtis and S. Davies

339

345

350

356

366

372

375

Low-dose vs High-dose IntravenousMethylprednisolone Therapy for Acute RenalAllograft Rejection in Patients ReceivingCyclosporin TherapyS. F. Lui, P. Sweny, J. E. Scoble, Z. Varghese.J. F. Moorhead and 0. N. Fernando 387

Successful Treatment with Ciprof loxacin ofMultiresistant Salmonella Arthritis in a RenalTransplant RecipientR. Diaz-Tejeiro, J. Dlez, F. Maduell, N. Esparza, P. Errastiand A. Purroy 390

Case ReportReversible Membranous Nephritis Associated wi thDiclofenacJ. M. Campistol, J . Galofre, A. Botey, A. Torras andLI. Revert 393

Brief CommunicationRenal Effects of Enalapril in Hypertensive Patientswith GlomerulonephritisG. Grazi, C. Cirami, V. Panichi, A. M. Bianchi, M. Parrini,A. Baronti, R. Cominotto, E. Montagnani and R. Palla 396

Letters 399

The First Twenty-five YearsIntroductionH. Klinkmann 400

The Founding of the EDTA: Facts and LessonsW. Drukker 401

EDTA and Industry: 25 Years of Symbiotic SynergismS. Shaldon 408

Plasma Alpha-human Atrial Natriuretic Peptide andVolume Status in Chronic Haemodialysis PatientsK. M. L. Leunissen, P. P. C. A. Menheere, E. C. Cheriex,B. W. van den Berg, T. C. Noordzij and J. P. van Hooff 382

EDTA to ERAD. N. S. Kerr

AbstractsEDTA-ERA 26th Annual Congress, Gothenburg,11-15 June 1989

Announcements

411

416

522

Dow



NephrologyDialy:Transplantation




Original ArticlesLong-term Outcome of Patients withMembranous Nephropathy After CompleteRemission of ProteinuriaPatrizia Passerini, Sonia Pasquali, B. Cessna,P. Zucchelli and C. Ponticelli 525

Specific Binding of Angiotensin II and AtrialNatriuretic Factor in Non-nephropathic Type IDiabetes MellitusJ. F. E. Mann, H. Miirtz, J. Sis, K. H. Usadel,Ch. Hasslacherand E. Ritz 530

Acute Renal Failure in Infants in the TropicsB. J. G. Pereira, A. Narang, S. Pereira, A. Gupta,V. Sakhuja and K. S. Chugh 535

Safety and Efficacy of Calcium Carbonate inChildren with Chronic Renal FailureA. G. B. Clark, A. Oner, Geraldine Ward, C. Turner,Susan P. A. Rigden, G. B. Haycock and C. Chantler 539

Intravenous Calcitriol Lowers Serum CalciumConcentrations in Uraemic Patients withSevere Hyperparathyroidism andHypercalcaemiaN. A. T. Hamdy, C. B. Brown and J. A. Kanis 545

Serum p2 Microglobulin and Extracellular FluidVolume During HaemodialysisJ. Chanard, O. Toupance. Sylvie Lavaud, F. Jaisserand P. Gillery 549

Risk of Aluminium Intoxication in Long-termAcetate Redy DialysisF. L. Van de Vyver, W. J. Visser, P. C. D'Haese,F. J. Silva, H. Thomas and M. E. De Broe 555

Echography of the Inferior Vena Cava is aSimple and Reliable Tool for Estimation o f DryWeight' in Haemodialysis PatientsE. C. Cheriex, K. M. L Leunissen, J. H. A. Janssen,J. M.V. Mooyand J. P.vanHooff 563

Activation of Mononuclear Cells by AqueousExtracts from Hollow-fibre HaemodialysersM. Blumenstein, H. W. L Ziegler-Heitbrock, BrigitteSchiller, Barbel Schmidt, R. A. Ward andH.J.Gurland 569

Increased Incidence of Renal TransplantArterial Stenosis in ChildrenP. H. Henning, M. Bewick, J. F. Reidy,S. P. A. Rigden, G. H. Neild and C. Chantler 575

Case ReportsPortal Vein Thrombosis in the NephroticSyndromeA. S. Woolf, P. R. Street, K. M. Walmsley andS. L Cohen

Successful Pregnancy in a Patient Treatedwith Continuous Ambulatory PeritonealDialysisD. N. Bennett-Jones, G. M. Aber and K. Baker

Superior Vena Caval Obstruction: A RareComplication of Quinton Double-lumenHaemodialysis CathetersB. Madden, A. P. Huissoon, E. N. ColhounandJ. A. B. Keogh

AbstractsAbstracts from the First International Congress of theMiddle-East Society for Organ Transplantation 2-4November 1988, Ankara. Turkey

Letters

Announcements

581

583

586

588

602

603

Dow







Original ArticlesHypertension in Primary GlomerulonephritisWithout Renal InsufficiencyP. Zucchelli, A. Zuccala and E. Mancini 605

Reactivity of Monoclonal Antibody P1 withGlomerular Basement Membrane inThin-Membrane NephropathyF. E. Dische, I. P. Brooke, S. J. Cashman, A. Severn,D. Taube, V. Parsons, M. Kershaw, A. Reed andC. D. Pusey 611

Phenotypic and Functional Analysis ofCirculating Phagocytic Cells in IgANephropathy PatientsD. Roccatello, R. Coppo, G. Piccoli, G. Cavalli,M. G. Guerra, A. Funaro, A. Amore, S. Roggero,R. Borgialli, M. C. Amprimo, B. Scalzo, M. Alessio,G. Quattrocchio and L M. Sena 618

The Inhibition of Thromboxane Synthesis HasNo Influence on HgCI2-lnduced Acute RenalFailure in the RatR. Vanholder, G. Laekeman, A. Herman,B. Saragananda, M. A. Waterloos, 0. Kestelooand N. La me ire 625

Incidence of Arrhythmias and MyocardialIschaemia During HaemodialysisandHaemofiltrationM. Zuber, E. Steinmann, B. Huser, R. Ritz, G. Thieland F. Brunner 632

Pharmacokinetics of Vancomycin in PatientsUndergoing HaemodialysisandHaemofiltrationV. Oe Bock, D. Verbeelen, V. Maes and J. Sennesael 635

Single-Dose Kinetics of Imipenem/CilastatinDuring Continuous ArteriovenousHaemofiltration in Intensive Care PatientsE. Keller, H. Fecht, J. Bonier and P. Schollmeyer 640

Allergy To Dialysis MaterialsA. Rockel. B. Klinke, J. Hertel, X. Baur, Cl. Thiel,S. Abdelhamid, P. Fiegel and D. Walb 646

High-Flux Synthetic Versus CellulosicMembranes for P2-Microglobulin RemovalDuring Hemodialysis, Hemodiafiltration andHemofiltrationJ. Floege, C. Granolleras, G. Deschodt, M. Heck,G. Baudin, B. Branger. 0. Tournier, B. Reinhard,G. M. Eisenbach, L. C. Smeby, K. M. Koch andS. Shaldon 653

Jejunal Dialysis in Man Using Mannitol as thePerfusateC. G. Newstead 658

Myoinositol Inhibits Proliferation of CulturedSchwann Cells: Evidence for Neurotoxicity ofMyoinositolT. Niwa, G. Sobue, K. Maeda and T. Mitsuma 662

Case ReportCyclosporin Requirement During Pregnancy inRenal Transplant RecipientsG. Biesenbach, J. Zazgornik, W. Kaiser, H. Stoger,K. Derfler, P. Balcke and Ch. Hauser 667

Abstracts 670Danish Society of Nephrology, Spring Meeting,15 April 1989, Herlev Hospital, Denmark

Letters 674

Announcements 680

Dow







Original A niciesRenal Haemodynamic and Hormonal Responses to aMixed High-Protein Meal in Normal MenC. P. Swainson and R.J.Walker 683

Water Immersion Induced Alterations of AtrialNatriuretic Peptide in Patients withNon-Inflammatory Acute Renal FailureF. Kokot, W. G rzeszczak and A. Wiecek 691

Short-Term Effect of Captopril on RenalHaemodynamics in Chronic Renal FailureW. G. J. Smith, A. D. Dharmasena, A. M. El Nahas,D. M.Thomas and G. A. Coles 696

Uninephrectomy and Repetitive Pregnancies inMice: A Combined Stimulus for Renal HypertrophyD. Modai, Z. Averbukh, J. Weissgarten. E. Bogin,E. Rosenmann, M. Cohn, E. Goren and U Shaked 701

Effects of Acute Administration of Acetazolamideand Frusemide on Lithium Clearance in HumansG. Colussi. G. Rombola. M. Surian, Maria Elisabetta DeFerrari, Cristina Airaghi. Elisabetta Benazzi, F. MalbertiandL. Minetti

Urinary Angiotensin Excretion During SodiumRestriction and DiureticsP. Boer, H. A. Koomans, W. H. Boer and E. J. DorhoutMees

707

713

Haemodialysis Efficiency After Long-TermTreatment with Recombinant Human ErythropoietinS. Casati, Mariarosaria Campise, Monica Crepaldi, J. Lobo,G. Graziani and C. Ponticelli 718

Quantitative Bone Scanning in the Diagnosis ofAluminium OsteomalaciaD. P. Worth, S. W. Smye, P. J. Robinson, A. M. Davisonand E.J.Will

The Use of Calcium Carbonate to Treat theHyperphosphataemia of Chronic Renal FailureB. Williams. M. Vennegoor, T. O'Nunan and J. Walls

721

725

Recurrent Glomerulonephritis in Renal Transplants:Fourteen Years' ExperienceY. O'Meara, A. Green, M. Carmody, J. Donohoe,E. Campbell, 0. Browne and J. Walshe 730

Circulating T-Lymphocyte Sub-Subsets and NK-LikeCells in Renal Transplant Patients: PatternsAssociated with RejectionE. Hands, T. H. Tdtterman, B. Fellstrom, R. Bergstrom andG. Tufveson 735

Hyperparathyroidism, Hypertension and LoopDiuretic Medication in Renal Transplant RecipientsA. E. Bittar, P. J. Ratcliffe, A. J. Richardson, R. C. Brown,J. S. Woodhead and P. J. Morris 740

Case ReportPneumatosis Intestinalts in a Patient on ChronicHaemodialysis TreatmentL. A. Christensen, E. B. Schmidt. P. B. Mortensen andJ. H. Hojhus 745

Brief ReportFructosamines in Uraemia and Renal ReplacementTherapyS. F. Beardsworth, Valerie Vernon and D. Harrison 748

CorrectionCorrection to article by C. S. Ubhi: 'Is there a TherapeuticRange for Monitoring Plasma Cyclosporin in RenalAllograft Recipients?' (Nephrology DialysisTransplantation 1988 3:814-819) 750

NoticeCitation from Combined Report on Regular Dialysis andTransplantation in Europe. XVIII, 1987, and the CombinedReport on Regular Dialysis and Transplantation of Childrenin Europe, 1987' (Supplement to Volume 4 Number 3(March) 1989 750

Abstracts6th Benelux CAPD Symposium, RAI CongressCentre. Amsterdam. 2 December 1988 751

Letters 757

Announcements 761

Dow







Review ArticleRenal Cell Carcinoma in Dialysis Patients withAcquired Renal CystsI. L. Noronha, E. Ritz. R. Waldherr, G. Stein andW. Fassbinder 763

Original ArticlesThe Glomerular Basement Membrane Defect inAlport-Type Hereditary Nephritis: Absence ofCationic Antigenic ComponentsL. P. W. J. van den Heuvel, C. 0. S. Savage,M. Wong, R. G. Price, L Noel, J. P. Grunfeld andC. M. Lockwood 770

Effects of WY 47987 (Atrial Natriuretic Factor102-126) in Patients with Renal Insufficiency:A Placebo-Controlled, Randomised StudyJ. F. E. Mann, Christine Reisch, R. Bergbreiter,Daniela Karcher, E. Hackenthal, P. Vecsei,J. Nussbergerand E. Ritz

Efficacy and Tolerance of Treatment withRecombinant-Human Erythropoietin inChronic Renal Failure (Pre-Dialysis) PatientsL. A. M. Frenken, R. Verberckmoes, P. Michielsenand R. A. P. Koene

Does Increasing Haemoglobin Concentrationand Haematocrit Have a Pressor Effect inDialysis Patients?B. Williams, Mair E. Edmunds, J. P. Thompson,P. R. Burton, J. Feehally and J. Walls

Plasma Oxalate Concentration. OxalateClearance and Cardiac Function in PatientsReceiving HaemodialysisC. R. V. Tomson, S. M. Channon, M. K. Ward andM. F. Laker

The Effect of Lactate-Buffered Solutions onthe Acid-Base Status of Patients With RenalFailureA. Davenport, E. J. Will and A. M. Davison 800

Peritoneal Ultrafiltration and FluidReabsorption During Peritoneal DialysisB. Lindholm, 0. Heimbiirger, J. Waniewski,A. Werynski and J. Bergstrom 805

Pseudomonas Peritonitis in CAPD Patients:Characteristics and Outcome of TreatmentM. K. Chan, P. C. K. Chan, I. P. K. Cheng, C. Y. ChanandW. S. F. Ng 814

Epstein-Barr Virus AssociatedLymphoproliferative Diseases (B CellLymphoma) After TransplantationJ. L. Gamier, F. Berger, H. Betuel, M. Vuillaume,C. Chapuis-Cellier, N. Blanc, J. L. Faure,J. M. Dubernard, G. Lenoirand J. L Touraine 818

Renal Allograft Rejection: Protection ofRenal Tubular Epithelial Cells fromLymphokine Activated Killer Cell MediatedLysis by Pretreatment with CytokinesJ. A. Kirby, J. L. R. Forsythe, A. Simm, G. Proud andR. M.R.Taylor 824

Brief CommunicationPhosphate Binding Efficiency of a PolyuronicAcid in Normal SubjectsN. A. T. Hamdy, E. V. McCloskey, V. A. Naylor,C. B. Brown and J. A. Kanis 829

AbstractsAbstracts from the Renal Association,Glasgow. 11-12 May 1989 831

Letters 839

792 Announcements 841

776

782

787

Dow






VOLUME4 NUMBER 10 1989Table of Contents

Review ArticleGlomerulosclerosis: Insights intoPathogenesis and TreatmentA. M. El Nahas

Original ArticlesRecurrent Thrombosis and Renal VascularDisease in Patients with a LupusAnticoagulantD. Kleinknecht, G. Bobrie. 0. Meyer, L. H. Noel,P. Callard and M. Ramdane

Similar Risks of Nephropathy in Patients withType I or Type II Diabetes MellitusCh. Hasslacher, E. Ritz, P. Wahl and C. Michael

C-Reactive Protein in Acute Renal FailureN. A. Harrison, R. G. Masterton, J. M. Bateman andD. J. Rainford

Continuous Arteriovenous Haemofiltration inthe Newlyborn with Acute Renal Failure andCongenital Heart DiseaseD. Heney, J. T. Brocklebank and N. Wilson

The Estimation of Dietary Protein Intake inChronic Renal FailureG. A. Coles, J. H. Meadows, C. Bright andK. Tomlinson

Critical Role of Iron Overload in the IncreasedSusceptibility of Haemodialysis Patients toBacterial Infections. Beneficial Effects ofDesferrioxamineC. L. Tielemans, C. M. Lenclud, R. Wens, F. E. Collartand M. Dratwa

843

854

859

864

870

877

Zinc Deficiency and Hyperprolactinaemia arenot Reversible Causes of Sexual Dysfunctionin UraemiaR. S. C. Rodger, W. L. Sheldon, M. J. Watson,J. H. Dewar, R. Wilkinson, M. K. Ward andD. N. S. Kerr 888

Peritoneal Clearances with Different DialysisRegimens in Children Undergoing ContinuousCycling Peritoneal DialysisH. E. Leichter, I. B. Salusky, T. v. Lilien, S. Laidlaw,J. C. Alliapoulos, Teresa L. Hall and R. N. Fine 893

A Longitudinal Study of the Effects of AminoAcid-Based CAPD Fluid on Amino AcidRetention and Protein LossesG. A. Young, J. B. Dibble, A. E. Taylor, S. Kendalland A. M. Brownjohn 900

Ganciclovir Therapy of SymptomaticCytomegalovirus Infection in Renal TransplantRecipientsC. Guerin, B. Pozzetto, C. Broyet, 0. Gaudin andF. Berthoux 906

Case ReportsFatal Cardiac Zygomycosis in a RenalTransplant Patient Treated withDesferrioxamineN. A. T. Hamdy, S. M. Andrew, J. R. Shortland,J. Boletis, A. T. Raftery, J. A. Kanis and C. B. Brown 911

Acute Renal Failure and Tubular DysfunctionAssociated with Minimal Change NephroticSyndromeM. Praga, M. A. Martinez, A. Andres, M. Alvarez deBuergo, I. Bello, V. G. Millet and J. Ma. Morales

Letters

883 Announcements

914

917

920

Dow







Review ArticleTreatment of Glomerular Disease with Cyclosporin AA. Meyrier 923

Original A rticlesComplement Receptor (CR1) and IgG or IgA onErythrocytes and in Circulating Immune Complexesin Patients with GlomerulonephritisR. Coppo, A. Amore, D. Roccatello, A. Amoroso, S. Maffei,G. Quattrocchio, A. Molino, B. Gianoglio and G. Piccoli 932

Triamterene Increases Lithium Excretion in HealthySubjects: Evidence for Lithium Transport in theCortical Collecting TubuleJ. F. M. Wetzels, J. D. van Bergeijk, A.-J. Hoitsma,F. Th. M. Huysmans and R. A. P. Koene 939

Frequency of Mesangial IgA Deposits in aNon-Selected Autopsy SeriesR. Waldherr, M. Rambausek, W. D. Duncker and E. Ritz 943

Proteinuria and Haematuria are Frequently Presentin Patients With Lung CancerH. Puolijoki. J. Mustonen, E. Pettersson, A. Pasternackand A. Lahdensuo 947

Carnitine and Carnitine Esters in Acute RenalFailureC. Wanner. W. Riegel. R. M. Schaefer and W. H. Horl 951

Reduced Deposition of Aluminium in TrabecularBone of Uraemic Rats Treated with DihydroxylatedVitamin D MetabolitesT. H. Ittel, F. Hofstadter, U. Gladziwa and H. G. Sieberth 957

Effects of Human Recombinant Erythropoietin onAnaemia. Systemic Haemodynamics and RenalFunction in Predialysis Renal Failure PatientsKaoru Onoyama. Harumitsu Kumagai, Kazuto Takeda,Kazumasa Shimamatsu and Masatoshi Fujishima 966

Hyperparathyroidism Does Not Influence theAbnormal Primary Haemostasis in Patients withChronic Renal FailureG. Vigand. E. Gotti. E. Comberti, A. Giangrande,R. Trevisan and G. Remuzzi 971

Platelet Lipid Peroxidation in HaemodialysisPatients: Effects of Vitamin E SupplementationM. Taccone-Gallucci, R. Lubrano, D. Del Principe,Adriana Menichelli, M. Giordani. G. Citti, M. Morosetti,C. Meloni, Valentina Mazzarelia, I. Meschini,Carmela Tozzo, M. Elli, O. Giardini and C. U. Casciani 975

Correction of Anaemia of Chronic Renal Failurewith Recombinant Human Erythropoietin: Safetyand Efficacy of One Year's Treatment in a EuropeanMulticentre Study* of 150 Haemodialysis-Dependent PatientsE. Sundal and U. Kaeser 979

Central Venous Access for Haemodialysis Using theHickman CatheterM. Cappello, L. De Pauw, G. Bastin, F. Prospert,C. Delcour, C. Thaysse, M. Dhaene, J. L. Vanherweghemand P. Kinnaert 988

Case ReportRenal Vein Thrombosis in a Dehydrated Patient onan Oral Contraceptive AgentJ. Bonier. K.-H. Hauenstein, Karola Hasler andP. Schollmeyer 993

Successful Treatment of Legionella-AssociatedHaemolytic Uraemic Syndrome with Acute RenalFailure and Malignant Hypertension byProstacyclin (Epoprostenol)B. Canaud, J. J. Beraud. C. Mion, P. Baldet and A. Mimran 996

Brief CommunicationGermicidal Effectiveness of Dialox*. A New StablePeroxyacetic Acid Solution, in the Re-Use ofHigh-Flux DialysersB. Canaud, Q. V. Nguyen. I . J. Garred, R. Nicolle andC. Mion 1000

Announcements 1003

Dow







Editorial

Uraemic Hyperphosphataemia—What is theTherapy of Choice?Klaus Schaefer 1005

Review ArticleAtrial Natriuretic Peptide and Renal DiseaseA. S.Woolf 1008

Original ArticlesRenal Prognosis in Alport's and RelatedSyndromes: Influence of the Mode ofInheritanceJ.-M. Pochet, G. Bobrie, P. Landais, B. GoldfarbandJ.-P. Griinfeld 1016

Effectiveness of Steroid Therapy in DifferentStages of Membranous NephropathyG. Fuiano, P. Stanziale, M. Balletta, V. Sepe,G. Marinelli, N.Comi, A. Esposito and V. E. Andreucci 1022Prevention of Radiocontrast-Media-lnducedNephrotoxicity by the Calcium ChannelBlocker Nitrendipine: A ProspectiveRandomised Clinical TrialH.-H. Neumayer. W. Junge, A. Kiifner andA. Wenning 1030

Interstitial Mononuclear Cell Infiltrates inExperimental Nephrosis: Effect of PAFAntagonistF. M. Mampaso, J. Egido, J. C. Martinez-Montero,T. Bricio, E. Gonzalez, M. E. Cobo, E. Pirotzky,P. Braquet and L. Hernando 1037

Prevention of Osteitis Fibrosa, AluminiumBone Disease and Soft-Tissue Calcification inDialysis Patients: A Long-Term Comparison ofModerate Doses of Oral Calcium ±Mg(OH)2vsAI(OH)3±1a OH Vitamin D3Ph. Moriniere, B. Boudailliez. Ch. Hocine, S. Belbrik,H. Renaud, P. F. Westeel, M. Cohen Solal andA. Fournier 1045

Dialysis-Associated Amyloid: Systemic orLocal?D. Sethi, N. R. B. Cary, Edwina A. Brown,D. F. Woodrow and P. E. Gower 1054

The Effect of Acetate on Ventilation inHaemodialysis PatientsR. M. Heyrman, W. A. De Backer,J. P. Van Waeleghemand M. E. De Broe 1060

Seizures in Haemodialysis Patients Treatedwith Recombinant Human ErythropoietinM. E. Edmunds, J. Walls, B. Tucker, L. R. I. Baker,C. R. V. Tomson, M. Ward, J. Cunningham,R. Moore and C. G.Winearls 1065

Dietary Fish Oil Supplements Preserve RenalFunction in Renal Transplant Recipients WithChronic Vascular RejectionP. Sweny, D. C. Wheeler, S. F. Lui, N. S. Amin,M. A. Barradas, J. Y. Jeremy, D. P. Mikhailidis,Z. Varghese, O. N. Fernando and J. F. Moorhead 1070

The Initiation of Erythropoiesis FollowingRenal TransplantationJ. H. Brown, T. R. J. Lappin, G. E. Elder, T. N. Taylor,J. M. Bridges and M. G. McGeown 1076

Case ReportsMembranous Nephropathy: Monoclonal IgGand Nephrotic-range Proteinuria in a RenalTransplant RecipientC. D. Short, Beatrice M. Coupes, P. E. Brenchley,Susan Martin, Shelley Williams, R. W. G. Johnson,M. P. Mallick and G. Williams

Letters

Announcements

Indexes to Volume 4

1080

1083

1085

1087

Dow



Nephrology / Dialysis Transplantation

Documents

Transcript of Nephrology / Dialysis Transplantation